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1. INTRODUCTION         
                 
In Europe there were an estimated 3,191,600 cancer cases diagnosed 
(excluding nonmelanoma skin cancers) and 1,703,000 deaths from cancer in 
2006 [1]. The most common forms of cancers were breast cancer, colorectal 
cancer and lung cancer. Lung cancer, with an estimated 334 800 deaths (19.7% 
of total), was the most common cause of death from cancer, followed by 
colorectal (207 400 deaths), breast (131 900) and stomach (118 200) cancers. 
The total number of new cases of cancer in Europe appears to have increased 
by 300 000 since 2004 [1]. Today, millions of people are living with cancer or 
have had cancer.  
 
Although there are many types of cancer, they share a number of 
common ‘hallmarks’ which distinguish them from the normal cells from which 
they are derived [2]. This usually includes a greatly increased rate of 
proliferation. An isolated abnormal cell that does not proliferate more than its 
normal neighbours causes no significant damage, irregardless of other 
abnormal properties it may have. However, loss of proliferative control will 
give rise to a tumor or neoplasm, which is defined as a growing mass of 
abnormal cells. As long as the neoplastic cells remain clustered together in a 
single mass, the tumor is classified as benign. At this stage, a complete cure 
can usually be achieved by removing the tumor mass surgically. A tumor is 
considered a cancer only if it is malignant, that is, only if the tumor cells have 
acquired the ability to invade surrounding tissue. Invasiveness usually implies 
an ability to break loose, enter the bloodstream or lymphatic vessels and form 
secondary tumors, called metastases at other sites of the body. The more 
widely a cancer spreads, the harder it becomes to eradicate.    
 
Cancers arising from epithelial cells are named carcinomas, those 
arising from connective tissue or muscle cells are named sarcomas, which both 
form solid tumors. Some cancers, like leukaemia, do not form solid tumors. 
Instead, these cancer cells involve the blood and blood-forming organs and 
circulate through other tissues where they grow.  
 
Cancer cells develop as a consequence of genetic changes that are often 
initiated as a result of damage to the DNA. An estimated 1016 cell divisions 
take place in a normal human body in the course of a lifetime. Even in an 
environment that is free of mutagens, mutations will occur due to fundamental 
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limitations on the accuracy of DNA replication, DNA repair, and cell division. 
Genes which when mutated stimulate cells to divide where they should not, are 
termed protooncogenes. These mutations have a dominant effect, and the 
mutant genes, known as oncogenes, are identified by their ability to drive a cell 
towards cancer. Other mutations, which result in loss-of-function mutations in 
so-called tumor suppressor genes, relieve cells of inhibitions that normally help 
to hold their cell numbers in check, thereby creating a risk towards cancer 
development. Clearly, to be cancer cells must acquire a series of changes that 
confer new properties on the cells as it evolves. Different cancers acquire 
different combinations of mutations in oncogenes and tumor suppressors which 
gives rise to these new properties. Nevertheless, Hanahan and Weinberg have 
suggested that the vast catalogue of cancer cell of genotypes is a manifestation 
of six essential alterations in cell physiology that collectively dictate malignant 
growth: self-sufficiency in growth signals, insensitivity to antigrowth signals, 
evading programmed cell death (apoptosis), limitless replicate potential, 
sustained angiogenesis and tissue invasion and metastasis. Each of these 
acquired capabilities during tumor development represent the successful 
breaching of an anticancer defence mechanism hardwired into cells and tissues 
[2]. 
 
However, because there are many genetic routes to the acquisition of 
these hallmarks, individual cancers contain unique sets of altered genes. Recent 
sequencing studies have suggested that the ‘landscape’ of mutations amongst 
cancers even of similar types is indeed vastly different [3]. As a result, 
individual cancers may behave very differently. This is especially true for the 
microenvironment of the tumor, which displays extreme heterogeneity amongst 
otherwise similar cancer types. These important differences amongst otherwise 
similar tumors confer unique growth, metastatic, and treatment properties on 
the tumor. This realization has stimulated recent efforts to develop more 
individualized treatment that is tailored to specific genetic or other properties 
of the tumor. This thesis is aimed at understanding the biological consequences 
of tumor hypoxia, one of the unique properties of human tumors that displays a 
large degree of heterogeneity amongst different tumors and which is thought to 
be a major contributor to patient prognosis and treatment response. 
 
The general introduction of this thesis is divided into three separate 
parts. The first discusses the evidence for hypoxia in tumors and its clinical 
relevance. The second focuses on how tumors adapt to hypoxic stress and 
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efforts aimed at targeting hypoxia tolerance in cancer. Finally, the third 
discusses the patterns of oxygenation (severity and duration) within tumors and 
their effect on the cellular hypoxic responses.  
 
 
2. TUMOR HYPOXIA AND ITS CLINICAL RELEVANCE  
 
Since the initial pioneering histological work of Thomlinson and Gray in 1955 
that led to their discovery of hypoxia in human lung cancer [4], it has been 
convincingly demonstrated that the majority of solid human tumors contain 
regions of poor oxygenation [5, 6]. Hypoxia within solid tumors arises as a 
result of insufficiencies and improper functioning of the tumor vasculature 
which impairs the ability to deliver both oxygen and treatment to isolated 
regions of tumors [7-9]. The oxygen delivered is consumed as it diffuses out 
from the blood vessel and consequently an oxygen gradient develops, reaching 
complete anoxia at distances of circa 150-200 μm. The limit in oxygen 
diffusion gives rise to what has been termed ‘chronic’ hypoxia. In this model, 
the continued proliferation of tumor cells adjacent to blood vessels, slowly 
pushes cells through the oxygen gradient and eventually into necrosis. 
However, hypoxia can also arise through transient changes in blood flow. The 
tumor vasculature is often immature, lacking smooth muscle cells and other 
structural components. Combined with high interstitial pressures in tumors, this 
leads to fluctuations in blood flow and/or red blood cell flux. Rapid and 
dramatic changes in perfusion, including complete shut down of vessels which 
has been experimentally demonstrated in animal tumors. Furthermore, 
pioneering work by Dewhirst [10] and others have shown that many tumors 
demonstrate cycling or periodic changes in blood flow and oxygenation. This 
results in a dynamically changing oxygen environment for tumor cells. 
Consequently these cells must endure frequent exposures to 
hypoxia/reoxygenation cycles.  
 
For radiotherapy, the initial interest in hypoxia was based on the fact 
that hypoxic tumor cells alter the chemical reactions which take place in the 
DNA upon radiation such that only about one third as many lethal DNA lesions 
are produced in hypoxic cells compared with aerobic cells [11]. The clinical 
importance of hypoxia for radiotherapy has subsequently been demonstrated in 
trials where tumor oxygenation was measured with needle electrodes. A recent 
report from a multi-centre trial in head-and-neck cancer showed that in a 
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multivariate Cox Proportional Hazards analysis, the hypoxic fraction was by 
far the most statistically significant factor explaining the variability in patient 
survival [12]. In this study, 5-year survival was almost constant for hypoxic 
fractions in the range from 0 to 20%, whereas the 5-year survival approached 
0% in the most hypoxic tumors. Cells in hypoxic tumor areas have also been 
shown to be resistant to chemotherapy [13]. This is due in part because 
metabolism of the chemotherapeutic drugs in well-perfused areas of the tumors 
limits their ability to reach the poorly perfused hypoxic cells. 
Chemotherapeutic drugs may also be less active in hypoxic cells due to their 
comparatively low rates of proliferation. 
 
Most recently, research efforts have concentrated on understanding the 
consequences of hypoxia on tumor cell biology. This has been stimulated in 
part by several clinical findings that implicate tumor hypoxia as a contributor 
to the malignant phenotype. Importantly, the prognostic value of hypoxia has 
been observed independent of treatment modality, even for patients treated 
with surgery where no ‘intrinsic’ resistance is expected [14]. In this cervical 
cancer study, hypoxia was also associated with greater lymph-vascular space 
involvement and parametrial infiltration. Furthermore, several clinical studies 
have found an association between hypoxia and metastases [15, 16]. It has 
therefore been proposed that hypoxia not only modifies therapy resistance, but 
may also affect malignancy. Clinical efforts towards overcoming hypoxia have 
focused on either eliminating it, for example by breathing high oxygen gas 
mixtures, or by replacing oxygen with drugs that can sensitize cells to radiation 
in a similar way to oxygen. Unfortunately, these clinical studies have only 
modestly improved outcome [17, 18].  
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3. MECHANISMS OF ADAPTATION TO HYPOXIA   
    
Hypoxic conditions encountered by normal cells during development and 
several physiological situations activate highly regulated molecular responses 
designed to restore oxygen homeostasis. In non-malignant pathologies such as 
severe wounds and stroke, hypoxia can cause cell death and tissue 
malfunctioning. In these cases, the normal biological responses to hypoxia are 
insufficient to maintain cell function and survival.  
 
So how does a tumor cell adapt to and survive in a nutrient deficient and low 
oxygen environment? 
 
During carcinogenesis, tumor cells often become more resistant to 
hypoxia-induced cell death, a property that is consistent with the negative 
impact of hypoxia on clinical outcome. This resistance can arise, for example, 
through the inhibition or loss of pathways that promote cell death in response 
to hypoxia. This is best exemplified by the p53 pathway, which when 
functional can result in the rapid death of hypoxic, oncogenically transformed 
cells [19]. A second mechanism involves an attempt by the tumor cells to 
increase tumor oxygenation by stimulating angiogenesis. Persistent hypoxia in 
tumors can provide the basis for the ‘angiogenic switch’, which has been 
suggested as one of the key six hallmarks of cancer [2]. Neo-angiogenesis was 
first proposed in the 1960s and its significance in tumors and anti-cancer 
strategies is underscored by the discovery that growth factors such as vascular 
endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) 
are synthesized and secreted by hypoxic tumor cells via transcriptional and 
post-transcriptional mechanisms. Hypoxia can also decrease expression of anti-
angiogenic factors like thrompospodin-1 [20, 21]. Finally, cancer cells become 
adept at regulating energy homeostasis during hypoxia where the efficiency of 
ATP production is impaired by the lack of oxidative phosphorylation. This 
regulation occurs through both increases in anaerobic glycolysis and through 
decreases in energy consumption via the suppression of cell proliferation and 
protein synthesis. 
 
Three main pathways that influence the tolerance and behaviour of 
tumor cells to hypoxia have been identified and intensively studied, including 
the hypoxia inducible factor HIF-1 which modulates angiogenesis and two 
other pathways that influence both effects on energy consumption and protein  
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synthesis (Figure 1). 
 
 
 
Figure 1: Cellular pathways that influence the tolerance and behaviour of tumors cells to 
hypoxia. Hypoxia dependent stabilisation and activation of HIF-1 mediates a transcriptional 
program that influences cell metabolism, angiogenesis and metastasis. Hypoxia also activates 
two independent pathways that inhibit mRNA translation. This inhibition is thought to 
influence hypoxic cell tolerance and behaviour through both effects on energy conservation 
and gene expression. 
 
 
The understanding of this hypoxia tolerance has made it possible to 
develop new therapies targeted directly at the perceived important cellular 
responses to hypoxia, some of which are undergoing clinical evaluation (Table 
1). However, it remains to be seen how effective these new therapies will be. 
These known pathways that control the cellular responses to hypoxia are highly 
dependent on both the severity of hypoxic areas in tumors (absolute levels 
oxygen), which spans the range from normal to anoxia and the duration of 
hypoxia, which is highly dynamic and characterized by both a rapid and slowly 
changing oxygenation levels.  
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Table 1: Therapeutic targeting of HIF-1, the UPR and mRNA translation 
 
 
Target Drug Reference 
    
Targeting the HIF pathway 
 
   
HIF-1 RNAi HIF-1 RNAi [22] 
Unknown Topoisemerase I Camptothecin [23] 
Blocking HIF-1 DNA binding 
activity 
HIF-1 Echinomycin 
(NSC-13502) 
[24] 
Translation/stability HIF-1α HSP90 GA, 17-AAG [25] 
Unknown Unknown YC-1 [26] 
Improving HIF-PH activity HIF-PH Ascorbate [27] 
Microtubule polymerization 
 
Unknown 2ME2 [28] 
Blocking PTEN inhibitor Thioredoxin-1 PX-12, 
pleurotin 
[29] 
Ras/MAPK activity RAF BAY 43-9006 [30] 
Targeting the UPR 
 
   
suicide gene driven by GRP-78 
promotor 
UPR tolerance HSV-tk suicide 
gene 
[31] 
Inhibiting GRP-78 transcription GRP-78 versipelostatin [32] 
Inhibiting the proteasome 
 
XBP-1 Proteasome 
inhibitors 
[33] 
Targeting mRNA translation 
 
   
Inhibiting eIF2α dephosphorylation eIF2α Salubrinal [34] 
PI3/AKT pathway, mRNA 
translation? 
PI3K Wortmannin, 
LY294002 
[35] 
mRNA translation FRAP/mTOR Rapamycin, 
CCI-779 
 
[36] 
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3.1. HIF transcription factors  
 
The most intensely investigated molecular response to hypoxia is the activation 
of the transcription factor HIF-1 and its downstream targets. HIF-1 is a 
heterodimer composed of the hypoxia responsive subunit HIF-1α and the 
constitutively expressed aryl hydrocarbon receptor nuclear translocator 
ARNT/HIF-1β. During normoxic conditions, HIF-1α is ubiquitinated by the 
von-Hippel Lindau (VHL) protein and targeted for degradation [37, 38].  
 
The oxygen sensitivity of HIF-1α is derived primarily from the fact that 
VHL protein only recognizes it when two proline residues (P402 and P564) are 
hydroxylated. These modifications are carried out in an oxygen-dependent 
reaction by one of three known HIF prolyl hydroxylases [39]. The 
transcriptional activity of HIF-1 is also inhibited by oxygen. This is mediated 
by an oxygen dependent hydroxylation of asparagine residue 803 in its C-
terminal transactivation domain (C-TAD) by factor inhibiting HIF-1 (FIH) 
[40]. A subset of HIF-1 target genes appear less sensitive to FIH activity, 
possibly through utilization of an alternative oxygen-insensitive transactivation 
domain in the N-terminus (N-TAD) of HIF-1α [41]. In addition to HIF-1α, two 
other family members have been identified, HIF-2α and HIF-3α. HIF-2α can 
also dimerize with HIF-1β and activate transcription of overlapping or distinct 
target genes [42, 43]. Inhibitory PAS (IPAS/HIF-3α) contains no endogenous 
transactivation function but may act as a dominant negative regulator of HIF-1 
[44].  
 
HIF-1 promotes the expression of numerous genes that function to 
improve oxygenation through erythropoiesis and angiogenesis [45]. HIF-1 
target genes also promote metabolic adaptation through regulation of glucose 
uptake, stimulation of glycolysis [46, 47] and through its recently reported 
ability to regulate the rate of cellular oxygen consumption [48]. During 
conditions of poor oxygenation, the generation of ATP shifts from the 
oxidative phosphorylation pathway in the mitochondria to the oxygen 
independent pathway of glycolysis in the cytoplasm. Although glycolysis is 
less efficient compared with oxidative phosphorylation, in the presence of 
sufficient glucose it can maintain ATP levels due to increases in the glycolytic 
enzymes. HIF-1 is a necessary mediator of this ‘switch’ in the cellular 
metabolic program, also known as the Pasteur effect [47]. In addition, HIF-1 
activation is associated with an increased metastatic capacity through the 
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upregulation of genes such as LOX, Met and CXCR4 [49-51]. The importance 
of HIF-1 in the growth and behaviour of tumors has been extensively 
investigated and these studies have stimulated the development of several 
different therapies based on targeting HIF-1 [45, 52] (Table 1). However, 
although many of these agents can significantly inhibit HIF-1 activity, decrease 
VEGF and impair xenograft growth, most of them are rather non-selective 
inhibitors. For example, three out of four compounds identified from a HIF-1 
cell-based high-throughput screen of 2000 agents within the NCI chemical 
diversity set were analogues of camptothecin, a topoisomerase I inhibitor [53]. 
Although these compounds show an interesting mechanism for HIF-1 
inhibition [23], they are likely to have other cellular effects, including 
activation of DNA damage responses. Due to this lack of specificity it remains 
difficult to define the exact contribution of HIF-1 inhibition and establish under 
what circumstances these agents should be used in the clinic. Several studies to 
develop more specific HIF-1 inhibitors and novel therapeutic drugs that target 
HIF-1 are underway. One of the more promising agents was derived from a 
two-step screening procedure of the NCI 140,000 small-molecule library [24]. 
The same cell-based screen discussed above was first used to identify 128 
molecules capable of blocking HIF-1. These 128 compounds were then 
screened for their ability to block HIF-1 DNA-binding activity. This procedure 
identified echinomycin (NSC-13502), a small-molecule known to bind DNA in 
a sequence-specific fashion. This molecule was clinically investigated 20 years 
ago based on demonstrated pre-clinical antitumor activity [54], but minimal or 
no antitumor activity was reported in phase II clinical trials [55-57]. However, 
because no surrogate measurements of HIF activity were made in these trials, it 
is not clear if the lack of clinical activity is due to ineffective inhibition of HIF-
1 or to HIF-1 being an inappropriate target in these patients.  
 
HIF-1α has also been specifically targeted in vitro [58] and in vivo [22] 
using RNA interference (RNAi). In vivo, early-stage D54MG-derived gliomas 
were reported to be more vulnerable to HIF-1 RNAi inhibition than their late-
stage counterparts. Interestingly, HIF-1α knockdown tumors showed no 
differences in vascular density compared to their wild-type counterparts, a 
phenomenon that was also observed in HIF-1α knockout tumors derived from 
Ras transformed MEFs [59]. These findings may be explained by a 
compensatory role of the proangiogenic cytokine interleukin-8 (IL-8), which 
has been shown to be induced in cells lacking HIF-1 [60]. If this proves to be a 
general phenomenon, it poses obvious limitations to targeting HIF in tumors. A 
neutralizing antibody to IL-8 substantially inhibited angiogenesis and tumor 
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growth in HIF-1α deficient tumors, suggesting that effective inhibition of HIF-
1 may also require suppression of the IL-8 compensatory response [60]. It 
should also be emphasized that the value of targeting HIF may depend on 
tumor type or location. HIF-1α knock-out astrocytomas, a class of oxygen-
dependent brain tumors, showed severe necrosis, reduced growth and vessel 
density in a vessel-poor subcutaneous environment, but when grown in the 
vessel-rich brain parenchyma the phenotype was reversed [61]. Several other 
papers have also reported that HIF-1 deficient tumors may grow at similar or 
faster rates than their wild-type counterparts [62]. Similarly, overexpression of 
HIF-2α has been shown to enhance angiogenesis, but to reduce overall tumor 
growth due in part to increased tumor cell apoptosis [63]. These examples 
illustrate that even when HIF-1 can be effectively inhibited, it is not always 
possible to predict the consequences for tumor growth. Thus, although 
targeting HIF-1 may have potential in cancer therapy, we still do not fully 
understand the dependence of different tumor cells on HIF-1 function. 
 
 
3.2. The Unfolded Protein Response UPR 
 
The endoplasmic reticulum (ER) serves as a site for protein folding, assembly, 
disulfide bond formation and glycosylation of newly synthesized secretory and 
transmembrane proteins. The protein flux into the ER is variable because it can 
change rapidly in response to programmes of cell differentiation, 
environmental conditions and the physiological state of the cell. To handle this 
dynamic situation, cells adjust the protein-folding capacity of the ER according 
to their requirements, thereby ensuring that the quality of cell-surface and 
secreted proteins can be maintained with high fidelity.  
 
During conditions of ER stress such as high ER protein load or an 
accumulation of unfolded proteins, an evolutionarily conserved program called 
the unfolded protein response (UPR) is activated. Recent evidence suggests 
that hypoxia is also capable of activating the UPR [64-67]. Hypoxia activates 
both the (PKR)-like ER kinase (PERK) and the inositol-requiring protein-1 
(IRE1), two of the three known UPR sensors that also include the activating 
transcription factor-6 (ATF6). Activation of these sensors during the UPR is 
thought to be mediated primarily by the dissociation of the ER chaperone 
immunoglobulin binding protein (BiP) from the luminal domains of PERK, 
IRE1 and ATF6 by preferentially binding misfolded proteins that accumulate 
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in the ER lumen [68]. BiP is upregulated during hypoxia and inhibition of BiP 
expression results in increased cell death in cells exposed to hypoxia [69, 70].  
 
PERK activation during hypoxia results in the phosphorylation at the 
Ser-51 residue of eukaryotic initiation factor 2α (eIF2α). Its phosphorylation 
inhibits the guanine nucleotide exchange factor eIF2B, which prevents 
formation of the eIF2-GTP-(Met)tRNA ternary complex and thus causes an 
overall inhibition of mRNA translation (Figure 2). This inhibition is thought to 
aid in the recovery of ER stress in part by preventing the production of new 
proteins. During hypoxia, the inhibition of mRNA translation may also help to 
conserve ATP since protein synthesis is one of the most energy consuming 
processes in the cell. Although phosphorylation of eIF2α causes a global 
inhibition in mRNA translation, it paradoxically stimulates the synthesis of a 
subset of proteins during hypoxia including the activating transcription factor-4 
(ATF4) [64, 65, 71, 72]. The selective translation of ATF4 under conditions of 
repressed protein synthesis appears to be the result of preferentially increased 
translation of mRNAs that contain inhibitory upstream open reading frames 
(uORFs) within their 5’ untranslated region (UTR) [65, 73, 74]. ATF4 
mediates the activation of many downstream genes, including those involved in 
recovery from oxidative stress [75]. Several other genes including the ATF4 
target genes CHOP and GADD34 are also preferentially translated during 
hypoxia [64, 65, 72]. Recently, it has been demonstrated that ER stress also 
triggers autophagy, which is a catabolic process for the degradation and 
recycling of cytosolic, long lived, or aggregated proteins and excess or 
defective organelles. So as the cell produces even more ER stress, this process 
promotes the degradation of the organelle and the damaged proteins within it 
[76]. In contrast to other types of autophagy, such as starvation induced 
autophagy, the autophagosomes that accumulate in UPR-induced yeast cells do 
not readily fuse with the vacuole until the stress is abolished, indicating that the 
sequestration of damaged ER is more important than its ultimate degradation 
[77]. Work by Kouroku demonstrated that PERK/eIF2α phosphorylation 
mediates the polyglutamine-induced LC3 conversion, an essential step for 
autophagy formation [78]. 
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Figure 2: Control of the initiation step of mRNA translation. Initiation of translation begins 
following assembly of eIF4F (containing the cap-binding protein eIF4E, the scaffold protein 
eIF4G, and the RNA helicase eIF4A) at the m7GpppN ‘cap’ structure of the mRNA. 
Interaction with eIF3 facilitates recruitment of the small subunit of the ribosome together with 
the ternary complex containing eIF2/Met-tRNA/GTP. This complex then scans through the 5’ 
UTR until it reaches the AUG start site. Here GTP is hydrolyzed releasing eIF2 and allowing 
recruitment of the large subunit of the ribosome. Control of initiation occurs principally at two 
steps. The first is through inhibition of eIF4F as a result of competitive binding of the 4E-BPs 
to eIF4E in their under-phosphorylated form. The second is through phosphorylation of eIF2α. 
Phosphorylation results in binding and inactivation of the GDP/GTP exchange factor eIF2B. 
 
 
Other transcription factors are also induced in response to UPR 
activation during hypoxia. This includes NF-κB and Nrf2, both of which 
require phosphorylation of eIF2α for their activation during ER stress [79, 80]. 
In addition, IRE1 activation during the UPR causes the excision of a 26-
nucleotide intron from the mRNA coding for the X-box binding protein-1 
(XBP-1) transcription factor, a necessary step in its activation [81] 
Collectively, these data suggest that in addition to its effect on translation, 
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hypoxic activation of the UPR also leads to a significant additional 
transcriptional response. 
 
The ability to phosphorylate eIF2α and inhibit translation appears to be 
an important protective response to hypoxia since PERK knockout cells show 
increased cell death during hypoxic exposure [64]. These cells also produce 
tumors that grow much more slowly than PERK wild-type cells, an effect that 
has been linked to decreased hypoxia tolerance. Cells derived from a knock-in 
mouse expressing a non-phosphorylatable S51A mutation in eIF2α show a 
similar phenotype [64]. A general role for the UPR in the hypoxic response is 
suggested by the fact that XBP-1 deficient cells also show defective tumor 
growth and are sensitive to hypoxia [67].  
 
Together these data suggest that targeting the UPR in order to prevent 
its activation during hypoxia would be an interesting approach for therapy. A 
selective inhibitor of eIF2α dephosphorylation (salubrinal) has been shown to 
protect against ER-stress [34], suggesting that this pathway can be exogenously 
regulated. Although there are no known specific inhibitors of the important 
proteins in this pathway including PERK, ATF4, IRE1 or XBP-1 that can be 
used clinically, efforts are underway to find such inhibitors [82]. It may also be 
possible to use agents that are known to stimulate ER-stress, for example 
through the use of proteasome inhibitors. Proteasome inhibitors that suppress 
the activity of IRE1α rendered myeloma cells extremely sensitive to ER-stress, 
which was translated in increased apoptosis [33, 83] (Table 1). 
 
 
3.3. mTOR and eIF4F 
 
Hypoxia also regulates mRNA translation by inhibiting the formation of a 
second translation initiation complex, eIF4F. This complex contains the mRNA 
cap binding protein eIF4E, the scaffold protein eIF4G, and the RNA helicase 
eIF4A. Inhibition of eIF4F during hypoxia occurs in part through activation of 
the inhibitory eIF4E binding protein 4EBP1. This protein binds to eIF4E in its 
underphosphorylated state and prevents it from binding to eIF4G [84, 85] (Fig. 
2). The phosphorylation of 4E-BP1 is controlled in large part by the 
mammalian target of rapamycin (mTOR) kinase [86]. Several recent reports 
have demonstrated that mTOR activity is at least partially inhibited during 
hypoxia, leading to decrease 4E-BP1 phosphorylation and decreased levels of 
translation [65, 87-89].  
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Three upstream pathways influence mTOR activity, two of which are 
implicated as targets of hypoxia. These pathways signal to mTOR by altering 
the activity of the tuberous sclerosis complex (TSC), a negative regulator of 
mTOR. The first is controlled by the hypoxia inducible gene REDD1/RTP801. 
Its induction during hypoxia causes activation of the TSC1/TSC2 complex and 
inhibition of mTOR [87]. The TSC1/TSC2 complex also regulates mTOR 
function in response to changes in energy status. Under low energy conditions 
(increases in AMP) LKB1 phosphorylates and activates AMPK, which then 
activates the TSC1/TSC2 complex [90, 91]. A reduction in ATP during 
hypoxia can thus also inhibit mTOR through this pathway [89] (Figure 3). 
 
 
 
Figure 3: Control of mRNA translation through mTOR. Activation of PI3K upon growth 
factor receptor signaling leads to an AKT-dependent inhibitory phosphorylation of the TSC2 
protein. The TSC1/TSC2 complex is a negative regulator of mTOR, and thus inhibition of 
TSC2 activates mTOR. Low energy levels inhibit mTOR signaling following an activating 
phosphorylation of TSC2 by AMPK. Phosphorylation of S6K and 4E-BP1 by mTOR promotes 
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synthesis of the translational machinery and stimulates cap-dependent translation, respectively. 
Hypoxia inhibits mTOR and cap-dependent translation by induction of REDD1in a TSC2-
dependent manner. Hypoxia may additionally inhibit cap-dependent translation through 
alternative mechanisms. 
 
 
Inhibition of eIF4F and translation initiation during hypoxia can also 
occur in an mTOR independent manner. It has been shown that during hypoxia 
eIF4E and the eIF4E translocator protein (4E-T) redistribute from the 
cytoplasm to the nucleus and to distinct cytoplasmic locations consistent with 
P-bodies [65]. Translocation of eIF4E into either of these cellular locations 
makes it unavailable to participate in translation initiation. The function of 
eIF4E in the nucleus is not known, although 5–20% of total eIF4E is 
consistently found there [92]. P-bodies are recently discovered sites where 
mRNA is either stored or degraded and where siRNA-based silencing takes 
place [93, 94]. 
 
Similar to the situation with eIF2α, inhibition of mTOR and/or eIF4F 
during hypoxia can also selectively influence gene expression. Inhibition of 
eIF4F blocks ‘so-called’ cap dependent translation. Although the majority of 
genes are translated in this way, a small fraction uses alternative initiation 
mechanisms. These include genes containing an internal ribosome entry site 
(IRES), a secondary structure in the 5’UTR of the transcript that facilitates 
direct binding of the ribosome. Many mammalian mRNAs have been reported 
to contain IRES activity including a number of hypoxia regulated genes such as 
HIF-1α, BiP and VEGF [95-97], although this is still controversial [98]. Thus, 
IRES dependent translation might contribute to selective gene expression 
during hypoxia when eIF4F integrity is disrupted. 
 
In addition to its effect on eIF4F, mTOR stimulates translation by 
phosphorylation and activation of S6 kinase (S6K). S6K promotes translation 
of a subset of mRNAs that contain terminal oligopyrimidine tract (5’TOP) 
sequences in their 5’UTR. This was originally thought to be due to its ability to 
phosphorylate the ribosomal protein S6, although this recently was shown not 
to be the case [99]. 5’TOP sequences are found in many components of the 
translational machinery, including all ribosomal proteins, and their translation 
is greatly stimulated by mTOR [100]. Interestingly the 5’UTR of HIF-1α has 
also been reported to contain TOP sequence [101, 102]. 
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At this point it is not yet clear what the functional consequences are of 
mTOR and/or eIF4F inhibition during hypoxia. As with eIF2α, the inhibition of 
mRNA translation is expected to conserve ATP and thus enable cells to 
maintain energy levels under hypoxia. However, substantial evidence also 
suggests that the cellular pathways, which regulate mRNA translation initiation 
through eIF4F are frequent targets for deregulation in cancer. Because eIF4E 
levels are limiting for cap-dependent translation in most tissues, overexpression 
of eIF4E in cancer cells is thought to promote the translation of a limited pool 
of mRNAs that encode key proteins involved in cellular growth, angiogenesis, 
survival and malignancy [103]. Overexpression of eIF4E in NIH 3T3 and Rat 2 
fibroblasts is sufficient to cause their malignant transformation [104]. eIF4E is 
elevated in numerous cancers types, including bladder, head and neck, 
bronchioalveolar, liver, colon and breast cancers, but not in typical benign 
tumors and normal tissues [105]. Furthermore, transgenic mice overexpressing 
eIF4E show significantly increased tumorigenesis [106, 107]. In contrast to 
eIF4E, overexpression of 4E-BP1 blocks transformation by both eIF4E and c-
myc by inhibiting cell cycle progression and increasing apoptosis [108]. 
Expression of a constitutively active 4E-BP1 enhances p27/Kip1 expression 
and represses cyclin D1 expression, which leads to cell cycle arrest of MCF7 
breast cancer cells [109]. 
 
Stimulation of mRNA translation via increased eIF4F activity also 
occurs due to increased activation of mTOR [110]. Several genes that 
participate in signaling pathways upstream of mTOR are frequently altered in 
cancer including the PI3K/AKT pathway. Mutations in the tumor suppressor 
gene PTEN [111] result in deregulation of AKT and subsequent activation of 
mTOR and mRNA translation. Similarly, receptors such as HER2/Neu, which 
signal to this pathway are also frequent targets of amplification or mutation in 
cancer [101]. Mutations in either TSC1 or TSC2 results in formation of benign 
tumors called hamartomas, which consist of multiple cell types [112]. 
Mutations in the LBK1 tumor suppressor gene, which regulates TSC1/TSC2 in 
response to reductions in energy levels, causes Peutz-Jeghers syndrome (PJS) 
[113]. This disease is characterized by the development of hamartomas and 
various neoplasms, which results as a direct consequence of mTOR 
deregulation [114]. 
 
Oncogenic deregulation of pathways that regulate translation may result 
in a decreased sensitivity to hypoxia-induced changes in eIF4F. Two recent 
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reports support this hypothesis [88, 115]. Connolly et al reported that hypoxia 
was less effective at inhibiting mTOR and translation in transformed cells 
compared to normal cells suggesting that translational control during hypoxia 
may be lost during transformation. This finding is also supported by Kaper et 
al. who also found that inhibition of mTOR is cell type specific [115]. 
Specifically, they found that mutations in the PI3K/PTEN/TSC2 pathway 
suppressed the ability of hypoxia to fully inhibit mTOR. These results are 
clinically important given that rapamycin and its analogues are currently 
undergoing several clinical trials to target mTOR signaling. There is also some 
clinical evidence that the efficacy of rapamycin is dependent upon its ability to 
suppress hypoxic cell signaling [116]. Clearly much more work needs to be 
done to understand the functional consequences of translation inhibition 
through eIF4F during hypoxia, its variability in various cancer cell lines, and 
its potential for targeting. 
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4. PATTERNS OF TUMOR OXYGENATION – SEVERETY 
AND DURATION 
 
In the 1990s, clinical studies with oxygen electrodes and molecular markers 
enabled investigators to directly measure hypoxia in human tumors. These 
results demonstrated that solid tumors not only are poorly oxygenated, but also 
that oxygenation is extremely heterogeneous. The most commonly used 
parameter to describe hypoxia within an individual tumor has been the hypoxic 
fraction, defined as the percentage of hypoxic readings below an arbitrary 
threshold of oxygen concentration. For oxygen electrode studies, this threshold 
has typically been set at 2.5 or 5 mmHg. Using such arbitrary definitions, the 
hypoxic fraction amongst different tumors ranges from zero to 100% [12, 117]. 
Histological examinations of hypoxia in human tumors using the exogenously 
administered hypoxia markers pimonidazole and EF5, have demonstrated that 
oxygenation is also heterogeneous with respect to its spatial distribution [118-
120]. A common misconception is that tumors consist of central hypoxic 
‘cores’ surrounded by better-oxygenated cells. In reality, hypoxia can be seen 
in all areas of the tumor and theoretically around every individual blood vessel. 
This fact makes it extremely difficult to spatially target treatment specifically 
at the hypoxic cells, for example by delivering higher radiation doses to these 
areas. However, the disorganized nature of the microvasculature found in most 
tumors does lead to spatial differences in microvessel density and perfusion 
and thus also to some spatial heterogeneity in the degree of hypoxia that is 
present. 
 
Oxygenation within a given tumor is also highly heterogeneous with 
respect to oxygen concentration. Although the hypoxic fraction has been used 
in most studies, the oxygen electrode and marker studies clearly indicate that 
human tumors also contain large tumor areas exposed to more moderate 
hypoxia. The diffusion limit of oxygen from a functional blood vessel is 
determined by the vessel oxygen concentration and by the rate of oxygen 
metabolism in tissues. Typically this value is on the order of 150 μm. If vessels 
are spaced at distances comparable to this value, radial gradients of 
oxygenation develop around the vessel, which was previously referred to as 
diffusion-limited or ‘chronic hypoxia’. Within these gradients, the oxygen 
concentration falls steadily from normal values at the vessel wall to anoxia on 
the border of tumor necrosis. As a result, cells surrounding these vessels exist 
at all possible levels of oxygenation (Figure 4). 
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Figure 4: Dynamic oxygenation patterns and their influence on biological responses of tumor 
cells surrounding different blood vessels. The oxygenation status of representative regions in 
tumors is depicted. Well-oxygenated regions are shown in bright red and hypoxic regions in 
blue. Grey symbols in the blue areas represent necrotic areas. Tumor cells in areas 1–4 are all 
exposed to hypoxia but with different severity and/or duration. It is likely that the resulting 
cellular responses are different in all of these areas. (1) Stable blood flow produces a constant 
gradient in oxygenation surrounding this vessel. Over time, the oxygenation of individual cells 
decreases as they move away from the vessel, leading to what has been termed “chronic 
hypoxia”. As cells move through this gradient, oxygen concentrations become low enough to 
stabilize and then fully activate HIF-1 as the PHD enzymes and subsequently FIH become 
inhibited. The oxygen concentrations in the peri-necrotic region are sufficiently low to fully 
activate both transcriptional and translational responses. However, the extended duration of 
hypoxia in this region may also result in activation of negative feedback loops that reduce HIF-
1 levels and/or eIF2α phosphorylation. (2–4) Fluctuations in perfusion lead to cycling oxygen 
levels in cells surrounding these vessels and the development of “acute hypoxia”. Cells in these 
areas experience fluctuations that differ in hypoxic severity and/or duration resulting in large 
differences in cellular response. For example, HIF-1α may be degraded in area (3) but not in 
area (2) due to differences in the degree of reoxygenation. Also, temporary exposure to near 
anoxic conditions in areas (2) and (4) may be sufficient to activate the UPR, inhibit translation 
and induce ATF4 and XBP-1 transcriptional responses. These responses may help to prepare 
these cells for reoxygenation. Cells in area (3) are exposed to only moderate hypoxia and may 
thus lack this response. Moderate hypoxia in area (3) may also lead to activation of a different 
subset of HIF-1 dependent genes that are less dependent upon inhibition of FIH, which occurs 
at oxygen concentrations lower that that needed for HIF-1α stabilisation. 
 
 
Another important consideration that is expected to influence the 
cellular consequences of hypoxia is the duration of hypoxic exposure. The 
formation of gradients around perfused tumor vessels that cause the chronic 
hypoxia described above is expected to result in a slow, steadily decreasing 
26 
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oxygen concentration in the individual tumor cells in these gradients. As the 
tumor cells proliferate near the vessel, they slowly ‘push’ adjacent cells further 
away into areas of decreasing oxygenation and eventually into necrosis. It has 
been estimated that in murine tumors, 5–10 h is required for cells to migrate 
from one cell layer to the next [121]. If a functional vessel can support 5–10 
cell layers around it, then it would require up to 100 h for cells to reach the 
outermost layer. Thus, the most hypoxic cells located furthest away from the 
vessel are expected to have been hypoxic for long periods of time. This 
theoretical example is supported by experimental studies demonstrating that 
hypoxic cells can exist in human tumor xenografts for up to 10 days [122]. The 
number of viable cells at these lowest levels of oxygenation is also expected to 
be influence by the tolerance of the tumor cells to hypoxia, a feature that may 
differ considerably in different tumors. Consequently, tumors with higher 
numbers of hypoxic cells may reflect an underlying molecular resistance to 
hypoxic exposure. The length of time that cells are exposed to different levels 
of hypoxia within the gradient would of course also be dependent on the 
proliferation rate of the tumor cells, as rapidly proliferating cells would push 
cells through the gradient more quickly than slowly proliferating cells. This 
hypothesis predicts that rapidly proliferating cells may have less pressure to 
select for changes that promote hypoxia tolerance, since they would not be 
exposed to hypoxia for as long as more slowly proliferating tumors. 
Experimental techniques using double hypoxic markers that allow labelling of 
hypoxic cells at two points in time have shown that the lifetime of hypoxic 
cells can vary tremendously, with half-lives ranging from 17 to 49 h [123]. 
 
Changes in tumor cell oxygenation are also influenced by dynamic 
changes in blood flow. The vasculature in tumors is susceptible to these 
changes in flow because it is often poorly developed, lacking smooth muscle 
cells and other structural components. Combined with high interstitial 
pressures, this can lead to rapid and dramatic changes in perfusion, including 
complete temporary shut down of vessels. This so-called ‘acute hypoxia’ can 
vary significantly amongst different tumors and in some cases account for a 
large proportion of the hypoxic cells at any given time [122, 124]. Recent data 
from spontaneous and experimental animal tumors have directly shown that 
these perfusion changes cause large fluctuations in tumor oxygenation levels 
independent of the overall tumor oxygenation status. Fluctuations in flow and 
oxygen concentration last on average between 30 min and 2 h [10], resulting in 
periodic cycling of tumor cells between different oxygen concentrations. 
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Complete vasculature shut down can lead to rapid establishment of very low 
oxygen (anoxic) levels in a large number of cells. In summary, perfusion 
changes in tumors lead to significant increases in the fraction of cells exposed 
to hypoxia as well as the duration and severity of the hypoxic exposure. 
 
 
4.1. Oxygenation patterns and cellular hypoxic responses 
 
Although the heterogeneity in patterns of oxygenation is expected to have 
different biological and clinical implications, it has been largely overlooked in 
many biological and clinical studies. Relatively few studies have been 
conducted to assess the activation and consequences of different hypoxic 
response pathways as a function of hypoxic severity or duration. Nonetheless, 
available data demonstrate large dependencies on these factors. 
 
4.1.1. HIF-1 
 
The HIF-1α transcription factor becomes stabilized at oxygen levels as high as 
1–3%. It is therefore expected to be present in the majority of all hypoxic cells 
in tumors, including many that would not have been considered as part of the 
hypoxic fraction in the clinical studies using oxygen electrodes. Activation of 
HIF-1 would also be expected in cells exposed to oxygen concentrations well 
above that required to cause significant increases in cell death [125]. Thus, 
expression and activation of HIF-1 (or its target genes) may not be a good 
surrogate for assessing the consequences of hypoxia on therapeutic response. 
This may explain results from the ARCON trial in which head and neck 
patients were treated with radiotherapy while breathing carbogen (95% oxygen, 
5% CO2) gas to improve tumor oxygenation. In these patients, pimonidazole 
staining predicted benefit from carbogen, but the HIF-1 target gene carbonic 
anhydrase 9 (CA9) did not [119]. Several other studies confirm the relatively 
poor overlap between the expression of HIF-1 target genes like CA9 and 
pimonidazole labelling [126, 127]. Although this may certainly be due to the 
contribution of hypoxia-independent regulation of these genes, it is also likely 
due to the different oxygen dependencies of pimonidazole and HIF-1. 
 
Although HIF-1 is stabilized at relatively high oxygen concentrations, 
recent data suggest that its transcriptional activity has a more complex 
relationship with oxygen concentration [128]. This results from the fact that the 
PHD and FIH enzymes have different Km values for oxygen and thus 
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presumably different oxygen affinities in vivo. As a result, hypoxic conditions 
that inhibit the PHD enzymes and thus stabilize HIF-1, may not be sufficient to 
inactivate FIH. In this situation, HIF-1 will only activate the subset of genes, 
which require only its N-TAD activity [41]. Activation of the C-TAD domain 
occurs only under more severe hypoxia where FIH is also inhibited. Thus, one 
would expect differential activation of HIF-1 target genes, and thus different 
cellular consequences of HIF-1 activation throughout the radial diffusion 
gradient surrounding blood vessels. This has potentially important 
consequences for therapeutic strategies aimed at targeting HIF-1. 
 
The duration of hypoxic exposure is also expected to significantly 
influence HIF-1 activity. The PHD enzymes are themselves transcriptional 
targets of HIF-1 [129], and might thus act in a negative feedback loop to 
increase the breakdown of HIF-1 during prolonged hypoxia. Thus, HIF-1 
dependent transcription may be highly temporal. The ability of the PHD 
enzymes to function in such a negative feedback loop would also be oxygen 
dependent, since they require some level of oxygen to function. Under severe 
hypoxia where oxygen concentrations are very low, increased expression of the 
PHD enzymes would not be expected to be able to negatively regulate HIF. A 
PHD negative feedback loop may explain in part the fact that HIF-1α 
expression was found to be absent in hypoxic (pimonidazole positive) cells 
near peri-necrotic regions of several human tumor xenografts although the 
HIF-1 target gene CA9 was present [127]. Cells in these areas are expected to 
be those that have been hypoxic for the longest period of time, and which may 
have increased levels of PHD proteins. This is a further example of how 
specific oxygen patterns within the tumor microenvironment can influence 
HIF-1 responses. The lack of HIF expression in these hypoxic cells would 
clearly have a negative impact on HIF directed therapies. 
 
4.1.2. UPR 
 
The regulation of mRNA translation through the various mechanisms described 
previously is also highly influenced by hypoxic severity and duration. 
Phosphorylation of eIF2α occurs extremely rapidly (~15 min) during anoxia 
(<0.02% O2), reaching a maximum after 1–2 h of anoxic conditions [65, 66]. 
Inhibition of translation and activation of ATF4 follow similar kinetics. A 
decline in the level of eIF2α phosphorylation is observed during longer 
exposures to anoxic conditions, and this is consistent with a GADD34-
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mediated negative feedback loop, which has been demonstrated to occur during 
the UPR [130]. Consistent with this transient eIF2α phosphorylation, MEFs 
expressing a non-phosphorylatable mutant allele of eIF2α (S51A) are only 
impaired in inhibition of overall mRNA translation during early (<4 h) 
exposures. Likewise, hypoxia-induced changes in gene-specific mRNA 
translation efficiency are dependent on eIF2α phosphorylation only during 
early exposure times [65]. However, it is important to realize that although the 
direct effects of eIF2α phosphorylation (i.e. altered overall and gene-specific 
mRNA translation efficiency) are transient, the complete cellular response is 
much longer lasting due to, e.g. the induction of transcriptional gene expression 
programs by ATF4 and other transcription factors. eIF2α is phosphorylated 
with significantly slower kinetics during moderate hypoxia (0.05–1.00% O2), 
and the level of phosphorylation is weaker [66]. The sensitivity of eIF2α 
phosphorylation to both oxygen concentration and duration may also explain a 
recently reported study in which eIF2α phosphorylation was not detected [88]. 
  
Since the IRE1 and PERK mediated arms of the UPR have not been 
simultaneously investigated under hypoxia, it is difficult to assess their relative 
levels of activation, kinetics and contribution to hypoxia resistance. 
Nevertheless, activation of the IRE1 mediated arm of the UPR appears to be 
slower than the PERK mediated pathway, since spliced XBP-1 mRNA and 
protein could only be detected following 24 h of severe hypoxia/anoxia [67]. 
Since both IRE1 and PERK are activated through the same mechanism, this 
might reflect a difference in the dependence upon BiP. Further studies are 
needed to assess the relative importance of IRE1 and PERK dependent 
pathways in hypoxia resistance and tumor growth. Both of these UPR sensors 
are responsible for the induction of a transcription factor (e.g. XBP-1 and ATF-
4), which activates a subset of the UPR genes. PERK is additionally 
responsible for the inhibition of overall mRNA translation during acute 
hypoxia, which probably serves to conserve energy as well as resulting in gene 
specific differential translation of the transcriptome. Therefore, targeting PERK 
might be expected to have a broader range of cellular effects than targeting 
IRE1. However, all these possible results of targeting PERK are dependent 
upon sensitivity to the effects of eIF2α phosphorylation. This sensitivity is 
partly governed by the expression levels of eIF2B, which also varies amongst 
cell lines. 
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4.1.3. mTOR and eIF4F 
 
From the present literature, it is clear that the impact of hypoxia on mTOR 
activity, eIF4F complex formation and translation efficiency is also highly 
dependent upon severity and duration of hypoxia, as well as the presence or 
absence of other stresses. The picture is far from clear because few studies 
have specifically investigated the oxygen sensitivity and (de)activation kinetics 
of these pathways. It also remains elusive to which extent these pathways 
contribute to hypoxiainduced inhibition of overall translation or whether the 
effects are limited to a smaller subset of genes. 
 
During severe hypoxia, overall mRNA translation remains low in spite 
of the transient nature of eIF2α phosphorylation. Furthermore, in contrast to 
short hypoxic exposures, S51A MEFs that are unable to inhibit translation 
through eIF2α, do efficiently inhibit mRNA translation during prolonged 
exposures [65, 66]. These results clearly demonstrate that there is a switch of 
the molecular mechanism that regulates mRNA translation during prolonged 
exposures, from being eIF2α dependent to independent. Disruption of the 
eIF4F complex is a candidate mechanism for this inhibition after prolonged 
hypoxia [65]. However, inhibition of eIF4F has also been reported to occur 
rapidly (2 h) following moderate hypoxia (0.5%), in a cell-line dependent 
manner [88]. 
 
The ability of hypoxia to inhibit mTOR also shows a complex 
dependency with duration of hypoxia. In normal culture conditions, inhibition 
of mTOR is quite slow where as in serum-deprived cells it can occur extremely 
rapidly [89]. This may be due to an antagonistic effect of PI3K signalling on 
TSC2, although this has not yet been demonstrated. 
 
Nonetheless, inhibition of mTOR in tumors is expected to differ 
significantly in cells exposed to hypoxia for different periods of time, and in 
different areas of the tumor, which may have better or worse access to 
nutrients. 
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5. CONCLUDING REMARKS 
 
Due to the complex patterns of oxygenation in human tumors and their 
influence on the known cellular pathways that respond to hypoxia, it is clear 
that a single hypoxia targeted therapy is unlikely to be effective on its own. 
Effective administration of HIF-1, UPR, or eIF4E/mTOR directed therapies 
will require some a priori knowledge not only of the amount of hypoxia 
expected, but also of the type of hypoxia present. From a clinical point of view 
this places a requirement for individualized treatment planning based on 
measurements or expectations of tumor hypoxia. Development of 
methodologies to characterize tumor oxygenation, including its temporal 
component, may thus hold the key to successful administration of hypoxia 
targeting agents. An approach that is already being pursued is the use of 
molecular imaging with various biomarkers associated with specific 
oxygenation patterns. Specific patterns of gene expression associated with the 
activation of different hypoxic responses could also prove to be useful. Chi et 
al. recently reported that a hypoxia gene-expression signature derived from 
exposure of cells cultured in vitro could serve as a strong predictor of clinical 
outcomes in breast and ovarian cancers [131]. If it becomes possible to extend 
this type of analysis to identify specific patterns of hypoxia in tumors, it may 
be possible to choose specific hypoxic-directed therapies with greater rationale. 
However, for this to occur a more complete understanding of the proteins 
regulated by different patterns of hypoxia and the contribution of individual 
hypoxia responses to these changes is required. A substantial effort at 
describing proteins and pathways regulated by HIF has occurred from many 
groups around the world. However, much less attention has been placed on the 
contribution of more recently described hypoxia response pathways that 
influence protein expression through changes in mRNA translation. The focus 
of this thesis is to investigate the mechanisms and consequences of changes in 
mRNA translation during hypoxia. In chapter 6 we address the presence of 
reactive oxygen species (ROS) in cancer cells and the effect on mRNA 
translation. 
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6. OUTLINE OF THIS THESIS 
 
The first goal of this thesis was to investigate the molecular pathways that 
mediate mRNA translation inhibition during hypoxia. In chapter 2 we 
investigated the involvement of the family of eukaryotic initiation factors 
(eIF2α and eIF4F complex) on the inhibition of protein synthesis during 
hypoxia. To assess the requirement of eIF2α phosphorylation for overall 
translation inhibition during hypoxia we examined the response of mouse 
embryo fibroblasts (MEFs) derived from eIF2α knock-in mice containing an 
S51A mutation, which are defective in phosphorylation of eIF2α during 
hypoxia. To investigate the contribution of the eIF4F complex on protein 
translation inhibition, we analyzed the levels of eIF4E and proteins that 
associate with it as an active complex (eIF4G) or as an inactive complex (4E-
BP1) during hypoxia. Using a sucrose gradient (polysome assays) we also 
analyzed the effect of hypoxia on specific gene expression by evaluating the 
translation efficiency for several hypoxia responsive genes. 
 
The influence of changes in mRNA translation initiation during hypoxia 
on hypoxic induced gene expression was then determined (chapter 3). To 
evaluate the contribution of changes in mRNA abundance versus mRNA 
translation for each gene, DU145 prostate carcinoma cells were exposed to 4 h 
of hypoxia (<0.02% O2). Efficiently translated mRNAs were isolated by 
sedimentation through a sucrose gradient. Affymetrix microarray technology 
was used to evaluate both the transcriptional and translational contribution to 
gene expression. 
 
In chapter 4, we evaluated the effect of 4EBP1 expression on 
translation in HeLa cells during both normoxic and hypoxic conditions. In 
other to investigate this we generated HeLa cells stably expressing a shRNA 
against 4E-BP1. Using polysome assays and a 2D gel electrophoresis approach, 
we assessed the effects of 4E-BP1 on overall protein translation and on specific 
protein expression, respectively.  
 
In chapter 5 we investigated if 4E-BP1 knock-down would 
demonstrate the same characteristics on tumor-growth as the overexpression of 
the oncogene eIF4E. We analyzed the clonogenic survival of shRNA 4EBP1 
HeLa cells under different time points of hypoxia and developed U87 cells 
stably expressing a shRNA against 4E-BP1, which were used for our in vivo 
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experiment. We monitored tumor growth and investigated the effect of 1 dose 
(10 Gray) of irradiation on our tumor model. Tumor sections were prepared 
and stained for hypoxia, proliferation and apoptosis. Immunohistochemistry 
was performed on tumor sections to assess differences in hypoxia, ATP levels, 
blood vessels density, proliferation and apoptosis between U87 tumors 
expressing a shRNA against 4E-BP1 and their wild type counterparts.  
 
In chapter 6, we analyzed the effect of reoxygenation on overall 
protein expression using a 2D gel electrophoresis approach to identify specific 
proteins that were upregulated during reoxygenation. 
 
Finally in chapter 7 a summary and discussion with future perspectives 
is presented.  
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ABSTRACT 
 
Hypoxia has recently been shown to activate the endoplasmic reticulum kinase 
PERK leading to phosphorylation of eIF2α and inhibition of mRNA translation 
initiation. Using a quantitative assay we show that this inhibition exhibits a 
biphasic response mediated through two distinct pathways. The first occurs 
rapidly reaching a maximum at 1-2 hrs and is due to phosphorylation of eIF2α. 
Continued hypoxic exposure activates a second, eIF2α independent pathway 
that maintains repression of translation. This phase is characterized by 
disruption of eIF4F and sequestration of eIF4E by both its inhibitor 4E-BP1, 
and its transporter 4E-T. Quantitative RT-PCR analysis of polysomal RNA 
indicates that the translational efficiency of individual genes varies widely 
during hypoxia. Furthermore, the translation efficiency of individual genes is 
dynamic, changing dramatically during hypoxic exposure due to the initial 
phosphorylation and subsequent dephosphorylation of eIF2α. Together our 
data indicate that acute and prolonged hypoxia regulate mRNA translation 
through distinct mechanisms, each with important contributions to hypoxic 
gene expression. 
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INTRODUCTION 
 
The presence of hypoxic and anoxic areas in human tumors is well 
documented, and is prognostic for poor outcome (reviewed in [1, 2]). The 
clinical importance of tumor hypoxia results from its ability to protect cells 
against both radiation and chemotherapy and from the fact that it can provide a 
selection pressure for apoptotically resistant cells [3]. Furthermore, the cellular 
response to hypoxia causes important changes in gene expression that affect 
cell behavior and influence patient prognosis. There has been particular focus 
on changes mediated through the family of hypoxia inducible transcription 
factors (HIFs). HIF-1 and HIF-2 promote transcription of more than 60 
putative downstream genes (for a review see [4]) that affect hypoxia tolerance, 
energy homeostasis, angiogenesis and tumor growth. Although the 
transcriptional response to hypoxia is clearly very important [5-7], tumor cells 
also experience short, transient exposures to hypoxia and/or anoxia that occur 
over time frames too fast for an effective transcriptional response. Transient 
changes in oxygenation occur due to the abnormal vasculature found in most 
tumors, characterized by immature, leaky and improperly formed vessels. 
Perfusion of these vessels can change dynamically in time, leading to rapid but 
transient episodes of severe hypoxia in the tumor cells dependent upon them 
[8, 9]. Consequently post-transcriptional responses are presumably important 
for adaptation to cycling oxygenation in tumors.  
 
Control of mRNA translation during hypoxia is emerging as an 
important cellular response to hypoxia [10, 11]. Since protein synthesis is 
energy costly, inhibition of mRNA translation may represent an active 
response to prevent loss of energy homeostasis during hypoxia. Indeed, it has 
been shown that overall mRNA translation is severely but reversibly inhibited 
during hypoxia [10, 12, 13] with kinetics that precede ATP depletion [14]. 
Furthermore, regulation of mRNA translation can have a significant and rapid 
impact on individual gene expression. This is because the sensitivity of 
individual genes to changes in overall translation varies widely and in a manner 
that reflects the molecular mechanisms responsible for controlling translation 
[15, 16]. Regulation of gene expression through control of mRNA translation is 
important during various pathologies including cancer [17]. The mechanisms 
responsible for inhibiting translation during hypoxia are not yet fully 
understood. 
Chapter 2                                                                                              
54 
We have previously investigated the involvement of the endoplasmic 
reticulum (ER) kinase PERK in the hypoxia-induced down-regulation of 
protein synthesis [10]. PERK is activated as part of the evolutionarily 
conserved unfolded protein response (UPR) (reviewed in [18]). It 
phosphorylates eIF2α, a subunit of eIF2, which in its GTP-bound form recruits 
the aminoacylated tRNA to the 40S ribosomal subunit. The exchange of GDP 
for GTP is mediated by the guanine nucleotide exchange factor eIF2B. Ser51-
phosphorylated eIF2α inhibits eIF2B, resulting in inhibition of translation 
initiation. eIF2α-phosphorylation results in a set of molecular events 
collectively termed the integrated stress response (ISR). These include the 
inhibition of global mRNA translation in conjunction with induced expression 
of the transcription factor ATF4 and its downstream target genes [19]. We 
showed that hypoxia rapidly activated PERK which led to reversible 
phosphorylation of eIF2α [10]. Hypoxia-induced inhibition of protein synthesis 
was severely attenuated in cells without functional PERK. After prolonged 
periods of hypoxia, PERK-deficient cells did show partial inhibition, 
suggesting that protein synthesis is regulated through additional mechanisms. 
 
Another candidate mechanism for inhibiting translation during hypoxia 
is disruption of the cap-binding protein complex eIF4F, which consists of 
eIF4E, eIF4A and eIF4G (for recent reviews see [20, 21]). eIF4E participates 
in a protein bridge between the mRNA and the ribosome by its simultaneous 
interaction with the mRNA 5’ cap-structure and the large scaffolding protein 
eIF4G, which in turn interacts with eIF3 that is bound to the 40S ribosomal 
subunit. eIF4E is regulated through a set of binding proteins (4E-BPs) that bind 
reversibly to eIF4E in their hypo-phosphorylated form, and this obstructs the 
interaction between eIF4E and eIF4G. The 4E-BP1 protein becomes hyper-
phosphorylated in response to a number of stimuli, such as insulin, hormones, 
growth factors, mitogens and cytokines, as a result of activation of the PI3-
kinase/Akt/FRAPmTOR pathway [22].  
 
It remains unclear to what degree the lack of eIF4F assembly 
contributes to inhibition of translation during tumor hypoxia. Several studies 
have investigated the combined consequences of ischemia/reperfusion on 
eIF4F-related proteins in rat brains (reviewed in [23]). Proteolysis of eIF4G 
was reported during ischemia and reperfusion in vivo [24, 25], but not in 
neuronal cells cultured in vitro (NGF differentiated PC12 cells) [26]. The 
reports addressing the expression and phosphorylation status of eIF4E during 
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ischemia are conflicting, but 4E-BP1 dephosphorylation has been demonstrated 
both in vivo and in vitro [25, 26]. The acuteness and complexity of 
ischemia/reperfusion stress and the high sensitivity of neurons to deprivation 
and reconstitution of both oxygen and nutrients are distinct properties of this 
model system and thus difficult to extrapolate to tumor hypoxia. In rat 
hepatocytes, 4E-BP1 becomes dephosphorylated and associates with eIF4E 
rapidly (15-60 min) upon mild hypoxia, but this could not explain the observed 
down-regulation of protein synthesis [27]. More recently it was reported that 
hypoxia could influence 4E-BP1 phosphorylation by affecting the activity of 
mTOR [28]. Serum starved and hypoxic human embryonic kidney cells failed 
to activate mTOR, phosphorylate 4E-BP1 and dissociate 4E-BP1 from eIF4E 
in response to insulin treatment. Nonetheless, it remains unknown whether 
hypoxia alone is sufficient to disrupt the eIF4F complex and to what extent this 
influences overall translation during hypoxia. Here we show that hypoxia 
induces a biphasic inhibition of mRNA translation characterized by transient 
phosphorylation of eIF2α and subsequent dissociation of eIF4F. These two 
mechanisms operate independently of each other and both have important 
consequences for gene expression during hypoxia.   
 
 
MATERIALS AND METHODS 
Cell culture  
Exponentially growing cervical carcinoma HeLa cells (American Type Culture 
Collection CCL-2), lung adenocarcinoma A549 cells, normal human 
fibroblasts (AG1522) or mouse embryo fibroblasts (MEFs) that were wild type 
or had a homozygous knock in mutation for eIF2α (S51A) [29] were grown on 
glass dishes or chamber slides in DMEM media supplemented with 10% fetal 
calf serum (FCS). The MEF media also contained MEM non-essential amino 
acids and 55μM 2-mercaptoethanol (all Sigma-Aldrich). For preparation of 
extracts and viability assessments, see supplementary materials and methods. 
Hypoxic conditions 
Cells were transferred to a hypoxic culture chamber (MACS VA500 
microaerophilic workstation, Don Whitley Scientific). The composition of the 
atmosphere in the chamber consisted of 5% H2, 5% CO2, 0.0% O2, and residual 
N2. 
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m GTP resin precipitation7
One mg of HeLa extract was incubated with 25 µl of m7GTP sepharose resin 
(Amersham Biosciences) for 3 h at 4°C. The resin was washed, boiled in 
Laemmli buffer and the polypeptides were resolved by SDS–PAGE. 
 
Western blotting 
Cell extracts were boiled in Laemmli buffer and polypeptides were resolved by 
SDS–PAGE and transferred onto 0.2 µm nitrocellulose membranes (Amersham 
Corp.). For primary antibodies, see supplementary materials and methods. 
Detection of peroxidase-coupled secondary antibodies was performed with 
Enhanced Chemiluminescence (Amersham Corp.).  
Immunofluoresence 
Cells were fixed with 4% paraformaldehyde and permeabilised in 4% 
paraformaldehyde and 0.1% Triton X-100. For antibodies, see supplementary 
materials and methods. Cells were mounted in ProLongTM Antifade Kit 
(Molecular Probes) and analyzed with a Zeiss inverted LSM 410 laser scan 
confocal microscope.  
Polysomal fractionation and analysis 
Polysomal fractionation and analysis was performed as previously described 
[30]. 
 
RNA isolation and reverse transcription 
RNA isolation and RT was performed as previously described [30]. 
 
Quantitative PCR analysis 
Real-time PCR was performed in either ABI 7700 or ABI 7500 (Applied 
Biosystems). For primers and probes, see supplementary materials and 
methods. Unfractionated samples were normalized by 18S rRNA signal. 
Samples from polysome fractions were normalized by 18S rRNA measured by 
PCR divided by 18S rRNA measured by spectrometry during fractionation, 
corrected for loading. This facilitated correction for any differences in RNA 
isolation or reverse transcriptase efficiency between samples. The abundance 
of every gene was calculated relative to a master reference using standard 
curves. 
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RESULTS 
 
Kinetics of translation inhibition 
To determine the effects of hypoxia on mRNA translation initiation in HeLa 
cells we examined the association of ribosomes with mRNA at various time 
points. In this assay, the number of ribosomes found within the ‘polysomal’ 
fraction of mRNA (mRNA containing 2 or more ribosomes) is a relection of de 
novo protein synthesis. This technique is advantageous to other methods such 
as 35S incorporation which requires prior amino acid starvation, a procedure 
that can itself influence translation initiation [31]. Figure 1A shows that at all 
time points examined, hypoxia causes a large decrease in polysomal mRNA 
and a corresponding increase in free ribosomes and ribosomal subunits. The 
reduction in translation is not influenced by cell death as cell viability remains 
above 90% following 16 hours of hypoxia (data not shown). Furthermore, the 
inhibition of translation is completely reversible upon reoxygenation (data not 
shown).  
 
To quantitatively assess overall mRNA translation from the polysome 
profiles, we calculated the percentage of rRNA participating in polysomes and 
defined this as the overall translation efficiency. This value is reduced from 
62% to 24% after one hour of hypoxia, and then recovers somewhat stabilizing 
at ~30% (Figure 1B). The drop in translation reproducibly exhibited this 
biphasic response with maximum inhibition after 1 to 2 hours, followed by a 
small recovery. The magnitude of inhibition is comparable to that observed 
following complete disruption of the cellular redox environment with 1mM 
DTT (17%) (data not shown).  
 
Analysis of the polysome profiles in Figure 1A shows that hypoxia also 
causes a change in the distribution of the polysomal mRNA, with 
proportionally less signal in the higher molecular weight fractions. This 
indicates that the average number of ribosomes per mRNA transcript is also 
decreased during hypoxia, reflecting a reduction in translation initiation 
efficiency even for those transcripts that remain translated. From the polysome 
profiles we calculated the average number of ribosomes per translated 
transcript (i.e. mRNAs containing two or more ribosomes) at different time 
points during hypoxia (Figure 1C). The kinetics of this parameter follow in 
large part that of the overall translation.  
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Figure 1: Hypoxia inhibits mRNA translation. HeLa cells were exposed to 0.0% O2 for 0–16 h 
and cell lysates were separated on a sucrose gradient. (A) The optical density (OD) at 254 nm 
is shown as a function of gradient depth for each time point. Actively translated mRNA is 
associated with high-molecular-weight polysomes deep in the gradient. (B) Translation 
efficiency in HeLa cells as a function of time in 0.0% O2. As a measure of overall translation 
efficiency, the relative amount of rRNA participating in polysomes was estimated. This 
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fraction is proportional to the integrated area under the curve containing polysomes, as marked 
in (A). (C) The average number of ribosomes per mRNA in the polysomes as a function of 
time in 0.0% O2. This was calculated by differential integration of the profiles in (A). 
 
 
eIF2α regulates translation during acute hypoxia 
The eIF2α kinase PERK is at least partly responsible for protein synthesis 
inhibition during acute hypoxia, as measured by radioactive labeling of newly 
synthesized proteins [10]. Thus, we hypothesized that the rapid inhibition and 
subsequent partial recovery in translation is due to changes in eIF2α 
phosphorylation. Indeed we found that the phosphorylation of eIF2α is greatest 
after 1-2hr and then decreases by 8hr of hypoxia in several cell lines (Figure 
2A). ATF4 protein levels also increase and then decrease during hypoxia in a 
manner that mirrors eIF2α phosphorylation. The dynamics of eIF2α 
phosphorylation and ATF4 protein induction thus correlate with the initial 
inhibition of translation and its subsequent recovery.  
 
To assess the requirement of eIF2α phosphorylation for translation 
inhibition during hypoxia we examined the response of mouse embryo 
fibroblasts (MEFs) derived from eIF2α knock-in mice containing a S51A 
mutation [29]. As expected, these cells were defective in phosphorylation 
eIF2α during hypoxia (Figure 2B). The translation efficiency in WT MEFs is 
similar to that in HeLa cells, with a rapid drop during acute hypoxia followed 
by a partial recovery (Figure 2C). In contrast, S51A MEFs display a substantial 
defect in their ability to inhibit translation during the initial phase. Nonetheless, 
after 16 hours of hypoxia both cell lines show a similar loss in translation 
efficiency. These data indicate that eIF2α phosphorylation is indeed necessary 
for inhibition of translation during acute hypoxia, but not at later times.  
 
When the polysome profiles are analyzed in terms of the average 
number of ribosomes per translated transcript, S51A MEFs exhibit an even 
stronger defect in their response during acute hypoxia. Despite a small but 
detectable drop in translation efficiency during the first 4 hours of hypoxia 
(Figure 2C), S51A MEFs show no decrease in the average number of 
ribosomes per translated transcript (Figure 2D). The same result was found in 
cells treated with DTT, a known activator of PERK that causes eIF2α 
phosphorylation. In contrast, WT MEFs show a strong reduction in average 
ribosomes per transcript during both acute hypoxia and DTT treatment. 
Interestingly, after 8 hours of hypoxia the average number of ribosomes per 
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translated transcript increases again towards normal levels in WT cells and is 
equivalent to that in S51A MEFs by 16 hours. These data provide further 
evidence that the inhibition of translation that occurs after acute and prolonged 
hypoxia are mechanistically distinct.                                                                                   
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Figure 2: Inhibition of translation during acute hypoxia is dependent on eIF2α. HeLa cells, 
A549 cells, human normal fibroblasts (NF) and WT or S51A MEFs were exposed to 0.0% O2 
for 0–16 h, 1 mM DTT or serum starvation (SS) for 1 h. Cell lysates were separated by SDS–
PAGE. Immunoblots for (A) HeLa, A549 and NF or (B) MEFs were performed using 
antibodies against total or phosphorylated eIF2α, ATF4 and β-actin. In (A), optical 
densitometry for phosphorylated eIF2α or ATF4 normalized by total eIF2α is also shown. Total 
eIF2α expression has previously been shown to be constant during hypoxia [10]. (C) Cell 
lysates were separated on a sucrose gradient, and OD at 254 nm was recorded. Translation 
efficiency as a function of time in 0.0% O2 in WT and S51A MEFs was estimated as in Figure 
1. (D) Average number of ribosomes per mRNA in the polysomes in WT and S51A MEFs as a 
function of time in 0.0% O2 was calculated as in Figure 1. 
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Disruption of the eIF4F complex during hypoxia 
The assembly of the cap-binding complex eIF4F is a common control point for 
translation initiation and was thus a likely candidate for maintaining low rates 
of translation during prolonged hypoxia. We examined the levels of eIF4E and 
proteins that associate with it as an active complex (eIF4GI) or as an inactive 
complex (4E-BP1). Figure 3A shows that the levels of eIF4E do not change 
during hypoxia. In contrast, 4E-BP1 (Figure 3B) shows both a small induction 
at 8 hours and a strong dephosphorylation after 16 hours of hypoxia. This 
protein runs as different migrating bands representing different 
phosphorylation levels [32]. The fastest migrating band is substantially 
increased after 16 hours of hypoxia, and represents the hypo-phosphorylated 
4E-BP1 which is known to have a higher affinity for eIF4E. A small decrease 
in the abundance of the scaffold protein eIF4GI (Figure 3C) was observed after 
8 hours, consistent with a decrease in its rate of synthesis measured in 
microarray study using polysomal RNA (unpublished data). Overexposure of 
the blots indicated no reproducible changes in cleavage of eIF4G. The 
influence of hypoxia on 4E-BP1 phosphorylation appears to be largely 
independent of eIF2α phosphorylation as it is not differentially affected in the 
WT and S51A MEFs (unpublished data). However until the relative 
contributions of various upstream signaling pathways to 4E-BP 
phosphorylation under hypoxia are better understood, it is premature to 
conclude that no connection between eIF2α and eIF4F exists. 
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Figure 3: Expression of eIF4E, 4E-BP1 and eIF4GI during hypoxia. HeLa cells were exposed 
to 0.0% O2 for 0–16 h and cell lysates separated by SDS–PAGE. Immunoblots were performed 
using antibodies against β-Actin, (A) eIF4E, (B) 4E-BP1 and (C) eIF4GI. The phosphorylation 
forms of 4E-BP1 have different electrophoretic mobilities and are represented by several bands 
on the immunoblot. Full-length eIF4GI run at about 220 kDa; the blot is overexposed to detect 
cleavage products. 
 
 
To more strictly assess the influence of hypoxia on eIF4F, we 
investigated the association of eIF4E with eIF4GI and eIF4GII as well as with 
its inhibitor 4E-BP1 in HeLa cells. During aerobic conditions where translation 
is efficient, eIF4E is associated with large amounts of both eIF4GI and 
eIF4GII, and only a small amount of 4E-BP1 (cap lanes in Figure 4A and B). 
Cap-associated eIF4G migrated somewhat slower than the overall pool of 
eIF4G, suggesting a possible modification of this phospho-protein when bound 
to the cap. In contrast, after 4 or 16 hours of hypoxia there is a dramatic loss in 
binding to both eIF4GI and eIF4GII indicating dissociation of the eIF4F 
complex. At 16 hours this dissociation correlates with a large increase in 
binding between eIF4E and 4E-BP1, consistent with the increase in the hypo-
phosphorylated levels of 4E-BP1 at this time. It also correlated with decreased 
phosphorylation of eIF4E (data not shown) at 16 hours, but the physiological 
significance of this remains unclear. However, although dissociation of eIF4G 
and eIF4E is complete after 4 hours of hypoxia, a corresponding change in 
eIF4E phosphorylation or eIF4E/4E-BP1 association is not seen at this time 
point. This suggests that a mechanism distinct from 4E-BP1 dephosphorylation 
may also inhibit eIF4F during hypoxia.  
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Figure 4: eIF4F is disrupted during prolonged hypoxia. HeLa cells were exposed to 0.0% O2 
for 0–16 h and cell lysates probed for the presence of various eIF4E complexes. Lysates were 
incubated with an m7-cap analogue (‘Cap’) or uncapped resin as a negative control. 
Immunoblots were performed with antibodies against actin, (A) eIF4GI, eIF4E, 4E-BP1 and 
(B) eIF4GII. ‘Cap’: proteins bound to the capped resin; ‘Resin’: proteins bound to the 
uncapped resin; ‘C-FT’: unbound fraction after incubation with capped resin; ‘R-FT’: unbound 
fraction after incubation with uncapped resin. 
 
 
Translocation of eIF4E by 4E-T 
A potential cause of eIF4F disruption that has not been well characterized is 
the translocation of eIF4E to the nucleus or to cytoplasmic bodies of mRNA 
processing (P-bodies). 5-20% of eIF4E is known to localize to the cell nucleus 
[33]. The shuttling protein 4E-T is the only known regulator of eIF4E 
localization and is capable of binding and transporting it to the cell nucleus 
[34]. eIF4E also colocalizes with 4E-T in P-bodies, where mRNA is degraded 
or stored [35]. Hypoxia caused a redistribution of both eIF4E and 4E-T from 
predominantly cytoplasmic staining under aerobic conditions to substantial 
nuclear staining during hypoxia (Figure 5A-C). This redistribution occurred 
progressively over time in hypoxic conditions, correlating with the gradual 
dephosphorylation of 4E-T (Figure 5D). In addition, hypoxic cells exhibit 
significant eIF4E and 4E-T staining in the peri-nuclear area which may be 
associated with the nuclear envelope or the endoplasmic reticulum. 
Interestingly, hypoxia also caused 4E-T to concentrate in peri-nuclear speckles 
which could represent P-bodies.  
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Figure 5: 4E-Tand eIF4E relocalize during hypoxia. HeLa cells were treated with 0.0% O2 for 
0–16 h. Cells were stained with DAPI and (A) a polyclonal antibody against eIF4E, (B) a 
polyclonal antibody against 4E-T or (C) a monoclonal antibody against eIF4E and a polyclonal 
antibody against 4E-T. Cells were visualized by confocal microscopy and individual pictures 
merged to determine colocalization. (D) Cell lysates were separated by SDS–PAGE and 
immunoblots performed using antibodies against 4E-T. A crossreacting band is indicated (*). 
 
 
Gene-specific regulation of translation 
Since translation efficiency is highly gene specific we anticipated that 
individual genes would show different patterns of translation efficiency during 
acute and prolonged hypoxia. To investigate this we fractionated polysomal 
mRNA and subsequently measured the mRNA abundance of individual genes 
by quantitative RT-PCR (Figure 6A). We first confirmed that concomitant with 
an increase in polysome-association, the non/sub-polysomal abundance 
decreased (data not shown). Subsequently we quantified both the transcript 
recruitment and distribution within the polysomes (expressed as the relative 
fraction of translated transcripts and the average number of ribosomes per 
translated transcript respectively).  
 
We first measured the translational profile of the housekeeping gene β–
actin (Figure 6B). In aerobic cells it is efficiently translated with a majority of 
the mRNA in polysome fractions 5 and 6. After 1 hour of hypoxia there is a 
marked reduction in translation as evidenced by a shift towards the lower 
polysome fractions, which recovers considerably by 16 hours. The drop in 
translation efficiency at 1 hour is due to reductions in both the relative fraction 
of translated mRNA as well as to a reduction in average number of ribosomes 
per translated transcript (Figure 6B). At later time points, only the average 
number of ribosomes per transcript remained low. The kinetic changes in 
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translation efficiency for β-actin are similar to those observed for overall 
translation efficiency.  
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Figure 6: Gene-specific regulation of translation during hypoxia. HeLa cells were exposed to 
0.0% O2 for 0–16 h and cell lysates were separated on sucrose gradients. (A) Fractions were 
collected as indicated, RNA was isolated and reverse transcribed. Thereafter, the total mRNA 
abundance of (B) β-Actin, (C) CAIX, (D) ATF4, (E) CHOP and (F) GADD34 was determined 
using real-time quantitative PCR. The left panel shows total mRNA levels from unfractionated 
samples, normalized by 18S rRNA signal. The following three panels use black, gray and 
white bars to represent the gene abundance in polysome fractions following 0, 1 or 16 h 
hypoxia, respectively. The last two graphs show components of translation efficiency. This 
includes the relative fraction of transcripts in polysomes (i.e. corrected for total mRNA 
abundance) and the average number of ribosomes per mRNA. Graphs show the average from 
two independent experiments, and the histograms show the results from one representative 
experiment. 
 
 
Many proteins are induced at the transcriptional level by hypoxia and 
we suspected that these genes might be preferentially translated during 
hypoxia. We investigated the translation of the HIF-1 target gene carbonic 
anhydrase IX (CAIX), which is important for tumor cell growth and survival 
during hypoxia [36]. Figure 6C shows a ~500 fold transcriptional induction of 
CAIX during hypoxia. Polysome analysis indicates that, similar to β-actin, 
CAIX is initially efficiently translated but severely inhibited after 1hr of 
hypoxia. A significant restoration of the polysome distribution occurs after 16 
hours and thus ensures protein synthesis at this time where there is also 
significantly more cellular mRNA. As for β-actin, the initial inhibition of 
CAIX translation is due to a drop in both recruitment of the mRNA into 
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polysomes and in the number of ribosomes per transcript. However, during 
prolonged hypoxia, the mRNA recruitment recovers and lower translation 
efficiency is attributed only to a small reduction in the average number of 
ribosomes per transcript.  
 
ATF4 is a central transcription factor mediating the unfolded protein 
response (UPR) following ER stress. Both thapsigargin (which causes ER 
stress) and 16 hours of hypoxia result in eIF2α phosphorylation and 
translational induction of ATF4 in a PERK dependent manner [13, 16, 37]. 
Under normal conditions, the translation efficiency of this gene is low with 
most of the mRNA found in fractions 1-3 (Figure 6D). In direct contrast to β-
actin and CAIX, its translation is substantially increased during acute hypoxia, 
due to both increased recruitment into the polysomes and to an increase in the 
average number of ribosomes per transcript. In agreement with Blais and 
colleagues, we also observed a further increase in ATF4 translation efficiency 
during prolonged hypoxia [37].  
 
An important transcriptional target of ATF4 is the C/EBP transcription 
factor CHOP [38], which induces cell cycle arrest and apoptosis during ER 
stress. Figure 6E shows that CHOP is both transcriptionally and translationally 
regulated by hypoxia. Translation is only moderately inhibited during acute 
hypoxia, as shown by a drop in average number of ribosomes per transcript. 
However, this reduction is much smaller than average overall reduction (Figure 
1C) and the reductions observed for both β-actin and CAIX. After 16 hours of 
hypoxia, translation of CHOP is stimulated as indicated by a recovery in the 
number of ribosomes per transcript and a marked increase in the fraction 
translated mRNA.  
 
Recovery from ER stress requires the GADD34 gene, which is induced 
in a PERK [39] and CHOP [40] dependent manner. GADD34 stimulates the 
activity of PP1c to dephosphorylate eIF2α. We found that, like CHOP, 
GADD34 is both transcriptionally and translationally regulated during hypoxia. 
Interestingly, its translation efficiency is highest after 4 hours of hypoxia, 
which coincides with the start of recovery from eIF2α phosphorylation and 
overall translation inhibition (Figure 6F). In contrast, GADD34 mRNA is 
unable to completely bypass the translation inhibition after 16 hours.  
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Gene-specific regulation of translation – dependence upon eIF2α 
The gene specific changes in translation noted above likely reflect the 
underlying eIF2α and eIF4F dependent mechanisms of translation control 
during hypoxia. We thus analysed gene-specific translation in WT and S51A 
MEFs to establish the dependence of individual genes on eIF2α regulation 
(Figure 7). In contrast to the WT MEFs, the S51A MEFs show no loss in 
translation efficiency of β-actin or CAIX during acute hypoxia (7A and B). 
The loss in translation efficiency for these genes in the WT cells is similar to 
that observed in HeLa cells and is due primarily to a reduction in the average 
number of ribosomes per transcript. For both of these genes the S51A MEFs 
show virtually no reduction in this parameter during the acute phase of 
hypoxia. However, in contrast to acute hypoxia, the translation efficiency 
during prolonged hypoxia is similar for these two genes in both cell lines.  
 
For ATF4, CHOP (data not shown) and GADD34 (Figure 7C), acute 
hypoxia causes a stimulation of translation in the WT MEFs that is similar to 
HeLa cells. However, the translational induction is entirely absent in the S51A 
MEFs. The increase in translation efficiency for GADD34 in the WT MEFs 
during acute hypoxia results mainly from an increase in the average number of 
ribosomes per transcript (Figure 7C). Cells that are defective in eIF2α 
phosphorylation show impaired regulation of this parameter. Thus, for all 
genes examined, the observed changes in translation efficiency during acute 
hypoxia are dependent on eIF2α phosphorylation.  
   A 
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Figure 7: Dependence on eIF2α-P for gene-specific translational regulation. WT and S51A 
MEFs were exposed to 0.0% O2 for 0–16 h and cell lysates were separated on sucrose 
gradients. RNA was isolated from polysome fractions and reverse transcribed. Thereafter, the 
abundance of (A) β-Actin, (B) CAIX and (C) GADD34 was determined using real-time 
quantitative PCR. The first three panels use black, solid grey, hatched grey and white bars to 
represent the gene abundance in polysome fractions following 0, 1, 4 or 16 h hypoxia, 
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respectively. The following graph depicts one component of translation efficiency, that is, the 
average number of ribosomes per mRNA. 
 
 
DISCUSSION 
 
Rapid and persistent down-regulation of protein synthesis is thought to be a 
means of energy preservation and to protect against the lethal effects of 
hypoxia [10, 11]. Here we show that the inhibition of global mRNA translation 
during hypoxia exhibits a biphasic response (Figure 8).  
 
 
Figure 8: Model of the effects of hypoxia on overall mRNA translation. Acute hypoxia causes 
transient eIF2α phosphorylation due to PERK activation as a part of the UPR. This results in 
inhibition of the rate of translation initiation. Following prolonged hypoxic conditions, 
activation of 4E-BP and 4E-T causes disruption of eIF4F, which inhibits the recruitment of 
mRNA to polysomes. Both molecular mechanisms affect specific mRNAs to varying degrees, 
resulting in differential gene expression. 
 
 
The initial rapid inhibition (i.e. 15 min – 4 hours) is primarily dependent on 
eIF2α phosphorylation, whereas inhibition during prolonged hypoxia is 
independent of eIF2α. Phosphorylation of eIF2α under conditions of anoxia is 
extremely rapid, occurring almost as quickly as we can establish hypoxia in our 
system (15-30 min). We have previously shown that eIF2α is also 
dephosphorylated under more moderate hypoxic conditions, although to a 
smaller degree and after longer times [10]. We speculate that this rapid 
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response may be especially important during the acute exposures to 
hypoxia/anoxia that frequently occur in tumors due to the transient opening and 
closing of blood vessels. This rapid response may explain the importance of 
eIF2α and ATF4 in the tolerance of cells to oxidative stress, which also occurs 
during hypoxia/reoxygenation cycles [19]. This hypothesis is supported by a 
recent study from Bi et al. showing that activation of the PERK-eIF2α pathway 
during hypoxia contributes to overall tumor growth. Both human tumor cells 
expressing a dominant negative PERK-allele and MEFs lacking PERK or 
expressing the S51A eIF2α produce smaller tumors with increased cell death 
in hypoxic areas than their wild-type counterparts [13]. Thus, although 
activation of eIF2α phosphorylation in response to hypoxia is transient, this 
response appears critical for long-term cell survival within hypoxic regions of 
tumors. 
 
 Inhibition of translation during prolonged anoxia is associated with 
disruption of the mRNA cap-binding complex eIF4F and sequestration of 
eIF4E by both dephosphorylated 4E-BP1 and 4E-T. To our knowledge, this 
report is the first to show a physiological stress-induced regulation of the 
localization of eIF4E and its transporter 4E-T. Accumulation of eIF4E in the 
cell nucleus or P-bodies renders it unavailable for cytoplasmic translation. 
Relocalisation of eIF4E may have additional roles apart from reducing cap-
dependent protein translation, including effects on mRNA processing, 
transport and degradation. Moderate hypoxia (1%) has also been shown to 
effect the eIF4F complex through inhibition of mTOR [28]. However, the 
kinetics and relative contributions of the eIF4F pathway on inhibition of global 
and gene-specific translation during more moderate hypoxia remains to be 
determined (see below). 
 
         Analysis of mRNA distribution within polysomes at different times also 
revealed interesting mechanistic differences during acute and prolonged 
hypoxia. Acute hypoxia caused a substantial drop in the average number of 
ribosomes per translated transcript. This presumably results from a reduction in 
the rate at which ribosomal subunits can be loaded onto mRNA, since each 
subunit requires a new non-phosphorylated eIF2α molecule. Inhibition of 
translation during prolonged hypoxia via eIF4F did not show this effect. 
Instead, translation was suppressed mainly by reducing the fraction of mRNA 
found within the polysomes. These results are consistent with a model in which 
the eIF4F cap-binding complex remains bound to the mRNA allowing 
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sequential rounds of initiation by available eIF2α complexes. When translation 
is inhibited via eIF4F, many transcripts will lack this cap binding complex and 
hence will not be competent to initiate translation. However, those transcripts 
that do contain eIF4F will be translated normally (Figure 8). A similar 
phenomenon has been observed for a subpopulation of mRNAs that contain 5’ 
terminal oligopyrimidine tracts (5’TOPs), which alternate between 
translationally repressed and active states in response to various stimuli 
(reviewed in [41]). It is thus conceivable that the overall reduction in mRNA 
translation observed during prolonged hypoxia affects a subset of genes, such 
as those with 5’TOPs, to a greater degree than others.  
 
An important issue that arises from our study is the nature of the 
oxygen sensing pathways upstream of eIF2α and eIF4F. Substantial evidence 
suggests that the oxygen sensors are largely independent of the HIF oxyen 
sensing pathway [42], [10]. In the case of eIF2α, its phosphorylation occurs in 
HIF independent manner. Instead it requires  PERK activation [10] and is 
associated with activation of the unfolded protein response (UPR) in response 
to ER stress [13, 43]. The upstream signaling that leads to eIF4F disruption is 
less clear, with perhaps both HIF dependent and independent components. 
Hypoxia has been shown to prevent insulin stimulation of mTOR and 
phosphorylation of its substrate 4E-BP1 during conditions of moderate hypoxia 
and serum starvation [28]. Similarly, Brugarolas and colleagues showed that 
induction of REDD1 during hypoxia resulted in activation of the mTOR 
inhibitory complex TSC1/TSC2 [44]. Since we also observe a decrease in the 
phosphorylation of 4E-BP1 after prolonged hypoxia, the eIF4F dependent 
changes in translation reported here may also be due in part to inhibition of 
mTOR via REDD1 and TSC1/2. However, it is unlikely that this accounts 
entirely for eIF4F disruption and translation inhibition during hypoxia. REDD1 
is a HIF dependent gene and both mTOR inhibition and translation inhibition 
during hypoxia occur in HIF1α knockout cells [10, 28]. There is no evidence 
that inhibition of REDD1 signaling prevents the inhibition of translation during 
prolonged hypoxia. Furthermore, our data indicate that eIF4F disruption occurs 
prior to substantial binding of eIF4E to 4E-BP1. Here we have identified 
redistribution of eIF4E into the cell nucleus via 4E-T as an additional 
mechanism for eIF4F disruption during hypoxia. Further work will be needed 
to establish to what degree inhibition of translation is due to suppression of 
mTOR/4E-BP1 phosphorylation and 4E-T activation, as well as to the 
requirements of HIF in both of these pathways. 
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The fact that both eIF2α and eIF4F independently affect translation 
during hypoxia has important implications for the regulation of gene 
expression. mRNAs preferentially translated during acute hypoxia must be less 
dependent on eIF2α availability, while mRNAs that are actively translated 
during prolonged hypoxia must be less dependent on eIF4F. The translation of 
ATF4, which contains 2  upstream open reading frames (uORFs) in its 5’UTR 
is perhaps the best example of a mammalian gene that displays this type of 
preferential translation [16]. When eIF2α availability is high, translation begins 
at the 5’ most uORF and re-initiation occurs efficiently at the subsequent uORF 
preventing translation from the correct start codon of ATF4. When eIF2α is 
phosphorylated, there is a higher probability of skipping the second uORF and 
re-initiating at the bona fide start codon [45]. Here, we found that in addition to 
ATF4, the downstream genes CHOP and GADD34 are also translationally 
induced during acute hypoxia. The S51A MEFs which are unable to 
phosphorylate eIF2α are defective in this translational regulation. This result is 
consistent with  a report showing that that ER stress-induced expression of 
GADD34 protein can be prevented by keeping eIF2α dephosphorylated [46], 
The ability of GADD34 to bypass the inhibitory effects of eIF2α 
phosphorylation may be responsible for its ability to provide the negative 
feedback necessary for dephosphorylation of eIF2α and recovery from ER 
stress. 
 
Our results predict that during prolonged hypoxia, gene transcripts with 
lower dependency on eIF4F should be preferentially translated. The translation 
of ATF4 and CHOP was in fact stimulated in HeLa cells after 16 hours of 
hypoxia when the eIF4F complex was disrupted. Preferential translation under 
conditions of limiting cap-binding complex activity can occur through a higher 
than average affinity for eIF4F [47]. Another group of mRNAs that can be 
translated independently of the eIF4F complex are those that contain an 
internal ribosomal entry site (IRES) in their 5’UTR [21, 48]. The presence of 
an IRES enables translation initiation under conditions where eIF4F dependent 
translation is inhibited. Importantly, both mouse HIF-1α and VEGF have been 
shown to contain functional IRESes within their 5’UTR [49, 50], although their 
biological importance is not yet firmly established. This provides a mechanism 
to ensure their translation during prolonged hypoxia where eIF4F is disrupted. 
The mechanism responsible for the selective translation of ATF4 and CHOP 
during prolonged hypoxia remains to be identified. 
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  In conclusion, we have shown that mRNA translation is inhibited 
through multiple independent pathways with differing activation kinetics 
during hypoxia. These distinct modes of translational control influence the 
translation of individual genes to varying degrees and consequently can 
influence hypoxia regulated protein expression in complex ways. An important 
finding is that inhibition of translation via eIF2α is transient leading to dynamic 
changes in the translation efficiency of genes over the first 8 hours of hypoxia. 
Our selected analysis of gene translation during hypoxia suggests that many 
genes may be differentially regulated by hypoxia. A complete survey of the 
genome for differentially translated genes during various exposures to hypoxia 
and their dependence of eIF2α is possible and will undoubtedly identify novel 
and important hypoxia regulated proteins. 
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ABSTRACT 
 
Hypoxia causes a rapid reduction in mRNA translation efficiency. This 
inhibition does not affect all mRNA species to the same extent and can 
therefore contribute significantly to hypoxia-induced differential protein 
expression. Our aim in this study was to characterize changes in gene 
expression during acute hypoxia and evaluate the contribution of regulation via 
mRNA translation on these changes. For each gene, the contribution of 
changes in mRNA abundance versus mRNA translation was determined. 
DU145 prostate carcinoma cells were exposed to 4 hours of hypoxia (<0.02% 
O2). Efficiently translated mRNAs were isolated by sedimentation through a 
sucrose gradient. Affymetrix microarray technology was used to evaluate both 
the transcriptional and translational contribution to gene expression. Results 
were validated by quantitative PCR. 120 genes were more than 4-fold 
upregulated by hypoxia in the efficiently translated fraction of mRNA, in 
comparison to only 76 genes at the level of transcription. Of the 50 genes 
demonstrating the largest changes in translation, 11 were found to be more than 
2-fold over represented in the translated fraction in comparison to their overall 
transcriptional level. The gene with the highest translational contribution to its 
induction was CITED-2, which is a negative regulator of HIF-1 transcriptional 
activity. Gene-specific regulation of mRNA translation contributes 
significantly to differential gene expression during hypoxia. 
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INTRODUCTION 
 
The presence of hypoxic (poorly oxygenated) areas in human solid tumors is 
well documented [1-9]. Hypoxia causes radiation resistance and limits 
radiotherapy efficacy [2-4, 10, 11]. Tumor hypoxia has also been associated 
with a lower susceptibility to apoptosis [12, 13], increased angiogenesis [14-
17] as well as higher metastatic and invasive potential [2, 10, 18-20]. The 
cellular response to hypoxia which underlies its negative impact on tumor 
biology is believed to be due in large part to dynamic changes in gene 
expression.  
 
A vast number of hypoxia-induced changes in gene expression have 
been described. There has been particular focus on changes mediated through 
the hypoxia inducible transcription factor HIF-1. HIF-1 promotes transcription 
of its target genes through binding a conserved hypoxia responsive element 
(HRE) gene promoter together with its co activator CBP/p300. More than 60 
putative downstream target genes have been identified (for a review see [21]), 
including genes involved in glycolysis (e.g. PGK-1) [22], angiogenesis (e.g. 
VEGF) [23, 24], pH regulation (CA9) and survival (e.g. EPO) [25, 26]. HIF-1 
is activated during hypoxia through protein stabilization of its subunit HIF-1α, 
which is targeted for ubiquitin mediated degradation by pVHL (von-Hippel 
Lindau) during normoxia [27]. 
 
Although the transcriptional response to hypoxia is clearly very 
important, cells in normal and cancerous tissue often experience short transient 
exposures to hypoxia which do not allow sufficient time for a productive 
transcriptional response [28-30]. However, a biological response to acute 
hypoxia is presumably required to maintain energy homeostasis and provide 
adaptation to the quickly changing redox microenvironment. A potentially 
important point for regulating gene expression that is able to respond rapidly to 
changes in the microenvironment is the process of mRNA translation (protein 
synthesis). Indeed, it has been shown that overall mRNA translation is severely 
but reversibly inhibited during hypoxic conditions [13, 31, 32], and this 
inhibition can be detected after only a few minutes of oxygen deprivation. The 
hypoxia-induced inhibition in mRNA translation is at least in part mediated 
through PERK-dependent phosphorylation of the translation initiation factor 
eIF2α [31]. PERK is known to be activated in response to endoplasmic 
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reticulum (ER) stress suggesting a possible mechanism through which oxygen 
activates this pathway.  
 
Protein synthesis is the highest cellular consumer of ATP [33, 34], and 
thus its inhibition during hypoxia probably serves to maintain energy 
homeostasis. However, it is important to realize that the inhibition of global 
mRNA translation potentially affects different mRNA species (different genes) 
to highly varying degrees. This variation is based on the fact that mRNAs from 
different genes have different dependencies and/or affinities for the cellular 
translation machinery [35, 36]. Thus while some mRNAs may be completely 
dependent on the translation factors that are inhibited during hypoxia, others 
can remain translated through alternative mechanisms and thereby bypass the 
overall translation block. For example, the transcription factor ATF-4 is 
translationally induced by ER stress in spite of PERK-dependent eIF2α 
phosphorylation [35], and ATF-4 in turn causes transcriptional activation of a 
conserved gene expression program called the unfolded protein response 
(UPR) (reviewed in [37]). Hence, the inhibition of overall translation is a 
potentially powerful cellular tool for rapidly changing gene expression during 
hypoxia. 
 
In this study, our aim was to evaluate the translational contribution to 
differential gene expression during acute hypoxia. Utilizing Affymetrix 
microarray technology we here show that there are significant changes in gene-
specific mRNA translation efficiency during hypoxia.    
 
 
MATERIALS AND METHODS 
Cell culture and hypoxic conditions 
Exponentially growing cervical (HeLa) and prostate (DU145) carcinoma cells 
were seeded on glass dishes in DMEM or McCoy media with 10% foetal calf 
serum (FCS) (Sigma-Aldrich) and transferred to a hypoxic culture chamber 
(MACS VA500 microaerophilic workstation, Don Whitley Scientific, Shipley, 
UK). The atmosphere in the chamber consisted of 5% H2, 5% CO2, the desired 
concentration of O2 and residual N2. An anoxic atmosphere was ensured by the 
inclusion of a catalyst in the hypoxic chamber that catalysed the conversion of 
H2 with any O2 to H2O. 
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2D gel electrophoresis 
Cells were washed twice with ice-cold 10 mM Tris/250 mM sucrose buffer pH 
7.0 and lysed in a 7 M urea/2 M thiourea based lysisbuffer. The samples were 
applied to 24 cm pH 3-10 NL IPG strips (Amersham Biosciences). Following 
isoelectric focusing, the strips were placed on the Protean Plus Dodeca Cell 
(Bio-Rad Laboratories) to perform a second dimension separation using 12% 
SDS-PAGE gels. The gels were stained with SYPRO Ruby dye (Bio-Rad 
Laboratories) and imaged on a Molecular Imager FX (Bio-Rad Laboratories). 
Polysomal fractionation and analysis 
Cells were treated with 0.1 mg/ml cycloheximide (CHX) for 3min at 37oC, 
washed twice with ice cold PBS/CHX and harvested by scraping in lysis buffer 
(1% Triton X-100, 0.3M NaCl, 15mM MgCl2, 15mM Tris (pH 7.4), 0.1mg/ml 
CHX, 100 units RNAse-In (Ambion)) at 4 oC. Nuclei were removed, 200ug/ml 
heparin was added and residual debris was removed by centrifugation. The 
lysate was layered on a 10ml continuous sucrose gradient (20-50% sucrose in 
15mM MgCl2, 15mM Tris (pH 7.4), 0.3M NaCl). After 90 min of 
centrifugation at 39.000 rpm in an SW41-Ti rotor at 4oC, the absorbance at 
254nm was measured continuously as a function of gradient depth in a BioRad 
Laboratories UV monitor. To assess overall translation efficiency, we 
integrated the area under the curve that represented mRNA attached to 2 or 
more ribosomes, and compared this to the total area under the curve. 
 
RNA isolation 
Samples were collected in 0.55 M final concentration of guanidinium-HCl, 
subjected to 4 precipitation steps (ethanol, sodium acetate and lithium 
chloride), one phenol-chloroform extraction and one column extraction 
(RNeasy Mini Kit, Qiagen) with extensive washing in between. RNA quantity 
and quality was checked using the ND-1000 spectrometer (NanoDrop 
Technologies) and RNA Nano LabChip kit on the 2100 Bioanalyzer (Agilent) 
respectively.  
 
Affymetrix gene array measurements 
20 ng RNA was pooled from 3 independent experiments, representing total and 
highly efficiently translated RNA from aerobic and hypoxic cells. The RNA 
was processed according to the manufacturer’s standard protocol (Affymetrix) 
for 2-cycle amplification. The biotin-labelled samples were hybridized to HG 
U133 Plus 2.0 chips. GCOS software (Affymetrix) was used for the absolute 
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call (present, marginal, absent) of 54.675 probe sets. Intensities were filtered 
with a threshold of 200. Two lists of genes were generated by sorted according 
to (Polysomal Hypoxia)/(Polysomal Normoxia) intensity ratios or (Total 
Hypoxia)/(Total Normoxia) intensity ratios respectively.  
 
Quantitative PCR analysis 
The RNA was reverse transcribed using random decamers (Ambion) and MML 
reverse transcriptase (Sigma-Aldrich). Real-time PCR was performed in ABI 
7500 (Applied Biosystems). The abundance of the following genes were 
detected with SYBR® Green I (Applied Biosystems) using the indicated 
forward and reverse primers: β-Actin: F-accatggatgatgatatcgcc and R-
gccttgcacatgccgg; ATF-4: F-tggccaagcacttcaaacct and R-
gttgttggagggactgaccaa; DDIT3: F-ggagcatcagtcccccactt and R-
tgtgggattgagggtcacatc; VEGF: F-gactccggcggaagcat and R- tccgggctcggtgattta. 
The following genes were measured using TaqMan® Gene Expression Assays 
(Applied Biosystems): 18SrRNA: Hs99999901_s1 and EGLN3: 
Hs00222966_m1. The abundance of every gene was calculated using standard 
curves, and the relative gene abundances were normalized by 18S signal.  
 
 
RESULTS 
 
We have reported that hypoxia results in a rapid inhibition of mRNA 
translation. In order to investigate the potential contribution of this inhibition 
on protein expression we analyzed the cellular proteome after short (1 hr) and 
long (24 hrs) exposures to hypoxia. The proteome from aerobic or hypoxic 
HeLa cells was separated in two dimensions on the basis of charge and mass 
and proteins visualized by staining with SYPRO-Ruby. The early time point 
(1hr) was chosen to minimize the contribution of changes in transcription on 
protein expression. Thus, most of the changes in protein expression are due to 
post-transcriptional changes including the inhibition of mRNA translation 
which is maximal at this time. We compared the results at 1hr with the 
proteomic changes in chronically (24 hrs) hypoxic cells, where differential 
gene expression was assumed to be affected by both transcriptional and post-
transcriptional changes. This allowed us to assess the relative importance of 
post-transcriptional regulation during hypoxia. This experiment was repeated 
in triplicate thus producing 3 separate 2D-gels for each condition 
(representative gels from each experimental condition are shown in Figure 1A). 
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Proteins were matched across all gels to identify those that consistently showed 
changes during each of the experiments. The levels of these matched proteins 
during hypoxia and normoxia are plotted in Figure 1B.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Hypoxia-induced changes in 
the proteome. HeLa cells were 
exposed to hypoxia for 0, 1 or 24 hrs. 
Whole cell extracts were separated by 
2D gel electrophoresis. (A) The 
resolved proteins were stained with 
SYPRO Ruby dye and imaged on the 
Molecular Imager FX (Bio-Rad). (B) 
The gels were analysed using PDQuest 
software (Bio-Rad). The relative 
abundance of each matched protein 
during normoxia vs. hypoxia was 
plotted with the diagonal lines 
representing 2-fold changes. 
B 
A 
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Table 1 also lists the number of protein spots that showed strong consistent 
expression under one condition, but were not present in the other.  These spots 
are therefore likely to represent real induced or repressed proteins, and are not 
a result of technical artifacts. The substantial change in the hypoxic proteome 
visible within 1 hour suggests that post-transcriptional events are important 
regulators of protein expression under these conditions. 
 
Table 1: Hypoxia-induced changes in the proteome 
 
Hours of 
hypoxia 
Detected 
proteins 
Matched 
proteins 
>2-fold 
change 
Present only 
in normoxia 
 
Present only 
in hypoxia 
0 
1 
        24 
1440 
  982 
1102 
 
685 
882 
 
70 
77 
 
30 
20 
 
10 
25 
 
 
Regulation of mRNA translation efficiency, which is known to occur 
during hypoxia, is a possible mechanism that can influence the rapid changes 
in protein expression shown above. To assess overall mRNA translation 
efficiency in DU145 cells during hypoxic conditions, we separated cell lysates 
on sucrose gradients and then measured RNA levels as a function of gradient 
depth. The resulting profiles are shown in Figure 2A. The two shallowest peaks 
(readily detected in the aerobic sample) represent the 40S and 60S ribosomal 
subunits respectively. The subsequent peaks represent mRNAs with increasing 
numbers of attached ribosomes. Efficiently translated mRNA is associated with 
many ribosomes (polysomes) simultaneously and therefore sediments deep in 
the gradient. Figure 2A demonstrates that hypoxia inhibits overall translation in 
DU145 cells since there is a clear reduction in the high molecular weight 
polysomal RNA. The percentage of ribosomes participating in translation can 
be determined by integrating the polysomal area and dividing by the total 
integrated area. The average results from three independent experiments are 
presented in Figure 2B. This figure shows that the fraction of ribosomes 
participating in translation dropped from 74% in aerobic cells to 45% after 4 
hours of hypoxia. We also calculated the fraction participating in highly 
efficient translation (Figure 2A), which we defined as mRNA with 5 or more 
ribosomes. This fraction dropped from 48% to 20% after 4 hours of hypoxia.  
 
In order to investigate the potential contribution of changes in mRNA 
translation on hypoxia induced gene expression, we utilized microarray 
90 
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technology. Changes in mRNA translation were assessed by isolating RNA 
from the highly efficiently translated polysomal fractions as depicted in Figure 
2A. Transcriptional changes were assessed by isolating total mRNA from the 
same samples. Since this technique allowed us to evaluate both transcriptional 
and translational contributions to differential gene expression, we chose to 
measure these entities after 4 hours of hypoxia. At this time point both 
transcriptional and translational control of gene expression are expected to be 
active, and with the microarray technique we could directly compare these 
events. In addition to providing more information, this also allowed us to 
validate our results through literature comparison, since many hypoxia-induced 
transcriptional changes are well described. Equivalent RNA amounts from 
three independent experiments from cultures growing under normoxia or 
following 4 hours of hypoxia were pooled and then assessed using Affymetrix 
microarray chips containing 54,675 probe sets (including 38,500 well-
characterized human genes). 
 
 
A 
 
 
 
Figure 2: Hypoxia inhibits 
mRNA translation. DU145 cells 
were exposed to hypoxia for 0 
or 4 h. Whole cell extracts were 
separated by sedimentation 
through sucrose gradients. (A) 
Optical density (O.D.) at 254 
nm as a function of depth in the 
gradient. The area representing 
RNA that participates in 
complexes containing 2 or more 
ribosomes is marked as 
‘polysomes’. RNA was isolated 
for microarray and PCR analysis from the 
fraction indicated ‘highly translated 
fraction’. (B) Quantification of translation 
efficiency as the percentage of rRNA 
participating in complexes of two or more 
ribosomes. This equals the integration of the 
area under the ‘polysomes’ part of the curve 
divided by the total area under the curve. The 
‘highly translated fraction’ is also indicated. 
 
B 
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Figure 3 shows the scatter plots of gene intensities (log base 2) for 
hypoxic and aerobic samples. For all genes that demonstrate a less than 2-fold 
change during hypoxia, the plotted points fall within the two indicated parallel 
lines on these plots. Figure 3A summarizes the transcriptional (total RNA) 
changes during hypoxia. Of the 22,332 gene probe sets that could be evaluated, 
654 (3%) were induced more than 2-fold during hypoxia with 76 of these 
increasing more than 4-fold. Changes in the highly translated RNA fraction are 
summarized in Figure 3B. In this highly translated fraction we found that 1082 
genes (~5%) increased more than 2-fold during hypoxia with 120 of these 
increasing more than 4-fold. The amount of an individual gene in the highly 
translated mRNA fraction reflects both the total mRNA available for 
translation, as well as the gene’s translation efficiency. However, since both the 
total mRNA and the highly translated fraction of mRNA are known, it is 
possible to calculate the relative translation efficiency for each gene on the 
array. This is simply equal to the signal in the highly translated fraction divided 
by the signal from the total cell. We calculated the translation efficiency for 
each gene under both aerobic and hypoxic conditions to determine those genes 
exhibiting the largest increases in translation efficiency. Figure 3C shows that 
the translation efficiency of 508 genes increased more than 2-fold with 41 of 
these increasing more than 3-fold and 5 more than 4-fold. These results 
demonstrate that although overall translation is inhibited during hypoxia, a 
significant number of genes are induced through specific increases in their 
translation efficiency. 
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 A 
            
 
Figure 3: Microarray signal 
distributions. DU145 cells were 
exposed to hypoxia for 0 or 4 h. 
Whole cell extracts were separated by 
sedimentation through sucrose 
gradients. Equal amounts of RNA 
from three independent experiments 
were pooled. Gene-specific mRNA 
abundance in highly efficiently 
translated or unfractionated mRNA 
was measured using Affymetrix 
microarray technology. (A) and (B) 
Logarithm of raw (not normalized) 
intensities of probe sets under hypoxia 
vs. normoxia for total mRNA. The 
upper and lower diagonal lines 
represent the threshold for 2-fold 
expression changes. (A) Total, i.e. 
unfractionated mRNA in aerobic 
versus hypoxic samples. (B) mRNA 
with high translation efficiency in 
aerobic versus hypoxic samples. (C) 
Representation of the number of genes 
with hypoxia induced translation 
efficiency, calculated by dividing the 
gene abundance from the ‘highly 
translated fraction’ by that obtained 
from the unfractionated sample. 
B 
 
  C 
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Table 2 shows a ranked list of the 50 genes showing the largest increase 
in mRNA translation during hypoxia (derived from Figure 3B). Table 2 also 
lists the increase in total mRNA abundance and hence the component that can 
be attributed to changes in mRNA production and/or stability. The change in 
mRNA translation efficiency during hypoxia can be deduced by comparing 
these values. Of the 50 most highly induced genes, 11 demonstrated a 
significant contribution from changes in translation efficiency (more than 2-
fold increase in translation efficiency). For each of these genes, their rank 
within the top 50 was much higher than their rank evaluated by the increase in 
total mRNA levels. 
 
Table 2: Genes most highly induced by hypoxia measured by microarray 
 
Probe Gene Poly Total Ratio Ratio Ratio  Hypoxia Pathway Reference(s)
Poly symbole rank rank poly total poly:total induced    
202934_at HK2 1 2 30.1 24.6 1.2 yes HIF [22, 38] 
221009_s_at ANGPTL4 2 6 21.3 15.2 1.4 yes HIF [39, 40] 
202769_at CCNG2 3 1 16.7 29.4 0.6 yes HIF [41, 42] 
209357_at CITED2 4 42 16.0 5.4 3.0 yes HIF [43, 44] 
217028_at CXCR4 5 13 15.0 10.2 1.5 yes HIF [38, 45] 
235857_at KCTD11 6 7 14.6 14.3 1.0    
218507_at HIG2 7 30 13.9 6.7 2.1 yes HIF [38, 46] 
204284_at PPP1R3C 8 10 12.1 12.1 1.0 yes HIF [41, 44] 
229830_at PDGFA 9 20 11.7 8.2 1.4 yes  [47] 
203438_at STC2 10 9 11.5 12.9 0.9 yes HIF,UPR [41, 48] 
227337_at Lrp2bp 11 14 10.8 10.1 1.1    
242517_at GPR54 12 5 10.2 17.2 0.6    
223333_s_at ANGPTL4 13 8 10.2 13.2 0.8 yes HIF [39, 40] 
202887_s_at DDIT4 14 12 10.1 11.5 0.9 yes HIF [41, 49] 
202364_at MXI1 15 47 9.6 5.2 1.8 yes HIF [38] 
209383_at DDIT3 16 4 9.3 20.3 0.5 yes HIF,UPR [50, 51] 
228499_at PFKFB4 17 3 9.2 22.2 0.4 yes HIF [44, 52] 
206424_at CYP26A1 18 32 9.0 6.5 1.4    
209201_x_at CXCR4 19 21 8.6 8.1 1.1 yes HIF [38, 45] 
218274_s_at FLJ10415 20 75 8.4 4.0 2.1    
212366_at ZNF292 21 52 8.3 4.7 1.8    
221567_at NOL3 22 22 7.8 8.1 1.0    
218149_s_at ZNF395 23 62 7.8 4.3 1.8    
201170_s_at BHLHB2 24 26 7.5 7.2 1.0 yes HIF [42, 53] 
201313_at ENO2 25 67 7.5 4.1 1.8 yes  [44] 
208763_s_at DSIPI 26 29 7.5 6.7 1.1    
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203574_at NFIL3 27 24 7.5 7.7 1.0 yes  [41] 
201466_s_at JUN 28 36 7.5 6.0 1.2 yes HIF,UPR [44, 54, 55] 
205463_s_at PDGFA 29 59 7.3 4.4 1.7 yes  [47] 
202843_at DNAJB9 30 16 7.3 9.0 0.8  UPR [56] 
226863_at  31 123 7.3 3.4 2.2    
231798_at NOG 32 23 7.0 7.8 0.9    
1554452_a_at HIG2 33 19 6.8 8.3 0.8 yes HIF [38, 46] 
203439_s_at STC2 34 18 6.8 8.6 0.8 yes HIF,UPR [41, 48] 
215446_s_at LOX 35 114 6.8 3.4 2.0 yes HIF [38, 44] 
212368_at ZNF292 36 37 6.7 5.8 1.2    
202973_x_at FAM13A1 37 68 6.7 4.1 1.6    
200632_s_at NDRG1 38 17 6.4 8.9 0.7 yes HIF [44, 57] 
241348_at FLJ10997 39 130 6.3 3.3 1.9    
1554462_a_at DNAJB9 40 35 6.2 6.1 1.0  UPR [56] 
210512_s_at VEGF 41 39 6.1 5.6 1.1 yes HIF,UPR [22, 57-59] 
204285_s_at PMAIP1 42 159 6.1 3.0 2.0 yes HIF [60] 
209339_at SIAH2 43 459 6.0 2.2 2.7 yes  [61] 
211527_x_at VEGF 44 270 5.9 2.5 2.3 yes HIF,UPR [22, 57-59] 
224610_at RNU22 45 286 5.9 2.5 2.4    
202672_s_at ATF3 46 11 5.6 12.0 0.5  UPR [62] 
224797_at ARRDC3 47 56 5.5 4.6 1.2    
224741_x_at GAS5 48 277 5.5 2.5 2.2 yes  [63] 
219232_s_at EGLN3 49 433 5.4 2.2 2.4 yes HIF [64, 65] 
204286_s_at PMAIP1 50 174 5.4 2.9 1.9 yes HIF [60] 
          
 
 
As shown in Table 2, a majority of the 50 genes showing the largest 
changes in translation have previously been shown to be induced by hypoxia 
either at the mRNA or protein level. This result helps to validate the results 
presented here. To further validate our microarray data, we performed 
quantitative real-time PCR (qPCR) on several of the genes shown to be 
transcriptionally upregulated. The results from these validation experiments are 
shown in Figure 4. As a negative control, we measured the abundance of β-
actin, which was not induced by hypoxia on the microarray. As expected, β-
actin was also not induced when measured by qPCR. We also measured the 
mRNA abundance for ATF-4, EGLN3, VEGF and DDIT3. The results from 
the qPCR were consistent with the data from the microarray. In general, the 
induction factors were somewhat higher when measured by qPCR. This might 
be related to the fact that the gene abundance using this method is normalized 
Chapter 3 
by the abundance of 18S rRNA, which may fall slightly during hypoxia. 
Nonetheless, the qPCR results verified the data obtained by microarray 
analysis. 
 
 
 
 
Figure 4: Microarray validation by quantitative PCR. DU145 cells were exposed to hypoxia 
for 0 or 4 h. Gene-specific mRNA abundance was measured for β-Actin, ATF-4, EGLN3, 
VEGF and DDIT3 using quantitative real-time PCR. Gene abundance was normalized by 18S 
rRNA signal and the induction factors were calculated using the abundance measured in three 
independent experiments. The standard error of the mean is shown. 
 
 
DISCUSSION 
 
There is substantial evidence that tumor oxygenation varies dynamically in 
time at frequencies that would be difficult to compensate for by changes in 
transcription. Thus, it is not clear to what degree the cellular proteome, and 
ultimately cell behavior, changes during acute exposures to hypoxia. To 
address this question we assessed the effect of both acute (1 hr) and chronic (24 
hrs) hypoxia on the overall pool of expressed proteins. Both 1 hour and 24 
hours of hypoxia clearly caused significant changes in the proteome, as 
demonstrated by a large number of proteins showing a greater than 2-fold 
change in expression. As listed in Table 1, significantly fewer protein spots 
were detected during hypoxia compared to normoxia, consistent with hypoxia-
96 
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A strong suppression of mRNA translation was observed after 4 hours 
of hypo
 majority of the genes showing the highest increases in translation 
have p
induced inhibition of mRNA translation (and transcription at later time points). 
Of the proteins that were detected in all conditions, approximately 10% 
changed their expression 2-fold or more during hypoxia. Of these, 59% had 
increased expression during 1 hour hypoxia, versus 34% after 24 hours. The 
results shown in Figure 1 and Table 1 demonstrate that significant changes in 
the proteome take place very early in the hypoxic exposure, at a time where 
transcriptional changes are thought to contribute to a negligible extent. These 
data provide evidence that a non-transcriptional mechanism is important for the 
changes in protein expression that occur during hypoxia. Although we argue 
that gene-specific mRNA translation can contribute significantly to the 
observed changes, other mechanisms may also be important contributors, 
including both mRNA and protein stabilization.  
 
xia. However, the global decrease in translation efficiency assayed in 
this way represents the average reduction in translational efficiency for all 
genes. The change in translational efficiency for any particular gene under 
these conditions may differ significantly from this global average. This 
variability is thus a potentially important contribution to changes in protein 
expression during hypoxia. In order to evaluate this contribution we used 
microarrays to characterize both transcriptional and translational changes of 
individual genes. After 4 hours of hypoxia we found a substantially higher 
number of genes that showed significant increases in translation in comparison 
to the number showing only transcriptional changes. This is due to the fact that 
increased translation arises from increases in both mRNA abundance and in 
gene-specific translation efficiency. Importantly, these translated genes 
accurately reflect de novo protein production and thus are likely contributors to 
biological behavior. The gene found to show the largest increase in translation 
during  hypoxia was the HIF-1 target gene hexokinase 2 (HK-2), which is 
involved in glucose metabolism [22]. The protein production of HK-2 
increased by 30-fold during 4 hours of hypoxia versus normoxia, while the 
mRNA abundance in the cells increased by 25-fold. The interpretation of this 
result is that HK-2 is both transcriptionally and translationally induced, with 
the transcriptional component being dominant.  
 
A
reviously been shown to be targets of the HIF transcription factors 
(Table 2). The criteria for this annotation were non stringent and genes that 
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ther genes that have a high translational component of induction 
include
The mechanistic basis for preferential translation is not well understood, 
althoug
contain putative HREs in their promoter, or that are induced by either 
overexpression of HIF or loss of pVHL have been included together with bona 
fide HIF targets. It is clear from the table that the potential influence of HIF 
through hypoxia-induced transcription is significant. However, the HIF target 
genes displayed a large spread in translation efficiency during hypoxia, ranging 
from 0.4 for PFKFB4 to 3.0 for CITED-2. CITED-2 was highly induced during 
hypoxia (number 4 on the list) with a 16-fold increase in translation and only a 
5-fold increase in total mRNA. This gene product binds p300 and thereby 
inhibits the HIF-1-p300 interaction required for HIF-1-dependent gene 
transcription [43, 66]. Hypoxia has previously been shown to induce both 
mRNA and protein levels of CITED-2 [43], and the results presented here 
indicate that gene-specific up regulation of mRNA translation contributes 
significantly to the increased protein levels. Interestingly, the CITED-2 
promoter also contains three HREs [43],  indicating that it is a part of a 
negative feedback loop controlling expression of HIF-1 target genes. 
Apparently, CITED-2 mRNA is in addition able to bypass the overall 
repression of mRNA translation to ensure its robust expression during hypoxia.  
 
O
 hypoxia-inducible protein 2 (HIG-2), MAX interactor 1 (MXI-1), zinc 
finger protein (ZNF) 292 and 395 and enolase 2 (ENO-2). As exemplified by 
HK-2 and CITED-2, several of the genes shown in Table 2 are induced both at 
the transcriptional level and through increased mRNA translation efficiency. It 
is conceptually not surprising that transcriptionally activated mRNA species 
possess the ability to be preferentially translated. Without this ability, the 
transcriptional induction would clearly be inefficient and result in 
uneconomical use of the cells limited energy sources.  
 
h elements in the regulatory (i.e. untranslated) parts of the mRNA seem 
to be important. ATF-4 is an example of a gene that, paradoxically, is more 
efficiently translated during ER stress when global translation is inhibited 
through PERK-dependent eIF2α phosphorylation [35]. PERK is also activated 
during hypoxia and necessary for at least a component of the hypoxia-induced 
inhibition in translation [31]. ATF-4 is thought to be translationally induced 
during eIF2α phosphorylation because its upstream open reading frames 
(uORFs) in the 5’ untranslated region (5’UTR) of the mRNA prevent proper 
ribosome initiation under normal conditions [35]. Phosphorylation of eIF2α 
makes initiation less efficient which increases the probability that ribosomes 
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ene-specific translation during hypoxia has also been reported for 
mouse 
n intriguing group of genes are those that have a large transcriptional 
inducti
will read through the false uORFs and start translating at the bona fide start 
site. In our microarray, ATF-4 was indeed translationally induced during 
hypoxia, consistent with results from a previous microarray experiment 
performed after a longer hypoxia exposure in HeLa cells [67]. Here, we 
obtained an induction of 3.5 in the polysomes versus 2.3 in the totals, resulting 
in a poly/total ratio of 1.52. It is also noteworthy that 8 of the 50 top induced 
genes listed in table 2 have been previously implicated in the UPR which 
requires ATF4 activation.  
 
G
HIF1-α and human VEGF. These genes have been reported to contain 
functional internal ribosomal entry sites (IRES) in their 5’UTR [68-71]. The 
presence of an IRES makes it possible for ribosomes to bind the mRNA 
independently of the 5’ cap-structure, and therefore bypasses the requirement 
for certain translation factors. However, although it has been shown that the 
IRES-dependent translation is relatively less affected by the overall hypoxia-
induced translation inhibition, it is not clear to which extent it contributes to 
overall protein expression and phenotype. HIF1-α did not appear as a 
translationally regulated gene on our list, perhaps indicating differences 
between mouse and human 5’UTRs in this gene. In contrast, VEGF was 
hypoxia-induced on our array and showed a poly/total ratio of 1.1 and 2.3 for 
two different probe sets. Many other genes had a higher contribution from 
changes in mRNA translation efficiency to their induction than ATF-4 and 
VEGF, and the molecular mechanisms responsible for this are yet to be 
identified. 
 
A
on, but not a corresponding increase in translation. (e.g. cyclin G2, 
GPR54, DDIT3, PFKFB4, ATF3). It is possible that this reflects different 
induction kinetics and that these genes will be efficiently translated after longer 
exposures to hypoxia. Our previous results have indicated that at least two 
distinct molecular pathways contribute to the inhibition of overall mRNA 
translation during acute and chronic hypoxia [31, 72]. It is likely that a switch 
of molecular mechanisms can facilitate different groups of genes to be 
efficiently translated at different times. Another possibility is that the 
transcriptionally induced but translationally inhibited mRNAs produce proteins 
that are important in coping with the stress represented by reoxygenation. It 
may be important for the cells to have mRNA available to be translated as soon 
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 conclusion, we identified a large number of genes that demonstrate a 
selectiv
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ABSTRACT 
 
Hypoxia causes a rapid and sustained inhibition in mRNA translation that is 
characterized by both a transient phosphorylation of eukaryotic initiation factor 
2-alpha (eIF2α) and by inhibition of the mRNA cap binding protein eIF4E via 
activation of two distinct inhibitory proteins, the mTOR target 4E-BP1 and the 
eIF4E transporter 4E-T. Although the importance of eIF2α phosphorylation 
during hypoxia has been clearly demonstrated, there is little information on the 
potential relevance of eIF4E regulation. We generated HeLa cells stably 
expressing a short hairpin interfering RNA (shRNA) against 4E-BP1 and found 
that despite efficient knockdown, no significant changes occurred in the overall 
inhibition of mRNA translation during hypoxia. However, using a proteomics 
approach we identified 7 proteins that were exclusively expressed in the 4E-
BP1 knock-down cells during both normoxic and hypoxic conditions. Further 
investigation of the transcriptional and translational regulation of these genes 
by quantitative RT-PCR indicated that the loss of 4E-BP1 causes a significant 
increase in the rate of protein synthesis of S100 calcium-binding protein A4 
(S100A4) and transgelin 2. These 4E-BP1 regulated proteins have previously 
been associated with tumor cell motility, invasion and metastasis and may thus 
contribute to an adverse tumor phenotype.  
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INTRODUCTION 
 
The presence of poorly oxygenated (hypoxic) areas within the tumor micro-
environment is well-documented [1]. Hypoxic tumors are associated with a 
more malignant phenotype and are more resistant to therapy as compared to 
better-oxygenated tumors. The adaptation to hypoxia is facilitated in large part 
through activation of a key regulator, hypoxia inducible factor-1 (HIF-1), 
which mediates transcriptional activation of genes involved in erythropoiesis, 
glycolysis, angiogenesis, invasion and cell survival decisions [2]. In addition to 
this transcriptional response, tumor hypoxia also results in a rapid drop in de 
novo protein synthesis [3]. Protein synthesis is the second highest cellular 
consumer of ATP after the Na+ pump [4], and thus its inhibition during 
hypoxia probably serves to maintain energy homeostasis. This inhibition in 
overall protein synthesis occurs at the level of mRNA translation initiation [5, 
6], a process that is regulated by a family of eukaryotic translation initiation 
factors (eIFs).  
 
We have recently shown that two distinct pathways regulate mRNA 
translation during hypoxia. The initial phase of inhibition in protein synthesis 
during hypoxic exposure occurs mainly through transient phosphorylation of 
eIF2α at serine 51 by the endoplasmic reticulum kinase PERK [5, 6]. Although 
the phosphorylation of eIF2α is transient, overall levels of translation remain 
low during prolonged hypoxia consistent with regulation of the eukaryotic 
initiation complex 4F. This complex consists of the eIF4E cap-binding protein, 
the eIF4G scaffolding protein and the ATP dependent eIF4A RNA helicase. 
Prolonged hypoxic exposures (>4h) cause disruption of the eIF4F complex 
through the sequestration of eIF4E by 4E binding proteins (4E-BPs) and 
relocation of eIF4E into the nucleus and/or P-bodies by the 4E-T transporter 
protein [5]. There are three known 4E-BPs (4E-BP1, 4E-BP2 and 4E-BP3), 
with 4E-BP1 also known as PHAS-1 being the best characterized [7, 8]. 4E-BP 
activity is regulated by its phosphorylation status. Hypophosphorylated 4E-BP 
binds eIF4E, thereby preventing its association with eIF4G and thus inhibiting 
cap-dependent translation. Phosphorylation of 4E-BP by the mammalian target 
of rapamycin (mTOR) results in an abrogated interaction with eIF4E and thus 
stimulates translation. Hypoxia has been demonstrated to inhibit mTOR and 
thus promote increased binding of eIF4E to 4E-BP [9, 10]. However, the 
functional consequences of hypoxia induced 4E-BP dephosphorylation remain 
unclear. Prevention of 4E-BP1 dephosphorylation by mTOR overexpression 
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during anoxia did not cause a relief in protein synthesis inhibition [11], while 
4E-BP1 knock-down models have provided some support for a role for 4E-BP1 
in regulating overall translation rates during more moderately hypoxic 
conditions [12, 13]. The importance of 4E-BP regulation for differential gene 
expression and phenotype during anoxia or hypoxia has not been addressed. 
 
4E-BP plays an important role in the regulation of gene expression and 
phenotype in many other settings. In Drosophila, 4E-BP activity strongly 
affects fat metabolism [14]. Similarly, mice lacking 4E-BP1 show markedly 
smaller white fat pads and decreased blood glucose levels as compared to their 
wild-type counterparts, implicating 4E-BP1 as a metabolic regulator [15]. 
Several studies have also implicated components of the protein initiation 
synthesis apparatus in carcinogenesis. eIF4E induces malignant transformation 
when overexpressed in mammalian cells [16]. Moreover, increased levels of 
eIF4E are commonly found in breast, prostate and head and neck tumors, but 
not in benign lesions [17]. In contrast to eIF4E, overexpression of 4E-BP1 
blocks transformation by both eIF4E and c-myc by inhibiting cell cycle 
progression and increasing apoptosis [18].  Expression of a constitutively 
active 4E-BP1 enhances p27/Kip1 expression and represses cyclin D1 
expression, which leads to cell cycle arrest [19].   
 
In this study, we established HeLa cells stably expressing a short 
hairpin interfering RNA (shRNA) against 4E-BP1 to address the contribution 
of 4E-BP1 on mRNA translation and protein expression during hypoxia and 
normoxia. We demonstrate that although 4E-BP1 knock-down does not affect 
the inhibition of overall mRNA translation during severe hypoxia, the absence 
of 4E-BP1 stimulates specific protein expression during both normoxic and 
hypoxic conditions. Overall, the stable knock-down of 4E-BP1 contributes to 
the translational induction of specific proteins that are involved in cytoskeletal 
organization and invasion, which may contribute to the adverse phenotype of 
tumor cells. Furthermore, we demonstrate that for two of these proteins, S100 
calcium-binding protein A4 (S100A4) and transgelin 2, 4E-BP1 directly 
regulates their translation efficiency.  
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MATERIALS AND METHODS 
 
Cell culture and cell transfections 
Cervix carcinoma (HeLa) cells were grown in Dulbecco’s modified Eagle’s 
medium (Sigma) supplemented with 10% fetal bovine serum (Sigma) at 37°C 
in a 5% CO2 incubator. HeLa cells were stably transfected with pRetroSuper 
[20] which was either empty (pRS) or which generated a short hairpin 
interfering RNA against 4E-BP1 (pRS 4E-BP1) with the following targeting 
sequence: gtttgagatggacatttaa. Exponentionally growing pRS HeLa and pRS 
4E-BP1 HeLa cells were plated on plastic culture dishes and hypoxic 
treatments (<0.01%O2) were performed as previously described [21].  
Growth curves 
HeLa cells were seeded at day 1.  After day 2, 3, 4 and 5 cells were harvested 
using trypsin and the cell number was counted using a Coulter Z counter 
(Beckmann). 
Polysomal fractionation and analysis 
Experiments were performed as previously described [21]. 
 
Western blot analysis 
Whole cell extracts (40 μg) were resolved in 15% SDS PAGE gels and 
transferred onto Hybond-Nitrocellulose membrane (Amersham Biosciences). 
Membranes were incubated overnight with primary antibody: 4E-BP1 (1:1000 
dilution, Cell Signaling Technology) followed by incubation with horseradish 
peroxidase-conjugated secundary antibody (1:2000 dilution, Cell Signaling 
technology). Protein signals were detected using the Super Signal West Pico kit 
(Pierce).  
 
2-DE and image analysis 
15 cm culture dishes of HeLa cells at 70% confluence were washed twice with 
5 mL of ice-cold 10 mM/250 mM sucrose buffer pH 7.0. Cells were scraped in 
1 mL of ice-cold Tris/Sucrose buffer and centrifuged at 400 g for 5 min at 4°C. 
The cells were washed again with 1 mL of ice-cold Tris/Sucrose buffer and 
centrifuged at 400 g for 5 min at 4°C. The supernatant was discarded and 200 
µL 2-DE lysisbuffer (7 M urea, 2 M thiourea, 4% CHAPS, 0.5% IPG buffer 
pH 3-10 NL (Amersham Biosciences), 1% DTT, complete EDTA-free protease 
inhibitor cocktail (Roche)) was added. Cells were exposed four times to a 
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quick freeze-thaw lysis, and then lysates were centrifuged at 13000 g for 30 
min at 4°C to remove contaminants like DNA. The supernatant was collected 
in a cold microcentrifuge tube. Protein concentrations were determined by 
Bradford protein assay (Bio-Rad Laboratories) [22]. Samples were applied to 
24 cm IPG strips pH 3-10 NL (Amersham Biosciences) by in-gel rehydration, 
15 hours at 50 V. Focusing System cycling conditions were 90 min at 200 V, 
90 min at 500 V, 2 hours gradient step to 1000 V, 90 min gradient step to 8000 
V and a final step of 6 hours at 8000 V with an IPGphor system (Amersham 
Biosciences). Following the IEF step, the strips were equilibrated for 20 min in 
equilibration buffer (6 M urea, 50 mM Tris-HCL pH 8.8, 30% glycerol, 2% 
SDS and 1% DTT), then treated for 20 min in the same buffer containing 2.5% 
iodoacetamide instead of DTT. Next, the IPG strips were placed on the Protean 
Plus Dodeca Cell (Bio-Rad Laboratories) to conduct a second dimension 
separation using 12% SDS-PAGE gels. The system was run at 150 V for 20 
min, followed by 5 hours at 200 V. Proteins were visualized by staining with 
SYPRO Ruby dye (Bio-Rad Laboratories). The 2-DE stained gels were imaged 
on a Molecular Imager FX (Bio-Rad Laboratories). This experiment was 
repeated in triplicate with a technical repeat for each condition. The resulting 
2-DE protein patterns were analyzed, using PD-Quest 7.1 software (Bio-Rad 
Laboratories). The densities of all spots were determined with normalization 
based on total protein density on each of the individual gels. The 
reproducibility of the 2-DE gels was expressed as a correlation coefficient, 
which was measured between the quantities of all spots in a gel and its 
quantities in another biological or technical repeat from the same matchset. 
This correlation coefficient was always higher then 0.83.  
 
In-gel trypsin digestion and ESI-Q-TRAP MS 
Stained protein spots of interest were excised from the gel with an automatic 
spot cutter (Bio-Rad Laboratories). Each gel piece was washed twice for 30 
min at 30°C with 200 mM NH4HCO3 in 50% ACN for 30 min. After 
incubation, the wash solution was removed and the samples evaporated to 
complete dryness using a SpeedVac. For digestion, gel pieces were chilled for 
60 min on ice in 8 μL of digestion buffer containing 150 ng modified trypsin 
(Promega) in 50 mM NH4HCO3. Then 5 μL of digestion buffer was added and 
the samples were incubated overnight at 37°C. After incubation, the 
supernatans was recovered and the remaining peptides were extracted from the 
gel by two consecutive extractions with 50% ACN/0.1% HCOOH. All the 
extracts were pooled and the samples were dried in a SpeedVac. The samples 
were resuspended in 8 μL of 0.1% HCOOH. The peptide mixture was loaded 
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and separated on a nano-HPLC system (Dionex-LC Packings) using a 75 µm 
ID PEPMAP C18 column (Dionex) and the separated peptides were then 
analysed by LCMS/MS by an ESI-Q-TRAP mass spectrometer (Applied 
Biosystems) as previously described [23]. All searches were done using the in-
house MASCOT server and the NCBInr database limited to proteins from 
Homo sapiens, a 1 Da peptide and fragment mass error was tolerated and 
carbamidomethylation and methionine oxidation were set as variable 
modifications. 
 
Quantitative PCR analysis 
Experiments and normalizations were performed as previously described [5]. 
The abundance of the following genes were detected with SYBR Green I 
(Applied Biosystems) using indicated forward and reverse primers: CA-IX: F-
catcctagccctggtttttgg and R-gctcacaccccctttggtt; 4E-BP1: F-
tatgaccggaaattcctgatgga and R-ccgcttatcttctgggctattg; 4E-BP2: F-
gtttctgttggatcgtcgcaa and R-ggagtcttcaattaaggtgcca; β-Actin: F-
accatggatgatgatatcgcc and R-gccttgcacatgccgg; 18SrRNA: F-
agtccctgccctttgtacaca and R-gatccgagggcctcactaaac. The following genes were 
measured using Taqman Gene Expression Assays (Applied Biosystems): 
S100A4: Hs00243202_m1, Transgelin 2: Hs00761239_s1.  
 
Transgelin 2 pulse-labeling 
Following 15 min starvation, cells grown on 60 mm dishes were incubated 
with 100 µCi 35-S labeled methionine/cysteine (GE Healthcare) for 7, 14 or 28 
min. The cells were washed in cold PBS and lysed in RIPA lysisbuffer. Total 
cell lysates labeled for 14 min were immunoprecipitated using a transgelin 2 
antibody (Abcam). Total or immunoprecipitated cell lysates were separated on 
SDS-PAGE and 35S incorporation detected by autoradiography. 
 
 
RESULTS 
 
HeLa cells stably expressing a shRNA against 4E-BP1 
Previously, we have shown that hypoxia regulates translation through two 
distinct pathways. Rapid but transient phosphorylation of eIF2α is followed by 
sequestration of eIF4E by its inhibitor 4E-BP1 and transporter 4E-T and 
disruption of the eIF4F complex [5]. Figure 1A demonstrates strong 
dephosphorylation of 4E-BP1 after 16 h exposure to hypoxia. This protein 
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appears as three different migrating bands (α-γ) when subjected to SDS-PAGE 
and western blot analysis, representing different phosphorylation states of 4E-
BP1, ranging from a fast-migrating hypophosphorylated form (α) to a slow-
migrating hyperphosphorylated form (γ) [7]. The hypophosphorylated band of 
4E-BP1, which is known to have a higher affinity for eIF4E, is substantially 
increased after 16 h of hypoxia.  
 
HeLa cells were transfected with a control shRNA or a shRNA directed to 
knock down the expression of 4EBP1. Following selection of stably expressing 
cell lines, total RNA was isolated for reverse transcription RT-PCR in order to 
characterize the transcript levels of 4E-BP1. Figure 1B shows >10-fold 
decrease in 4E-BP1 transcript expression in cells expressing a shRNA against 
4E-BP1 (referred to as pRS 4E-BP1) compared to the wild type counterparts. 
The shRNA against 4E-BP1 has no effect on 4E-BP2 transcript levels, 
demonstrating the specificity of the shRNA for 4E-BP1 and absence of 
compensation by the homolog. Western blot analysis for 4E-BP1 expression 
confirmed reduced protein levels for 4E-BP1 in the pRS 4E-BP1 HeLa cells 
(Figure 1C).  
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A B
C Figure 1: (A) A representative Western blot 
showing 4E-BP1 and β-Actin expression 
levels in HeLa pRS or pRS 4E-BP1 cells 
exposed to normoxia or 16 h hypoxia. β-
Actin is used as a loading control. The 
different phosphorylation forms (α,β,γ) are 
indicated. (B) 4E-BP1 and 4E-BP2 transcript 
levels in pRS and pRS 4E-BP1 HeLa cells as 
mean ± SEM of triplicate q-RT-PCR 
measurements. (C) A representative Western 
blot demonstrating reduced 4E-BP1 protein 
levels in the pRS 4E-BP1 cells. 
 
 
4E-BP1 expression does not affect proliferation or overall rates of mRNA 
translation  
Expression of a shRNA against 4E-BP1 might be expected to increase the rate 
of cellular proliferation through increased eIF4E activity. To test this, the 
growth of pRS 4E-BP1 HeLa cells was determined by counting cell number 
during standard cell culture. The data presented in Figure 2A show that the rate 
of proliferation was unaffected by the levels of 4E-BP1.   
 
To determine the influence of 4E-BP1 on overall rates of mRNA 
translation in HeLa cells during normoxic and hypoxic conditions, we 
examined the association of ribosomes with mRNA under normal growth 
conditions and after 16 h of hypoxia. The resulting polysome profiles are 
shown in Figure 2B. In this assay, the first two peaks represent the 40S and 
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60S ribosomal subunits, respectively. The subsequent peaks represent mRNA 
transcripts with increasing numbers of attached ribosomes (polysomes), which 
is indicative of de novo protein synthesis. The results presented in Figure 2B 
demonstrate that hypoxia inhibits overall mRNA translation in HeLa cells, 
evident by a clear reduction in the high molecular weight polysomal RNA. 
Interestingly, knockdown of 4E-BP1 does not significantly alter the overall 
mRNA translation inhibition during hypoxia. The amount of ribosomal RNA 
participating in polysomes can be determined by integrating the fractional area 
under the absorbance curve which corresponds to polysomal RNA. The 
resulting data presented in Figure 2C show that the fraction of rRNA found in 
polysome complexes dropped from 60% in aerobic cells to 27% after 16 h of 
hypoxia, irrespective of 4E-BP1 expression levels. In summary, these results 
indicate that 4E-BP1 expression does not significantly influence cell 
proliferation and does not affect overall rates of mRNA translation during 
normoxic or hypoxic conditions.   
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Figure 2: (A) Proliferation rates of pRS HeLa and pRS 4E-BP1 HeLa cells was monitored by 
counting cells following 1, 2, 3, 4, or 5 days of growth. Data represent mean 6 SEM of three 
independent experiments. (B) Cell lysates were sedimented through a sucrose gradient and OD 
at 254 nm was recorded as function of gradient depth. Actively translated mRNA is associated 
with high molecular weight polysomes in the gradient. Positions of the 40S and 60S ribosome 
subunits, 80S monosome, and polysomes are indicated. (C) The fraction of rRNA associated 
with polysomes is used as an estimate of overall translation efficiency. This fraction is 
proportional to the integrated area under the curve-containing polysomes. Data represent mean 
± SEM of two independent experiments. 
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Identification of 4E-BP1 dependent proteins  
Although the data presented above indicate that 4E-BP1 expression does not 
affect overall mRNA translation, we hypothesized that 4E-BP1 may 
nonetheless affect specific protein expression. To address this we exposed 
wild-type and 4E-BP1 knockdown cells to normoxia or 16 h of hypoxia. 
Subsequently, proteins were isolated from the cells and separated by 2-DE. 
Representative gels stained with SYPRO Ruby are shown in Figure 3A.  
Approximately 1300 spots were detected per gel within a pH range of 3-10 and 
a molecular mass range of 10-150 kDA. In order to increase our likelihood of 
identifying proteins regulated by 4E-BP1 directly at the translational level, we 
imposed stringent criteria for selecting spots for further MS analysis. We 
selected those spots that were reproducibly present in the pRS 4E-BP1 HeLa 
cells during both normoxic and hypoxic conditions but absent (undetectable by 
Sypro Ruby staining) in the wild-type pRS HeLa cells. Thus, for this first 
analysis, proteins that demonstrated quantitative changes in their levels 
(present in both wild type and 4E-BP1 knockdown cells) were not further 
investigated. 
 
 
 
A 
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Figure 3: (A) Representative 2 D gels stained with SYPRO Ruby of pRS HeLa and pRS 4E-
BP1 HeLa cells exposed to normoxia or 16 h of hypoxia. Around 1300 spots are visible within 
a pH range of 3–10 and a molecular mass range of 10–150 kDa. (B) The insets show the 
expression and quantification of the protein spots identified as S100A4 and transgelin 2 during 
normoxic (N) and hypoxic (H) conditions for both cell lines. 
 
 
Overall, the 2-DE gel protein spot profiles across all of the gels for both 
cell lines were similar. However the image analysis software PDQuest revealed 
the expression of a small number of proteins that were exclusively expressed in 
the pRS 4E-BP1 cells during both normoxia and hypoxia. Seven of these were 
successfully identified by ESI-Q-TRAP MS analysis followed by database 
searching; enolase 1, lactate dehydrogenase-B, S100A4, annexin A3, 
peptidylprolyl isomerise A, transgelin 2 and heat shock protein 70 kDA 9B. 
The identified peptides, Swiss-Prot accession numbers, MS-MS scores, and 
other details of these proteins are summarized in Table 1. We chose to focus 
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further mechanistic studies on two proteins, S100A4 and  transgelin 2 that are 
described in the literature as being involved in tumor progression and invasion 
[24, 25] and which were expressed repeatedly and exclusively in cells lacking 
4E-BP1 during normoxia and hypoxia (Figure 3B).  
 
Table 1. List of identified proteins ESI-Q-TRAP MS. 
 
Swiss-
Prot 
Accessi
on No. 
Protein 
name 
HUG
O 
Gene 
name 
Putativ
e 
functio
n 
Mr 
(kDa)
/pI 
Num
ber 
of 
pepti
des 
Sequ
ence 
cover
age 
(%) 
MS/
MS 
score 
>31a)
Peptide  
sequences 
P06733 Enolase 1 ENO1 
Cellular 
metabolis
m 
47/7,01 1 3 33 
R.YISPDQLAD
LYK.G 
P07195 
Lactate 
dehydroge
nase B LDHB 
Cellular 
metabolis
m 37/5,71 2 6 
44 
43 
K.IVVVTAGVR.
Q 
R.GLTSVINQK.
L 
P26447 
S100 
calcium-
binding 
protein 
A4 
S100A
4 
Calcium-
binding 
protein 
12/5,85 1 12 52 K.ALDVMSTFHK.Y 
P12429 Annexin A3 
ANXA
3 
Calcium-
binding 
protein 36/5,63 3
b) 27 
46 
57 
38 
K.LTFDEYR.N 
K.GIGTDEFTLN
R.I 
R.SEIDLLDIR.T 
P62937 
Peptidylpr
olyl 
isomerase 
A 
CYPA Protein folding 18/7,68 2
c) 33 49 38 
K.KITIADCGQL
.E   
R.VLDELTLAR.
T 
P37802 Transgelin 2 
TAGL
N2 
Cytoskele
tal protein 22/8,41 1 7 42 
R.TLMNLGGLA
VAR.D 
P38646 
Heat 
shock 
protein 70 
kDA 9B 
HSPA9 Proliferation 74/6,03 1
d) 3 34 K.DAGQISGLNVLR.V 
a) MS/MS score is given as S=-10*log (P) where P is the probability that the observed match is  
 
   a random event. 
b) 7 peptide sequences were identified, 4 had a MS/MS score < 31.    
c) 4 peptide sequences were identified, 2 had a MS/MS score < 31. 
d) 2 peptide sequences were identified, 1 had a MS/MS score < 31. 
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4E-BP1 dependent regulation of S100A4 and transgelin 2 expression 
Although 4E-BP1 is directly involved in regulating mRNA translation, it could 
affect gene expression indirectly by e.g. by regulating the translation of a 
transcription factor. To address whether 4E-BP1 prevents transcription or 
translation of S100A4 and transgelin 2, we conducted real time quantitative 
RT-PCR for these two genes during normoxia or hypoxia (16 h) from both 
total cellular mRNA and from polysomal mRNA. This allows us to evaluate 
changes in cellular levels of mRNA as well as changes in the translation 
efficiency of these individual genes. As shown in Figure 4A total cellular 
mRNA levels of S100A4 and transgelin 2 did not significantly change 
following 4E-BP1 knockdown during normoxia or hypoxia. As expected, the 
hypoxic treatment caused a 10-fold increase in the HIF-1 target gene CA-IX in 
both cell lines, demonstrating the effectiveness of hypoxic treatment.  
 
To evaluate mRNA translation and estimate de novo protein synthesis 
rates of these two genes, we separated lysates over sucrose gradients and 
collected 4 separate fractions from increasing gradient depth (Figure 4B). 
These 4 fractions contain mRNAs associated with an average of 2, 4, 6 and 10 
ribosomes per mRNA transcript. The transcript abundance of S1004A and 
transgelin 2 was determined from each fraction with quantitative RT-PCR. In 
order to estimate the relative rate of protein production from each fraction, the 
mRNA abundance was multiplied by the average number of ribosomes per 
transcript.  A relative measure of de novo protein production was estimated by 
summing this value from each of the 4 fractions. Figure 4C demonstrates that 
the rate of protein production of S100A4 and transgelin 2 is increased by more 
than 2-fold in the pRS 4E-BP1 cells during normoxia. In contrast, the hypoxia 
induced repression of protein production is not dependent on 4E-BP1 
expression. The repression of S100A4 and transgelin 2 during hypoxia is 
similar to that observed for β-actin, and reflects the general decrease in cellular 
protein production under these conditions. Translation efficiency was 
determined by comparing the amount of protein production divided by the total 
amount of mRNA in the cell. Since the changes in mRNA abundance were 
negligible (Figure 4A), the observed changes in protein production (Figure 4C) 
were in large part a result of changes in translation efficiency (Figure 4D). The 
translation efficiency increased 2-fold for S100A4 and 4-fold for transgelin 2 
during normoxia in the 4E-BP1 knock down compared to the wild type cells 
(Figure 4D).  
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To validate the polysomal data and independently assess that 4E-BP1 
expression directly influences protein production we measured the rates of new 
protein synthesis using 35S methionine/cysteine labeling during normoxia for 
transgelin 2. Following 15 min starvation, cells were incubated with 35-S 
labeled methionine/cysteine for 7, 14 or 28 min during normoxic exposure. 
Total cell lysates were separated on SDS PAGE and examined by 
autoradiography. Figure 4E demonstrates equal 35S labeling for both cell lines 
indicating no significant changes between overall rates of protein synthesis, 
similar to what was found by the polysomal analysis (Figure 2B). Total cell 
lysates labeled for 14 min were then immunoprecipitated using a transgelin 2 
antibody. In this case, the pRS 4E-BP1 HeLa cells demonstrate a clear increase 
in 35S incorporation for transgelin 2, thus independently validating the 
increase in translation observed by polysomal mRNA analysis (Figure 4F). 
These data suggest that 4E-BP1 inhibits efficient mRNA translation of S100A4 
and transgelin 2 during normoxia and affects protein levels during both 
normoxia and hypoxia. 
 
 
 
A 
B 
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Figure 4: (A) Gene-specific transcript levels are shown for S100A4, transgelin 2, and β-Actin. 
CA-IX is used as a control for the hypoxic treatment. Data are normalized to 18S rRNA signal. 
(B) Schematic representation of the method to assess protein production. mRNA levels for 
genes of interest are measured in each of four separate fractions isolated at increasing depth in 
the gradient. The average number of ribosomes per transcript in each of the fractions is 
estimated based on the positions of the polysome peaks in the gradient. The amount of protein 
production, which reflects the de novo protein synthesis, is calculated by multiplying the 
mRNA levels in each fraction by the average number of ribosomes per transcript followed by 
summing this value in each of the four fractions. (C) Protein production was estimated as 
described in (B) for S100A4, transgelin 2, CA-IX, and β-Actin. (D) The relative translation 
efficiency is assessed by dividing the protein production by the mRNA abundance. Data 
represent the mean ± SEM of two independent experiments. (E) Following 15 min starvation, 
cells were incubated with 100 mCi 35S labeled methionine/cysteine for 7, 14, or 28 min during 
normoxia and total cell lysates were separated on an SDS-PAGE gel and autoradiographed. (F) 
Total cell lysates labeled for 14 min were immunoprecipitated using a transgelin 2 antibody 
followed by SDS-PAGE and autoradiography. 
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DISCUSSION 
 
Previous work from us and others has demonstrated a rapid inhibition of 
mRNA translation during hypoxia and two distinct pathways have been 
implicated in this effect. The best understood is the phosphorylation and 
inhibition of eIF2α, which is responsible for a rapid inhibition of initiation 
during anoxia. The other is via a reduction in 4E-BP1 phosphorylation, a 
protein that is regulated by mTOR. Surprisingly, we show here that stable 
knockdown of 4E-BP1 in HeLa cells does not lead to any significant changes 
in overall translation, or its inhibition during hypoxia. However, using 2-DE 
techniques we showed that 4E-BP1 does regulate the protein levels of many 
different individual proteins. We identified 7 proteins that are robustly and 
exclusively observed in cells where 4E-BP1 had been knocked down. These 
proteins are involved in various cellular processes, including metabolism, 
invasion, protein folding and proliferation. Several of these proteins have 
previously been linked to cancer and/or hypoxia. The enolase 1 gene promoter 
contains essential binding sites for the transcription factor HIF-1α [26] and 
lactate dehydrogenase-B has previously been shown to be hypoxia regulated in 
primary rat and chick retinal cells [27].  Peptidylprolyl isomerise A, also 
termed cyclophilin A, is found to be overexpressed in different cancer cells and 
can lead to resistance to hypoxia and cisplatin-induced cell death [28]. 
Similarly, overexpression of heat shock protein 70kDA 9B (also known as 
mortalin) has been reported to be prognostic in colorectal cancer [29]. 
 
From the seven proteins that we identified, we focused further 
mechanistic studies of regulation on S100A4 and transgelin 2. Both proteins 
have been implicated in tumor progression and invasion [24, 25] but are not 
known to be influenced by hypoxia. S100A4 overexpression is associated with 
tumor development and progression in colorectal cancer [24]. S100A4 has also 
been shown to act as a prognostic factor in thyroid carcinoma, where 
overexpression is associated with the most advanced thyroid carcinomas and 
lymph node metastasis [30]. A potential mechanism through which S100A4 
may exert its effect on tumor progression and metastasis of some tumors is via 
regulation of matrix metalloproteinase-2 (MMP-2) and matrix 
metalloproteinase-9 (MMP-9) activity [31, 32]. Similarly, a recent study to 
identify tumor and tumor-associated antigens in patients with hepatocellular 
carcinoma (HCC) pointed to transgelin 2 as a potential diagnostic marker for 
HCC [25]. This protein is thought to be involved in cell proliferation and 
                                                4E-BP1 contributes to specific protein expression  
 
                                                                                                                         127 
migration, suggesting that its overexpression may contribute to tumor 
progression. 
 
We report here that 4E-BP1 expression negatively regulates the 
expression of S100A4 and transgelin 2 during normoxia at the level of mRNA 
translation initiation. Regulation of translation efficiency is increasingly being 
recognized as a way to control differential protein expression in response to 
different conditions including hypoxia [5, 21], hypoxia followed by 
reoxygenation [33], ionizing radiation [34] as well as by oncogenic signalling 
pathways [35]. Interestingly, although S100A4 and transgelin 2 are still 
expressed at the protein level after 16 h hypoxia in the 2-DE gels, the de novo 
synthesis of these proteins is still repressed in the pRS 4E-BP1 cells. The 
reduction in translation efficiency of S100A4 and transgelin 2 was similar to 
that of β-actin reflecting the general inhibition in protein synthesis during 
hypoxia. Thus, in addition to the 4E-BP1 regulation reported here, the 
synthesis of these proteins is subject to control by additional mechanisms 
during hypoxia that are similar to that observed for most cellular proteins. 
There are two likely candidates for this additional regulation. The first is the 
phosphorylation of eIF2α, which results in the suppression of mRNA 
translation initiation on a global level and thus affects the rate of synthesis for 
the vast majority of proteins in the cell. The second candidate is 4E-BP2, 
which like 4E-BP1 is also dephosphorylated during hypoxia and capable of 
blocking translation initiation. Given the sensitivity of transgelin-2 and 
S100A4 on 4E-BP1, activation of 4E-BP2 during hypoxia may have strong 
inhibitor effects on the synthesis of these proteins. However, it is important to 
point out that the strong affect of 4E-BP1 on the regulation of these proteins 
during normoxia results in their continued presence in cells exposed to hypoxia 
for up to 16 hours.  
 
In conclusion we have demonstrated that 4E-BP1 negatively regulates 
the expression of specific proteins involved in tumor progression and 
metastasis. This observation may contribute to the increasingly appreciated 
association between 4E-BP1 and malignancy. For example, an inverse 
correlation between 4E-BP1 expression and progression in gastrointestinal 
cancer has been reported [36]. In this study, higher 4E-BP1 levels were found 
in node-negative patients and patients without distant metastasis. Others have 
recently shown that phosphorylation and inhibition of 4E-BP1 correlates with 
poor prognosis in both tumors showing HER2/neu overexpression or 
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amplification and high-grade breast tumors in which HER2/neu amplification 
or overexpression was not detected [37].  It will be interesting to investigate the 
4E-BP1 translational regulation of S100A4 and transgelin 2 as potential 
mediators of progression and treatment response in these settings. 
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ABSTRACT 
 
Eukaryotic initiation factor 4E (eIF4E) is an essential rate-limiting factor for 
cap-dependent translation in eukaryotic cells. Elevated eIF4E activity is 
common in many human tumors and is associated with disease progression 
through its ability to enhance the translation of genes such as cyclin D1, c-Myc 
and VEGF. The growth promoting effects of eIF4E are in turn negatively 
regulated by 4E-BP1. However, although 4E-BP1 harbors anti-growth activity, 
its expression is paradoxically elevated in some tumors. We investigated the 
consequences of loss of 4E-BP1 expression in HeLa and U87 cells following 
stable expression of a short hairpin interfering RNA (shRNA) specific for 4E-
BP1. We found that loss of 4E-BP1 expression did not significantly alter 
growth during optimal in vitro conditions but did accelerate the growth of U87 
tumor xenografts, consistent with the growth promoting function of 
deregulated eIF4E. However, cells lacking 4E-BP1 were significantly more 
sensitive to hypoxia induced cell death in vitro. Furthermore, 4E-BP1 
knockdown cells produced tumors that were more sensitive to radiation due to 
a reduction in the viable fraction of radioresistant hypoxic cells. Decreased 
hypoxia tolerance in the 4E-BP1 knockdown tumors was evident by increased 
levels of cleaved caspase-3 and was associated with a reduction in ATP. These 
data suggest that although tumors often demonstrate increases in cap-
dependent translation, regulation of this activity is required to facilitate energy 
conservation, hypoxia tolerance and tumor radioresistance. Our results suggest 
that targeting translational control may be an effective way to target hypoxic 
cells and radioresistance in metabolically hyperactive tumors.  
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INTRODUCTION 
 
Regulation of mRNA translation, the synthesis of protein from mRNA, has 
emerged as an important mechanism for controlling cell growth and 
proliferation. Several canonical signaling cascades function in part by 
mediating changes in mRNA translation efficiency that influence the synthesis 
of various proteins that are critical for cell growth, differentiation, and 
adaptation to cellular stress [1, 2]. The process of translation can be divided 
into initiation, elongation, and termination phases, with the initiation step being 
rate-limiting and the most common target of regulation. Translational initiation 
is controlled by a large family of eukaryotic initiation factors (eIFs) [3] and for 
most eukaryotic mRNAs begins with the recruitment of the small ribosomal 
subunit (40S) to its 5’ cap (mP7 PGpppX). This occurs via a series of interactions 
between the cap-binding protein eIF4E, the scaffolding protein eIF4G, the 
ATP-dependent RNA helicase eIF4A (collectively named the eIF4F complex) 
and the ribosome-associated eIF3 complex.  
 
eIF4E availability is rate-limiting for the initiation step and is tightly 
controlled by a class of inhibitory proteins termed eIF4E binding proteins (4E-
BP1, 4E-BP2 and 4E-BP3), with 4E-BP1 being the best characterized [4, 5]. In 
its hypophosphorylated form, 4E-BP binds to eIF4E and prevents its 
association with eIF4G, thereby inhibiting cap-dependent translation. 
Conversely, translation is stimulated following phosphorylation of 4E-BP1 on 
multiple residues which stimulates dissociation from eIF4E. Changes in the 
availability of eIF4E differentially influence gene expression. Many growth 
and proliferation related proteins are encoded by mRNAs containing long and 
highly structured 5’UTRs, which have low translational efficiency. Examples 
include genes with important roles in cancer such as cyclin D1, c-Myc, VEGF 
and MMP9. These transcripts have been termed “weak” mRNAs and show 
strong sensitivity to the availability of eIF4E [6]. In contrast, “strong” mRNAs 
with relatively short and unstructured 5’UTRs, show less eIF4E dependency 
and typically code for more generally expressed and house-keeping proteins [7, 
8]. Through this mechanism, malignancy-associated events are directly linked 
to eIF4E activity [9].  
 
Phosphorylation and inactivation of 4E-BP1 is carried out in response 
to activation of the mammalian target of rapamycin complex 1 (mTORC1), 
which acts downstream of the PI3K/AKT and AMPK kinase signaling 
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pathways. Consequently, receptor signaling in response to mitogenic 
stimulation leads to increased rates of cap-dependent translation in an mTOR 
and 4E-BP1 dependent manner [10]. In cancer, increased eIF4E activity has 
been reported in many tumors as a consequence of increased signaling through 
the PI3K/AKT/mTOR pathway and/or overexpression of eIF4E itself [6]. 
Overexpression of eIF4E is sufficient to transform cells in culture and has been 
reported to occur in breast, head and neck, lung, colon, non-Hodgkin’s 
lymphoma, cervical and bladder cancers [11]. Similarly, the PI3K/AKT/mTOR 
pathway is commonly upregulated in many cancers through inactivation of the 
PTEN tumor suppressor or mutation/overexpression of various receptor 
tyrosine kinases [12, 13].  
 
Consistent with its ability to inhibit eIF4E, 4E-BP1 has been reported to 
have a number of anti-proliferative and tumor suppressor functions. 
Overexpression of either wild-type 4E-BP1 or the dominant active mutant 
(A37/A46) results in enhanced translational repression and pronounced cell 
death following treatment with anticancer agents and decreased tumorigenicity 
in xenograft models [14]. 4E-BP1 has been suggested as a prognostic factor in 
ovarian cancer, where increased levels of phoshorylated (inactive) 4E-BP1 are 
associated with high-grade tumors and a poor prognosis [15]. Furthermore, we 
recently showed that loss of 4E-BP1 results in increased translation of S100 
calcium-binding protein A4 (S100A4) and transgelin 2, proteins associated 
with tumor cell motility, invasion and metastasis [16]. These data support a 
potential tumor suppressor function for 4E-BP1. Nevertheless, there are no 
reports that loss of 4E-BP1 expression occurs in cancer and knockout mice 
lacking 4E-BP1 show no tumor predisposition [17]. In fact, it was recently 
reported that a large fraction of advanced breast cancers overexpress 4E-BP1 
[18]. 
 
Thus, despite its anti-growth properties, 4E-BP1 may participate in 
functions that are important in cancer. In this regard, we and others have 
recently shown that hypoxia, a frequent condition of solid tumors, inhibits 
mRNA translation in part through decreased mTOR signaling and disruption of 
the eIF4F complex [19-22]. Hypoxia associated inhibition of cap-dependent 
translation occurs through sequestration of eIF4E by 4E-BP1 and by the 
transporter 4E-T, which translocates eIF4E to the nucleus and to cytoplasmic 
bodies of mRNA processing (P-bodies) [21]. The aim of this study was to 
evaluate the biological consequences of 4E-BP1 expression on hypoxia 
tolerance and tumor growth. Our results indicate that inhibition of cap-
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dependent translation through 4E-BP1 is important for maintaining energy 
homeostasis and hypoxia tolerance.  
 
 
MATERIAL AND METHODS 
 
Cell culture and cell transfections 
Cervix carcinoma (HeLa) cells and glioblastoma (U87) cells were grown in 
Dulbecco’s modified Eagle’s medium (Sigma) supplemented with 10% fetal 
bovine serum (Sigma) at 37°C in a 5% COB2 B incubator. HeLa and U87 cells 
were stably transfected with pRetroSuper [23] which was either empty (pRS) 
or which generated a short hairpin interfering RNA against 4E-BP1 (pRS 4E-
BP1) with the following targeting sequence: gtttgagatggacatttaa.  
In vitro cell growth 
26000 pRS and pRS 4E-BP1 U87 cells were seeded in duplicate wells of a 24-
well plate. After 2-4 days of incubation under normal culture conditions, cells 
were washed with phosphate-buffered saline and trypsinized. Total cell 
numbers were enumerated using a Coulter Counter (Beckman Coulter) and 
normalized to the number of cells present at day 0. 
Polysomal fractionation and analysis 
Experiments were performed as previously described [21]. 
 
Western blot analysis 
Experiments were performed as previously described [16]. Briefly, whole cell 
extracts were resolved in SDS-PAGE gels and transferred onto Hybond-PVDF 
membranes (Amersham Biosciences). The membranes were probed overnight 
with antibodies directed to 4E-BP1 (Cell Signaling Technology) or β-actin 
(Sigma). Bound antibodies were visualized using horseradish peroxidase-
conjugated secondary antibody (anti-rabbit (Cell Signaling Technology) and 
anti-mouse (Sigma)) and ECL luminescence (Pierce). 
 
Clonogenic survival assay 
Clonogenic survival assays were studied in pRS and pRS 4E-BP1 HeLa cells 
after hypoxic treatment. Cells were seeded in triplicate into 60 mm dishes in a 
range of 200 - 100 000 cells per dish, depending on the stringency of the 
treatments. Once the cells were attached, a hypoxic treatment of 0, 16, 24 or 48 
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h was applied. After hypoxia, cells were cultured at 37°C in a 5% COB2 B 
incubator for an additional 14 days. The colonies were stained with crystal 
violet and methanol for 1 h and colonies containing ≥50 cells were counted. 
The fraction of surviving cells was normalized to the surviving fraction of the 
corresponding control. The clonogenic survival assays after ionizing radiation 
were performed in a similar set-up and cells received a single dose of 0, 2 or 4 
Gy.  
 
Cell viability assay 
A total of 5000 pRS and pRS 4E-BP1 U87 cells were cultured in a 96-well 
plate for 24 h. The cells were exposed to either normoxia or hypoxia (<0.01% 
OB2 B). After 1 or 2 days of hypoxic treatment, 20 µL of CellTiter 96 AQBueous B One 
Solution Reagent (Promega) was added directly to 100 µL of culture medium 
and incubated for 2 h at 37°C. The absorbance was measured at 490 nm using a 
96-well plate reader (Bio-Rad Laboratories) to quantify the number of viable 
cells. For the ionizing radiation (IR) experiments cells received a single dose of 
0, 4 or 10 Gy. 72 hours post treatment the number of viable cells was evaluated 
as described for the hypoxic experiment.    
 
Animal experiments 
3x10 P6 P pRS U87 and pRS 4E-BP1 U87 cells were resuspended in 100 µl growth 
medium and injected subcutaneously into the lateral flank of adult NMRI-nu 
(nu/nu) female mice (28–32 g). Tumors were measured with a Vernier Calliper 
in three orthogonal diameters A, B and C, each corrected for thickness of the 
skin. Tumor volumes were calculated based on the formula A x B x C x π/6. 
Once tumor volumes reached an average of 250 mm³, animals were 
anaesthetized with 0.1 ml per 100 g body weight (b.w.) sodium pentobarbital 
(Nembutal; Sanofi, Belgium), placed on a lucite plate and the tumor was 
positioned in the irradiation field using a custom-built jig. All irradiated tumors 
received a single dose of 10 Gy (16 meV eP-P) using a Linear Accelerator (Linac 
Systems). When tumors reached four times the volume at the time of 
irradiation, animals were sacrificed and tumors were excised. The animal 
facilities and experiments were all performed in agreement with the national 
guidelines for animal welfare and approved by the Animal Ethics Committee 
of the University ‘KU Leuven’ Belgium.  
 
ATP assay 
0.1 g of pRS U87 and pRS 4E-BP1 U87 tumor tissue was homogenized in 500 
µL of RIPA buffer (150mM NaCl, 1% NP-40, 0.5% Na-deoxycholate, 0.1% 
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SDS, 50mM Tris pH 7.5 and CompletePTMP (Roche) protease inhibitor cocktail). 
Lysates were centrifuged at 16000 g for 2 min at 4°C to remove contaminants 
like DNA. The supernatant was collected in a cold microcentrifuge tube 
containing 5% trichloroacetic acid (TCA) and ATP concentrations were 
determined using an Adenosine 5’ triphosphate (ATP) Bioluminescent Assay 
Kit (Sigma). 
 
Detection of hypoxic areas in tumors 
To allow assessment of the hypoxic regions within tumors, mice were injected 
i.p. with the hypoxic marker pimonidazole (60 mg/kg b.w.; Hypoxyprobe-2, 
Chemicon) 1 hour prior to sacrifice. Tumors were excised, fixed overnight in 
4% neutral buffered formaldehyde and embedded in paraffin. 5 µm sections 
were deparaffinized in xylene, rehydrated in a graded alcohol series and finally 
with water. Endogenous peroxidase was quenched using 0.3 % hydrogen 
peroxide in absolute methanol. Epitope retrieval was done by microwave 
treatment in the presence of 10 mM sodium citrate (pH 6.0). Sections were 
incubated with a FITC-labeled mouse monoclonal antibody against 
pimonidazole (1:50 dilution, Chemicon) for 60 min at RT. A secondary mouse 
anti-FITC HRP conjugated antibody was applied (1:50 dilution, Chemicon) 
and staining was visualized using the DAB chromogen (Dako). Sections were 
rinsed and counterstained with hematoxylin (Klinipath).  
 
Immunohistochemical analysis of proliferation 
Briefly, 5 µm sections were deparaffinized and incubated with mouse on 
mouse (MOM) blocking reagent in 10% normal goat serum for 70 min at RT. 
A mouse monoclonal PCNA antibody (1:500 dilution, Chemicon) was applied 
for 30 min at RT. A secondary biotinylated goat anti-mouse antibody (1:500 
dilution, DakoCytomation) was applied, followed by incubation with the 
vectastain ABC kit (1:200 dilution, Vector Laboratories). Staining was 
visualized using DAB chromogen (Dako). Sections were rinsed and 
counterstained with hematoxylin (Klinipath). 
 
Visualization of blood vessels 
In order to visualize blood vessels, deparaffinized sections were incubated with 
rabbit polyclonal CD31 antibody (1:400 dilution, Santa Cruz) for 50 min at RT. 
A secondary biotinylated goat anti-rabbit antibody (1:500 dilution, 
DakoCytomation) was applied, followed by incubation with the vectastain 
ABC kit (1:200 dilution, Vector Laboratories). Staining was visualized using 
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DAB chromogen (Dako). Sections were rinsed and counterstained with 
hematoxylin (Klinipath). 
 
Immunohistochemical analysis of apoptosis 
Deparaffinized sections were incubated with a rabbit cleaved caspase-3 (Asp 
175) monoclonal antibody (1:100 dilution, Cell Signaling) overnight at 4°C. A 
secondary PowerVision HRP anti-rabbit antibody (undiluted, Immunologic) 
was applied. Staining was visualized using DAB chromogen (Dako). Sections 
were rinsed and counterstained with hematoxylin (Klinipath). 
 
Statistical analysis 
Comparisons between cells transfected with the 4E-BP1-targeting shRNA 
(pRS 4E-BP1) and control cells (pRS) and ATP measurements within tumors 
were determined using a Student’s t test. For in vivo experiments, statistical 
analyses were performed with a two-tailed, unpaired Mann-Whitney U test. 
Error bars indicate standard deviations and P values less than 0.05 are 
considered statistically significant. 
 
 
RESULTS 
 
To investigate the role of 4E-BP1 on tumor growth, hypoxia tolerance and 
response to treatment we used  previously constructed HeLa cervix carcinoma 
cells stably expressing an shRNA against 4E-BP1 (referred to as pRS 4E-BP1 
HeLa) [16]. To facilitate analysis of the role of 4E-BP1 in tumor xenografts, 
we also stably expressed this same shRNA or an empty vector control in 
glioblastoma U87 cells. The U87 cells form rapidly growing xenografts in vivo 
that are resistant to radiotherapy due in part to the presence of tumor hypoxia 
[24]. The shRNA against 4E-BP1 was effective in U87 cells as assessed by 
quantitative RT-PCR and similar in magnitude to that which we have 
previously reported in HeLa cells (Figure 1A). The shRNA against 4E-BP1 has 
no effect on 4E-BP2 transcript levels, demonstrating the specificity of the 
shRNA for 4E-BP1 and absence of compensation by the paralog. Stable 
knockdown of 4E-BP1 in U87 cells was also observed at the protein level and 
similar in magnitude to that for the previously generated HeLa cells (Figure 
1B). We previously reported that stable knockdown of 4E-BP1 in HeLa cells 
does not alter their proliferation under standard tissue culture conditions [16]. 
Similarly, no effect on proliferation was observed in the U87 4E-BP1 
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knockdowns compared with their wild-type controls (Figure 1C). These data 
suggest that under optimal growth conditions in vitro, proliferation rates are not 
limited by eIF4E availability.  
 
 
 
 
   
 
Figure 1: (A) 4E-BP1 and 4E-BP2 transcript levels in pRS and pRS 4E-BP1 U87 cells 
reported as mean ± SD of triplicate q-RT-PCR measurements (*P < 0.05 vs control cells). (B) 
Western blots demonstrating reduced 4E-BP1 protein expression levels in the pRS 4E-BP1 
cells. (C) Proliferation rates of pRS U87 and pRS 4E-BP1 U87 cells were monitored by 
counting cells following 2, 3 and 4 days of growth. Error bars represent standard deviation of 
the mean. Data points represent the mean ± SD of triplicate measurements. 
 
 
Recent reports by us and others have shown that signaling to 4E-BP1 
occurs during hypoxia and is responsible for important changes in gene 
A B 
   C 
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expression [16, 21, 22]. However, the consequences of this effect for hypoxia 
tolerance in vitro or in vivo have not been adequately addressed. We therefore 
assessed the tolerance of these cells to conditions of severe hypoxia (<0.02%) 
that are sufficient to induce cell death [25]. Figure 2 indicates that loss of 4E-
BP1 significantly (P < 0.05) reduces the tolerance of both HeLa and U87 cells 
to prolonged (48hr) hypoxia exposure. In the HeLa cells, hypoxia tolerance 
could be assessed by direct measurements of clonogenic survival (Figure 2A). 
However, lack of sufficient U87 colony formation in vitro necessitated the use 
of a less informative cell viability assay. However, a significant decrease in cell 
survival (P < 0.05) was also observed in the U87 4E-BP1 knockdown cells 
after 48 h of hypoxia compared to the empty vector controls (49% survival for 
pRS U87 cells versus 24% survival for pRS 4E-BP1 U87 cells) (Figure 2B). 
The data from both cell lines are thus consistent and indicate an important 
function for 4E-BP1 in maintaining cell survival during hypoxic stress.   
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Figure 2: (A) A clonogenic survival assay was performed after pRS and pRS 4E-BP1 HeLa 
cells were exposed to 16, 24 and 48 hours of hypoxia (<.02%). Data points represent the mean 
± SD of triplicate measurements (*P < 0.05 vs control cells). (B) Cell viability assay for pRS 
and pRS 4E-BP1 U87 cells after 24 and 48 hours of hypoxia. Columns report the mean ± SD of 
duplicate measurements (*P < 0.05 vs control cells). 
A 
B  
Chapter 5                                                                                            
146 
To investigate the consequences of 4E-BP1 knock-down in tumor 
growth and treatment pRS U87 and pRS 4E-BP1 U87 cells were injected 
subcutaneously into the lateral flank of adult NMRI-nu (nu/nu) female mice. 
The rate of tumor growth was assessed by regular measurements of tumor size 
as a function of time (Figure 3A). Consistent with its role in negatively 
regulating eIF4E, knock-down of 4E-BP1 resulted in a small but significant (P 
< 0.01) increase in growth rate. The median doubling-time determined from 
analysis of growth curves from individual 4E-BP1 knockdown tumors was 
2.71 days compared to 4.04 days in the controls (Figure 3B). These data are in 
contrast with the in vitro growth results and suggest that regulation of eIF4E 
plays a more important role in proliferation in vivo. This is not surprising 
considering that features of the microenvironment, including fluctuations in 
oxygen, nutrient and growth factor availability all signal to 4E-BP1 via 
mTORC1. The data are also consistent with previous studies showing that 
eIF4E activity is an important contributor to tumor growth [26, 27]. 
 
The tumor microenvironment is a strong determinant of tumor response 
to radiotherapy. To determine if 4E-BP1 influences tumor response to 
radiation, tumors were irradiated with a dose of 10 Gy after they reached a size 
of 250 mmP3 P. This dose resulted in a significant growth delay for both tumor 
types and caused little to no skin toxicity. We determined the specific growth 
delay which is calculated by determining the difference in time required to 
meet a defined tumor size relative to the doubling time of the tumor. This value 
is thought to closely reflect the relative number of cells killed by treatment. 
Interestingly, we found that the specific growth delay determined at 2, 3, or 4 
times the  starting tumor volume was significantly higher (P<0.01) in the pRS 
4E-BP1 U87 tumors compared to the pRS U87 control tumors (Figure 3C). 
The response of tumors to such a large single dose is governed primarily by the 
fraction of viable hypoxic cells since these cells require up to three times more 
dose to achieve a similar level of cell kill as well-oxygenated cells. Thus, these 
data are consistent with a smaller number of viable hypoxic cells in the 4E-BP1 
knock-down tumors. 
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Figure 3: (A) Tumor xenografts were established and followed in immunodefecient mice 
before and following irradiation. A single dose of 10 Gy was administered when tumors 
reached a size of 250 mmP3P. Data shown are the average and standard deviation of from a total 
of 4-6 tumors in each group and are normalized to the mean size at the time of irradiation. (B) 
The doubling times of individual untreated pRS U87 and pRS 4E-BP1 U87 xenografts tumors 
were calculated (*P < 0.01 vs control tumors). (C) The specific growth delay for individual 
irradiated tumors from both tumor types was calculated as the time required to reach 2, 3 or 4 
times the starting volume divided by the time to reach the same volume in the unirradiated 
controls. The 4E-BP1 knockdown tumors have a significantly longer specific growth delay (*P 
< 0.01 vs control tumors).  
A 
B C
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The increased sensitivity of the 4E-BP1 knock-down tumors could also 
result from a direct effect on tumor cell radiosensitivity. This was investigated 
by measuring the response of both HeLa and U87 4E-BP1 knock-down and 
control cell lines to a range of radiation doses in vitro (Figure 4). In HeLa cells, 
loss of 4E-BP1 provides a small level of protection rather than sensitization to 
irradiation with 2 Gy or 4 Gy as measured by clonogenic survival (Figure 4A). 
In contrast, a growth/viability assay indicated a small but non-significant 
increase in radiosensitivity to doses of 4 or 10 Gy in U87 cells with stable 
knock-down of 4E-BP1 (Figure 4B, P = 0.075). Thus, although we cannot rule 
out a contribution of changes in radiosensitivity to the increased growth delay 
in the 4E-BP1 knock-down tumors, this effect is small and not consistent 
between the two cell lines.   
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Figure 4: (A) A clonogenic survival assay was performed after HeLa pRS and pRS 4E-BP1 
cells were exposed to 2 and 4 Gy of irradiation. Data points are the mean ± SD of duplicate 
measurements. (B) Cell viability assay for U87 pRS and pRS 4E-BP1 cells after 4 and 10 Gy 
of irradiation. The mean ± SD of duplicate measurements is reported. 
A 
B 
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To investigate more directly if the increased radiosensitivity of pRS 4E-
BP1 U87 tumors was instead due to changes in the microenvironment we 
prepared tumor sections and performed immunohistochemical analyses with 
markers for hypoxia, blood vessel density, proliferation and apoptosis. 
Evaluation of the different markers was performed blindly by semi-quantitative 
measurement. To identify the hypoxic areas within the tumors, we used 
pimonidazole (PIMO) staining, which was quantified as < 10% tumor area 
positive, ≥ 10% and < 50% positive or ≥ 50% positive. Furthermore, the 
intensity of PIMO staining was indicated as weak or strong. PIMO staining 
was detected primarily within the peri-necrotic areas within all tumors and no 
significant differences in the amount or severity of hypoxia was detected 
between control and 4E-BP1 knock-down tumors (Table 1). Similarly, both 
tumor types were highly proliferative with greater than 50% PCNA positive 
cells in the viable areas of the tumors. These data indicate that development of 
hypoxia is similar in both tumor types. 
 
To evaluate the cellular consequences of hypoxia, we assessed blood 
vessel density (CD31) and apoptosis (cleaved caspase 3) within the hypoxic 
areas in the tumors. We did not observe any CD31-positive endothelial cells in 
PIMO-positive areas in parallel sections of all tumor types (Table 1). These 
data suggest that the hypoxia detected by PIMO staining is typical of diffusion 
limited hypoxia in both tumor types. Hypoxia in poorly vascularized regions 
develops due to gradients of oxygenation around perfused vessels and is 
referred to as chronic hypoxia. Overall, both tumor types demonstrated low 
expression of cleaved caspase-3. However, apoptosis in hypoxic regions (as 
indicated by positive PIMO staining) was significantly greater in the 4E-BP1 
knock-down tumors compared to the control tumors (Figure 5A, Table 1). 
Control tumors did not demonstrate any enhancement of cleaved caspase-3 
staining in these areas compared to non-hypoxic regions, whereas caspase 3 
activity was highly enriched in the hypoxic areas of 4E-BP1 knock-down 
tumors. These data suggest that although overall levels of hypoxia are similar 
in the two tumor types, the viability of hypoxic cells is lower in those tumors 
with knock-down of 4E-BP1. 
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Table 1: Immunohistochemical analysis for pRS and pRS 4E-BP1 U87 tumors. 
 
Name % PIMO 
pos.P*P 
Intensity 
PIMOP**P 
PCNAP* 
 
CD31 in 
PIMO pos. 
areaP* P 
CASP-3 in 
PIMO pos. 
areaP$ P 
pRS U87 
(n =3) 
 
1 
2 
3 
 
1 
2 
2 
3 
3 
3 
1 
1 
1 
2 
1 
1 
 
pRS 4E-BP1 
U87 
(n = 4) 
3 
2 
2 
1 
2 
2 
2 
1 
3 
3 
3 
3 
1 
1 
1 
1 
2 
2 
2 
2 
P
*
P 1: < 10% tumor area positive; 2: ≥ 10% and <50% tumor area positive; 3: ≥ 50% tumor area 
    positive 
P
**
P 1: weak; 2: strong 
P
$
P 1: absent; 2: present 
 
 
 We hypothesized that the reduction in hypoxia tolerance in the 4E-
BP1 knockdown cells could be related to their ability to regulate energy status. 
ATP production is challenged during hypoxia due to the dependence on 
glycolysis rather than oxidative respiration. Activation of 4E-BP1 during these 
conditions may thus act to maintain energy levels by inhibiting protein 
synthesis, a large consumer of ATP. In support of this hypothesis we found that 
ATP levels were consistently lower in the 4E-BP1 knock-down tumors. Figure 
5B shows ATP measurements derived from 4 control and 4 4E-BP1 knock-
down tumors. The ATP levels in these tumors show some overlap, but in 
general the 4E-BP1 knockdown tumors display lower values. This did not 
reach significance (P = 0.14), due in part to a single tumor in the control group 
that had an unusually high ATP level. If this tumor is ignored, the average 
difference between the two groups becomes smaller, but also reaches 
significance (P < 0.05). 
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Figure 5: Tumors were scored blindly for CD31 and cleaved caspase-3 in PIMO-rich areas. 
(A) No CD31-positive endothelial cells in PIMO-positive areas were observed in parallel 
sections of all tumor types. pRS 4E-BP1 U87 tumors demonstrated cleaved caspase-3 activity, 
while control tumors did not demonstrated cleaved caspase-3 activity in these hypoxic areas. 
(B) Concentration of ATP in pRS and pRS 4E-BP1 U87 tumors. Symbols represent 
measurements from individual tumors with horizontal bars indicating the mean of each group.  
 
A 
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DISCUSSION 
 
The idea that translation initiation and eIF4E may be good targets for cancer 
therapy is not a new one. eIF4E is active in virtually all tumors, and plays a key 
role in promoting malignant behavior [11]. The contribution of eIF4E to 
malignant transformation and progression has been extensively elucidated and 
derives in large part from its ability to translationally regulate important growth 
regulatory genes. A number of trials have explored the effects of targeting 
eIF4E in preclinical tumor models. Antisense-RNA-mediated reduction of 
eIF4E suppressed both the tumorigenic and angiogenic properties of the FaDu 
head and neck cancer cells, as demonstrated by loss of capacity to grow in soft 
agar, reduced expression of angiogenic factors, and loss of tumorigenicity in 
nude mice [28]. Similarly, targeting eIF4E mRNA with an antisense RNA in 
cloned rat embryo fibroblasts (CREF) cells caused reversal of ras-mediated 
transformation and tumorigenesis [29].  
 
Although these results are promising, the fact that eIF4E is regulated 
primarily through protein protein interactions makes it a poor candidate for 
direct drug development. An alternative approach to target its activity is 
through inhibition of pathways that regulate 4E-BP1. These include the 
PI3K/Akt/mTOR pathway, which plays a central role in regulating cell growth, 
proliferation and survival. Signaling through PI3K/Akt pathway is propagated 
to a diverse array of substrates, including the mammalian target of rapamycin 
mTOR, which promotes translation initiation through increased 4E-BP1 and 
ribosomal p70S6 kinase (p70S6K) phosphorylation. Rapamycin, a clinically 
approved mTOR inhibitor, activates 4E-BP1, which blocks eIF4E from 
engaging and activating the eIF4F complex. Currently, there are a number of 
clinical trials investigating the use of rapamycin or its analogs as new 
therapeutic agents. However, although 4E-BP1 clearly has anti-growth 
properties, its function in cancer is multi-factorial. We and others previously 
identified it as playing a role in the adaptation to hypoxic stress by suppressing 
translation initiation [16, 21, 22]. Furthermore, malignant tumors have recently 
been reported to maintain high levels of 4E-BP1 [18]. Here, we have 
demonstrated that knockdown of 4E-BP1 has opposite effects on tumor growth 
and response to treatment. Loss of 4E-BP1 accelerated tumor growth, as 
predicted by its role in negatively regulating translation but resulted in an 
increased tumor response to treatment with radiation. This increased response 
appears to result primarily from a reduced tolerance to hypoxia that was 
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apparent both in vitro and in vivo. The reduction in hypoxia tolerance may be 
related to the inability of these cells to maintain energy homeostasis through 
regulation of translation initiation since the 4E-BP1 knockdown tumors also 
had reduced ATP levels. Remarkably, the use of 4E-Bp1 genes/proteins as 
hypoxia sensitive metabolic brakes seems to reflect a vital and widespread 
survival strategy even in healthy organisms. In hypoxia tolerant cells from 
embryonic fruitflies, the gene encoding the 4E-BP1 homolog is strongly 
induced by oxygen deprivation and its loss-of-function correlates with a poor 
adaptation and slowed recovery of hypoxia-challenged male Drosophila (TAG, 
pers. communication). 
 
Despite the exact mechanism, these data indicate that some caution 
should be taken in clinical regimes that include drugs that indirectly target 4E-
BP1 in combination with radiation or other hypoxia influenced therapies [30, 
31].  For example, our data suggest the possibility that by activating 4E-BP1, 
rapamycin could potentially increase hypoxia tolerance and radioresistance and 
thus offset the other benefits of inhibiting mTOR. Indeed, we have previously 
demonstrated some evidence for this effect in U87 tumors treated with a 
combination of radiation and rapamycin [24]. Despite providing a clear 
inhibition in tumor growth, rapamycin failed to increase the response of tumors 
treated with fractionated radiotherapy. Furthermore, the tumors treated with 
rapamycin demonstrated evidence of increased hypoxia consistent with a role 
of 4E-BP1 in mediating hypoxia tolerance.  
 
Hypoxia regulates translation initiation through two distinct 
pathways[21, 22]. Rapid but transient eIF2α phosphorylation is responsible for 
a rapid inhibition in translation and this is followed by sequestration of eIF4E 
by both 4E-BP1 and by its transporter 4E-T [21]. Tumors derived from 
transformed mouse embryo fibroblasts (MEFs) that are unable to inhibit 
translation through eIF2α phosphorylation (lacking the PERK eIF2α kinase or 
expressing the non-phosphorylateable S51A eIF2α allele) form tumors that 
grow slowly and which have increased levels of apoptosis in hypoxic regions 
[20]. Interference with eIF2α phosphorylation also leads directly to reduced 
hypoxia tolerance in vitro in both MEFs and human tumor cells [20, 32]. Thus, 
together with the data reported here it appears that regulation of mRNA 
translational during hypoxia through both eIF2α and 4E-BP1 is important for 
hypoxia tolerance and has important implications for the tumor 
microenvironment. 
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Tumors are known to demonstrate greatly increased rates of metabolism 
due to mutations in oncogenes and tumor suppressors that regulate cell growth 
decisions. In U87 cells, increased rates of metabolism result from mutations in 
the PTEN gene, which lead to increased AKT activity and cell growth [33]. 
Loss of 4E-BP1 in these cells presumably removes an important regulatory 
control on mRNA translation and thus the potential for even higher ATP 
consumption and/or demand. Consistent with this, we observed substantially 
lower overall ATP levels in the 4E-BP1 knockdown tumors compared to their 
wild-type controls. We hypothesize that cancer cells with elevated metabolism 
may become increasingly dependent on 4E-BP1 for energy homeostasis and 
may thus explain selection of tumors cells with high levels of this protein [18]. 
Consequently, targeting 4E-BP1 may be especially effective in killing hypoxic 
cancer cells that have sustained mutations which result in deregulated 
translational control. This approach is similar to the concept of ‘synthetic 
lethality’ which has been proposed for targeting of tumor cells harbouring 
specific mutational events. For example, treatment of repair deficient BRCA1 
and BRCA2 mutant cells with Poly (ADP-ribose) polymerase (PARP) 
inhibitors [34] results in selective killing due to increased reliance of the PARP 
pathway. Changes in the reliance of metabolic pathways during hypoxia may 
similarly lead to vulnerabilities that can be exploited for specific cancer 
therapy. 
 
In conclusion, our data provide a unique example in which targeting a 
gene with tumor suppressor activities can be exploited to improve cancer 
therapy. Our interpretation of the mechanism responsible for explaining the 
increased sensitivity of tumors lacking 4E-BP1 to hypoxia and irradiation is 
based on the inability of these cells to properly regulate ATP consumption 
during hypoxic conditions. We suggest that this approach may be most 
beneficial in cancers with mutations in signaling pathways that lead to over-
activation of metabolic processes regulated by mTOR. This idea should be 
testable in current clinical trials targeting mTOR with rapamycin and its 
analogs in combination with radiotherapy. 
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ABSTRACT 
 
Human tumors are characterized by large variations in oxygen concentration 
and hypoxic tumors are associated with poor prognosis. In addition, tumors are 
subjected to periodic changes in oxygenation characterized by hypoxia 
followed by reoxygenation. Cellular adaptation to hypoxia is well documented, 
nevertheless little is known about adaptive mechanisms to reoxygenation. 
Here, we investigate the changes in protein expression during reoxygenation 
using proteomics. HeLa cervix carcinoma cells were exposed to 4 h of hypoxia 
(<0.01%O2) followed by 1 hr of reoxygenation. The cellular proteome was 
examined using 2D gel electrophoresis coupled with mass spectrometry. 
Validation and investigation of the underlying basis for induced protein 
expression was investigated using western blot analysis and quantitative RT-
PCR. We identified proteins involved in several cellular processes that are 
responsible for regulating RNA metabolism, protein synthesis and degradation, 
including ribosomal protein P0, VCP/p97 and FUSE binding protein 2. Our 
results suggest that these newly identified proteins function in pathways that 
may assist in the recovery of ER stress and protein synthesis during 
reoxygenation. These proteins may thus be important determinants of the 
behaviour and survival of tumor cells to transient hypoxic exposures. 
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INTRODUCTION 
 
The consequences of lack of oxygen (hypoxia) within solid tumors has been 
intensively investigated over the past decade based on the observations that 
hypoxic tumors are more resistant to therapy, have a worse prognosis, and may 
be more malignant [1-4]. However, many areas within solid tumors are 
subjected not only to hypoxia but also to periodic changes in oxygenation 
characterized by hypoxia followed by reoxygenation. Reoxygenation is an 
important stress characterized by the production of reactive oxygen species 
(ROS) that cause damage to cellular macromolecules, including DNA [5]. It 
can be argued that any hypoxic cell that contributes to tumor repopulation or 
metastasis, must at one point reoxygenate and thus tolerate this stress. 
Consequently, it is important to consider the effects of reoxygenation on tumor 
biology. Nevertheless, there is little data regarding the contribution of 
reoxygenation to the biology within solid tumors [6].  
 
 Most studies of reoxygenation come from ischaemia-reperfusion 
experiments and myocardial injury where readmission of oxygenated blood 
into previously ischaemic myocardium can initiate a cascade of events that  
produce additional myocardial cell dysfunction and cell necrosis via generation 
of ROS [7-9]. Adaptation of solid tumors to cycles of oxygenation may 
promote tolerance to ROS generation during reoxygenation periods. Repeated 
cylces of hypoxia have been shown to select for death-resistant cells that are 
cross-resistant to apoptosis induced by staurosporine, azide, and cisplatin 
through upregulation of Bcl-XL, resulting in mitochondrial integrity and cell 
viability [10].  
 
 In this study, we used proteomic techniques to search for changes in 
protein expression that are specific to cells exposed to the stress of 
reoxygenation and identified 8 proteins.  These included a number of proteins 
involved in protein synthesis and quality control.   
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MATERIALS AND METHODS 
 
Cell culture and hypoxic conditions 
Cervix carcinoma (HeLa) cells were grown in Dulbecco’s modified Eagle’s 
medium (Sigma) supplemented with 10% fetal bovine serum (Sigma) at 37°C 
in a 5% CO2 incubator. Exponentionally growing cells were plated on plastic 
culture dishes and hypoxic treatments (<0.01%O2) were performed as 
previously described [11]. 
2-DE and image analysis 
Briefly, 15 cm culture dishes of exponentionally growing HeLa cells were 
washed twice with ice-cold 10 mM/250 mM sucrose buffer pH 7.0 and lysed in 
7 M urea/2M thiourea based lysisbuffer. Cells were exposed to a quick freeze-
thaw lysis, then lysates were centrifuged at 13000 g for 30 min at 4°C to 
remove contaminants. Protein samples were applied to 24 cm IPG strips pH 3-
10 NL (Amersham Biosciences). Following isoelectric focusing, the strips 
were placed on the Protean Plus Dodeca Cell (Bio-Rad Laboratories) to 
perform a second dimension separation using 12% SDS-PAGE gels. The 
system was run at 200 V for 5 hours. Proteins were visualized by staining with 
SYPRO Ruby dye (Bio-Rad Laboratories). The 2D stained gels were imaged 
on a Molecular Imager FX (Bio-Rad Laboratories). The resulting 2D protein 
patterns were analyzed, using PD-Quest 7.1 software (Bio-Rad Laboratories). 
 
In-gel trypsin digestion and ESI-TRAP MS 
Protein spots of interest were excised from the gel using an automatic spot 
cutter (Bio-Rad). After two washes with 150 µL 200 mM NH4HCO3/50% 
ACN the gel plugs were completely dried using a Speedvac (Thermo Savant). 
To the dried gel plugs 8 µl 50 mM NH4HCO3 containing 150 ng trypsin 
(Promega) per µl was added and the gel pieces were kept on ice for 1 hour. 
Trypsin buffer was added to cover the gel plugs completely and the samples 
were incubated overnight at 37°C. The peptides were extracted by two 
consecutive washes with 50% ACN/0.1% HCOOH and the pooled extracts 
dried. The samples were resuspended in 8 µl 0.1% HCOOH and analysed using 
an nano-HPLC system (Dionex) hyphenated to a Q-TRAP mass spectrometer 
(Applied Biosystems) [12]. The MASCOT search engine was used for protein 
identification allowing a 1 Da peptide mass and fragment mass tolerance. 
Carbamidomethylation and methionine oxidation were set as variable 
modification.   
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Western blot analysis 
Whole cell extracts (30 μg) were resolved in 10% SDS PAGE gels and 
transferred onto Hybond-PVDF membrane (Amersham Biosciences). Then the 
membranes were incubated overnight with primary antibody: VCP (1:1000 
dilution, Cell Signaling Technology) followed by incubation with horseradish 
peroxidase-conjugated secundary antibody (1:2000 dilution, Cell Signaling 
technology). For the preparation of nuclear and cytoplasmic protein extracts we 
performed a gently lysis based on a 1% Triton X-100 lysisbuffer to isolate the 
cytoplasmic fraction followed by 10% glycerol lysisbuffer treatment for the 
nuclei. Protein signals were detected using the Super Signal West Pico kit 
(Pierce).  
 
Quantitative PCR analysis 
Experiments and normalizations were performed as previously described [13]. 
The abundance of the following genes were detected with SYBR Green I 
(Applied Biosystems) using indicated forward and reverse primers: RPP0: F-
ggcgacctggaagtccaact and R-ccatcagcaccacagccttc; CA-IX: F-
catcctagccctggtttttgg and R-gctcacaccccctttggtt; 18SrRNA: F-
agtccctgccctttgtacaca and R-gatccgagggcctcactaaac. The following genes were 
measured using Taqman Gene Expression Assays (Applied Biosystems): 
FBP2: Hs00269352_m1 and FBP3: Hs00383472_m1.  
 
 
RESULTS 
 
To investigate the potential impact of reoxygenation on global protein 
expression, HeLa cells were incubated for 4 h of hypoxia (<0.01%O2) or 4 h of 
hypoxia followed by 1 h of reoxygenation. Proteomic analysis of whole cell 
extracts from aerobic, hypoxic and reoxygenated HeLa cells was performed by 
two dimensional gel electrophoresis on the basis of the charge and mass 
followed by visualization with SYPRO-Ruby. This experiment was repeated in 
triplicate with a technical repeat for each condition (representative gels from 
each experimental condition are shown in Figure 1A). Proteins were matched 
across all gels to identify protein spots that were exclusively expressed during 
reoxygenation. The densities of the spots were determined with normalization 
based on total protein density on the gel. Overall, the 2D gel protein spots 
profiles across all of the gels from the hypoxic and reoxygenation treated and 
controls groups were similar. Fourteen spots were found to be expressed 
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exclusively during reoxygenation, eight of which were successfully identified 
by analysis of ESI-TRAP MS followed by database searching. These proteins 
were separately involved in different cellular processes and stress response 
pathways (Table 1). These proteins were also expressed after 16 h hypoxia 
followed by 1 h reoxygenation (data not shown). In our 2D gels, we found 
VCP/p97, FUSE binding proteins 2 and 3 (FBP2/FBP3) and ribosomal protein 
P0 (RPP0) to be expressed after reoxygenation (Figure 1B).  
 
Table 1: List of protein spots and their identification 
 
Swiss-Prot 
Accession 
No. 
Protein  
name 
Putative 
function 
Mr(kDa)/pI Mass 
Fingerprint 
>65 
Pep 
No. 
P55072 Vasolin containing protein Proteosome 97/5,14 252 8 
Q92945 FUSE binding protein 2 
RNA 
metabolism 72/8,02 216 5 
Q92946 FUSE binding protein 3 
RNA 
metabolism 64/8,84 309 10 
P05388 Ribosomal protein P0 
Protein 
translation 34/5,72 118 5 
Q07244 
Transformation 
upregulated 
nuclear protein 
Pre-mRNA 
processing 51/5,39 71 5 
O15460 
Prolyl 4-
hydroxylase, 
alpha II subunit 
Collagen 
synthesis 61/5,49 215 6 
P50552 
Vasodilator-
stimulated 
phosphoprotein  
Cell adhesion 40/9,05 46 2 
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A 
B 
 
Figure 1: (A) Representative 2D gels treated with 4 h hypoxia or 4 h hypoxia followed by 1 h 
reoxygenation. Protein (150 µg) was loaded on IPG strips (24 cm, pH 3-10 NL), followed by 
the second dimension on 12% SDS-PAGE gel, visualized with SYPR Ruby. (B) The insets 
show the expression and quantification of proteins listed in table 1 during normoxia (N), 
hypoxia (H) and reoxygenation (R).   
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To confirm the results found by proteomics and to determine the 
underlying basis for the increase in protein found during reoxygenation we 
evaluated the transcriptional, translational, and potentially post-translational 
changes in these proteins. For VCP we found no evidence of a transcriptional 
or translational change during hypoxia or hypoxia plus reoxygenation. 
Furthermore, we conducted western blot analysis using whole cell extracts 
from cells exposed to 4 h hypoxia or 4 h hypoxia followed by 1 h 
reoxygenation and found no significant differences in total expression levels 
between the different conditions (Figure 2A). This prompted us to test whether 
the change in VCP found in the proteomic analysis could be due to a change in 
the cellular distribution of VCP. We analyzed the distribution of VCP 
separately in nuclear and cytoplasmic protein extracts. As shown in Figure 2B, 
after 4 h hypoxia followed by 1 h reoxygenation we detected a significant 
translocation of VCP from the nucleus to the cytoplasm. This translocation of 
VCP was also observed after 16 h hypoxia followed by 1 h reoxygenation (data 
not shown). Based on this data we hypothesize that reoxygenation might 
primarily regulate VCP at the post-translational level. 
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A 
Figure 2: (A) Western blot 
analysis of whole cell extracts 
(30 µg) with antibody recog-
nizing VCP was carried out. 
Representative image of three 
independent experiments. (B) 
Western blot analysis for VCP 
using nuclear and cytoplasmic 
protein extracts from HeLa 
cells. Representative image of 
two independent experiments. 
β-Actin was used as a loading 
control. Histone H3 was used as 
a control for the preparation of 
nuclear and cytoplasmic 
extracts. 
 
 
 
 
B 
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To confirm the increased protein expression of FBP2, FBP3 and RPP0 
during reoxygenation, we conducted experiments that would allow us to 
monitor both potential transcriptional and translational changes. Lysates from 
cells exposed to 4h hypoxia or 4h hypoxia followed by 1 h reoxygenation were 
separated over sucrose gradients to analyze the distribution of polysomes. The 
resulting profiles are shown in Figure 3A. In this assay, the first two peaks 
represent the 40S and 60S ribosomal subunits, respectively. The subsequent 
peaks represent mRNAs with increasing numbers of attached ribosomes 
(polysomes), which is a reflection of de novo protein synthesis. Figure 3A 
demonstrates that hypoxia inhibits overall mRNA translation in Hela cells 
since there is a clear reduction in the high molecular weight polysomal RNA. 
Interestingly, 1 h of reoxygenation is enough to restore overall mRNA 
translation to control levels. The amount of mRNA participating in translation 
can be determined by integrating the polysomal area and dividing by the total 
integrated area. The average results of two independent experiments are 
summarized in Figure 3B. The fraction of ribosomes participating in translation 
dropped from 67% in aerobic cells to 55% after 4 h of hypoxia and recovers 
after reoxygenation to 69%. This drop in translation agrees with that observed 
during exposure to moderate hypoxia (0.2%) in many other cell lines 
(Koritzinsky et al. submitted data). A more severe inhibition in translation 
occurs at oxygen concentrations less than 0.02%, but achieving these levels of 
oxygenation require culture on glass petri dishes. All of our experiments were 
performed on plastic. 
 
Next we performed real time quantitative RT-PCR for FBP2, FBP3 and 
RPP0 from both total cellular mRNA and from polysomal mRNA. This allows 
us to obverse both changes in transcription as well as changes in the efficiency 
that individual genes are translated into protein. Translation efficiency was 
determined by comparing the amount of mRNA found in the polysomes 
divided by the total amount in the cell. As shown in Figure 3C total cellular 
mRNA levels of FBP2, FBP3 and RPP0 did not significantly change during 
reoxygenation compared to hypoxia or normoxia. In comparison, hypoxic 
treatment caused a nine fold increase in CA-IX transcript levels. However, 
Figure 3D shows that the translation efficiency increased more then 2-fold for 
FBP2 and more then 3-fold for RPP0 during reoxygenation compared to 
hypoxia and normoxia. The slight increase in translation efficiency for FBP3 
was not significant. These data suggest that although no changes in 
transcription occur for FBP2 and RPP0 during reoxygenation, the synthesis 
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into protein is stimulated during reoxygenation through an increase in their 
translation efficiency. 
 
 
A 
C DB 
 
Figure 3: (A) Optical density (OD) at 254 nm is demonstrated as function of gradient depth for 
each time point. Actively translated mRNA is associated with high-molecular-weight 
polysomes in the gradient. (B) Amount of mRNA efficiently translated as a function of time. 
This fraction is proportional to the integrated area under the curve containing polysomes, as 
marked in (A). Gene-specific mRNA transcript levels were measured for FBP2, FBP3, RPP0 
and CA-IX. Data was normalized to 18S rRNA signal. (D) Relative translation efficiency was 
calculated for the genes of interest by dividing the signal in the polysome to the signal from the 
mRNA abundance. Figure 3 represents the data from two independent experiments. SEM is 
shown. 
 
 
DISCUSSION 
 
Our overall goal was to identify proteins that may play an important role in 
cellular adaptation to the stress of reoxygenation. Hypoxia/reoxygenation, 
generates cytotoxic reactive oxygen species which cause damage to DNA, 
RNA and proteins [5, 14] and we hypothesized that changes in individual 
170 
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protein levels may be important for adaptation to this damage. Using 
proteomics, we identified three proteins that are involved in different cellular 
processes which involve protein quality control and expression. VCP/p97 
(Cdc48 in yeast) is a hexameric ATPase of the AAA family that mediates 
numerous and diverse cellular functions, including endoplasmic reticulum-
associated degradation (ERAD) via the ubiquitin-proteosome system (UPS) 
[15]. The endoplasmic reticulum (ER) serves as a site for protein folding of 
newly synthesized secreted and transmembrane proteins. VCP is a highly 
abundant protein that is required for the removal of misfolded proteins from the 
ER to allow their degradation by the proteosome in the cytoplasm. Loss of 
VCP causes polyubiquitinated cellular proteins to accumulate indicating an 
impaired ability to present them to the proteosome [16].  
 
During conditions of ER stress such as the accumulation of unfolded 
proteins, an evolutionarily conserved program called the unfolded protein 
response (UPR) is activated. A number of recent reports from our group and 
others has demonstrated that hypoxia activates the UPR [13, 17] presumably in 
response to ER stress that occurs during hypoxic conditions. Our data here 
demonstrate that VCP translocates to the cytoplasm during reoxygenation, and 
might thereby transport unfolded proteins to the proteosome for degradation 
during conditions of reoxygenation where cells are recovering from hypoxia 
induced ER stress. We hypothesize that this effect may contribute to tumor cell 
survival, due to increased protein quality control and decreased cell toxicity. 
Interestingly, increased VCP expression levels have been associated with the 
recurrence of gastric carcinoma (GC) and hepatocellular carcinoma (HCC) [18, 
19]. Further investigation of the function of VCP during reoxygenation, might 
demonstrate the potential of VCP as a target in cancer therapy.  
 
 Oxidative stress also results in RNA damage and incorporation of 
oxidized nucleotides during RNA synthesis can impair protein synthesis and 
other RNA functions [14]. This is interesting, given the fact that two of the 
other proteins we identified, FBP2 and FBP3 are involved in RNA processing. 
We found that the efficiency by which FBP2 is translated into protein increases 
by more than 2-fold during reoxygenation. Regulation of translation efficiency 
is increasingly being recognized as a way to control differential protein 
expression in response to various conditions including hypoxia [11, 13], 
irradiation [20], and oncogenic signalling [21]. FBP2 (also termed KHRSP) is 
a member of the far-upstream element (FUSE) binding protein family that 
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promotes rapid mRNA decay by recruiting the degradation machinery to AU-
rich elements (ARE) containing mRNAs [22]. In addition, in COS cells it has 
been demonstrated that FBP2 co-localizes with TIA proteins in the nucleus and 
migrates into TIA-enriched cytoplasmic stress granules (SG) upon oxidative 
stress [23]. SG have recently been described as reservoirs for untranslated 
mRNAs, which are either routed back to polysomes or are transferred to 
processing bodies in which they are degraded [24].  The presence of FBP2 in 
TIA-1-containing SG suggests that FBP2 contribute to these complex routing 
mechanisms of ARE-containing mRNAs, thereby regulating the transcription 
of specific mRNAs.  During reoxygenation FBP2 might contribute to the 
degradation of oxidized RNAs, contributing to the quality control of RNA 
metabolism.  The fact that FBP3 seems not to be regulated at the transcriptional 
or translational levels, indicates that FBP3 may be regulated at the protein level 
or through post-translational modifications during reoxygenation. 
 
Finally, we also investigated in detail the regulation of the ribosomal 
protein P0, which is an essential component of the eukaryotic ribosomal stalk, 
composed of a pentameric complex of ribosomal protein P0 and the acidic 
proteins P1 and P2. This is a highly flexible structure involved in the 
interaction of elongation factors with the ribosome during protein synthesis 
[25]. We found that RPP0 is also translationally upregulated during 
reoxygenation. This protein may thus contribute to the restoration of protein 
synthesis during reoxygenation which was completely restored after only 1 h 
roxygenation (Fig. 3A). This may also lead to gene-specific changes in 
translation in a manner similarly reported in in S cerevisiae [26]. 
 
In summary, our results shed light on the contribution of reoxygenation 
on specific protein expression. The identified proteins are involved in different 
cellular processes that regulate protein quality control, mRNA translation and 
gene expression, and which may contribute to the cellular adaptation and tumor 
cell survival during reoxygenation. We hypothesize that during reoxygenation, 
these proteins act as part of a larger mechanism facilitating cellular recovery 
from ER stress and mRNA translational inhibition that occurs during hypoxia. 
Further investigation of the involvement of these proteins during reoxygenation 
may result in new attractive therapeutic targets. 
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SUMMARY AND DISCUSSION 
 
Poor oxygenation (hypoxia) influences important physiological and 
pathological conditions, including development, ischemia, stroke, and cancer. 
Hypoxia within solid tumors arises as a result of insufficiencies and improper 
functioning of the tumor vasculature, which negatively impacts treatment 
response. A series of measurements of pO2 values in primary and metastatic 
tumors of the cervix, breast, head-and-neck and rectum [1-3] have shown that 
patients with poorer tumor oxygenation exhibit a significantly lower 
probability of 5-year survival than patients with better-oxygenated tumors. 
These findings are supported by more recent studies of head-and-neck tumors 
and soft tissue sarcomas, and strongly suggest that hypoxia fundamentally 
alters tumor physiology to a more aggressive phenotype [4]. 
 
This appears at first glance to be paradoxical, since hypoxia is a 
condition unfavourable to cell growth and in many situations can even directly 
stimulate cell death. The resolution of this paradox lies in our understanding of 
the biological consequences of hypoxia for the tumor as a whole. In the past 
decade we have become aware of many important biological changes that 
occur when cells lack oxygen and the potential contribution of these pathways 
to the malignant phenotype of tumors. This biological response to hypoxia is 
capable of promoting metastasis, angiogenesis and selection of cells with 
diminished apoptotic potential. The inhibition or loss of pathways that promote 
cell death in response to hypoxia (e.g. p53 pathway) provide the basis for the 
selection of cells which have increased hypoxia tolerance [5].  
 
A general mechanism of adaptation, which received a lot of attention in 
research during the past decade, is the activation of a conserved transcriptional 
program mediated in large part by the hypoxia inducible factors termed HIFs, 
which modulates the expression of numerous genes involved in various 
processes such as angiogenesis and glucose metabolism.  
 
In this thesis, we have investigated the rapid and sustained inhibition in 
mRNA translation which seems to be another mechanism that contributes to 
hypoxia tolerance. Since protein synthesis is extremely energy costly, the 
inhibition of mRNA translation may act as a cellular survival mechanism by 
conserving energy demand during hypoxia in which energy production is 
inefficient. However, the inhibition of overall mRNA translation paradoxically 
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induces the expression of certain proteins that are essential for the adaptation to 
the hypoxic stress. We have focused on understanding how hypoxia inhibits 
overall protein synthesis and on determining which specific proteins are 
translationally regulated during hypoxia. Furthermore, we have investigated 
specific changes in protein expression during reoxygenation and their potential 
contribution to the adaptation of the tumor cell to this stress.  
 
 
mRNA translation is regulated by a family of translation initiation factors 
The first goal of this thesis was to investigate how the inhibition of overall 
mRNA translation during hypoxia is regulated. In chapter 2 we demonstrated 
that the inhibition of global mRNA translation during hypoxia exhibits a 
biphasic response, which is regulated at the level of translation initiation. The 
initial rapid inhibition is primarily dependent on eukaryotic inititiation factor 
2α (eIF2α) phosphorylation, whereas inhibition during prolonged hypoxia is 
independent of eIF2α. Phosphorylation of eIF2α under conditions of anoxia 
(<0.02% O2) is extremely rapid, occurring almost as quickly as we can 
establish hypoxia in our system (15-30 min). Recently, we demonstrated that 
the inhibition of mRNA translation during acute hypoxia (0.2% O2) also 
depends on eIF2α phosphorylation. Clonogenic survival assays demonstrated 
that the disruption of eIF2α phosphorylation increased the sensitivity to 
hypoxia and anoxia [6].  
 
We speculate that this rapid response may be especially important 
during acute exposures to hypoxia/anoxia that frequently occur in tumors due 
to the transient opening and closing of blood vessels. This rapid response may 
explain the importance of eIF2α and ATF4 in the tolerance of cells to oxidative 
stress, which also occurs during hypoxia/reoxygenation cycles [7]. This 
hypothesis is supported by another study demonstrating that  activation of the 
PERK-eIF2α pathway during hypoxia contributes to overall tumor growth [8]. 
Human tumor cells expressing a dominant-negative PERK allele as well as 
MEFs lacking PERK or expressing the S51A eIF2α produce smaller tumors 
with increased cell death in hypoxic areas than their WT counterparts [8]. 
Thus, although activation of eIF2α phosphorylation in response to hypoxia is 
transient, this response appears critical for long-term cell survival within 
hypoxic regions of tumors. Disruption of eIF2α phosphorylation might 
therefore be a potential target for hypoxia-directed molecular cancer therapy. 
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Furthermore, in chapter 2 we demonstrated that the inhibition of 
translation during prolonged anoxia is associated with disruption of the mRNA 
cap-binding complex eIF4F and sequestration of eIF4E by both 
dephosphorylated 4E-BP1 and 4E-T. After 4 h or 16 h hypoxia, there is a 
dramatic loss in binding of eIF4E to both eIF4GI and eIF4GII, indicating 
dissociation of the eIF4F complex. At 16 h, this dissociation correlates with a 
large increase in binding between eIF4E and 4E-BP1, consistent with the 
increase in the hypophosphorylated levels of 4E-BP1 at this time. Exposure to 
16 h of hypoxia also caused a redistribution of both eIF4E and 4E-T from the 
cytoplasm to the nucleus and to P-bodies. Mammalian P bodies are 
cytoplasmic foci enriched with 5' → 3' mRNA degrading enzymes where 
mRNA is degraded or stored [9]. Furthermore, microRNAs (miRNAs) which 
mediate translational repression and/or mRNA degradation at the 
posttranscriptional level accumulate in P-bodies [10].    Accumulation of eIF4E 
in the cell nucleus or P-bodies renders it unavailable for cytoplasmic 
translation. The initial phosphorylation and subsequent dephosphorylation of 
eIF2α during hypoxic exposure changed the translation efficiency of individual 
genes such as ATF4 and CHOP. 
 
In conclusion, we demonstrated in chapter 2 that mRNA translation is 
inhibited through multiple independent pathways with different activation 
kinetics during hypoxia. These different mechanisms of translational control 
influence the translation of individual genes to varying degrees and 
consequently can influence hypoxia-regulated protein expression in complex 
ways. An important finding is that inhibition of translation via eIF2α is 
transient, leading to dynamic changes in the translation efficiency of genes 
over the first 8 h of hypoxia. Our selected analysis of gene translation during 
hypoxia suggests that many genes may be differentially regulated by hypoxia.  
 
 
Microarrays can be applied as a tool to assess both transcriptional and 
translational changes during hypoxia 
In chapter 2 we demonstrated that although hypoxia causes a rapid reduction 
in overall mRNA translation, not all mRNA species are affected to the same 
extent. Therefore, mRNA translation efficiency can contribute significantly to 
hypoxia-induced differential protein expression. In chapter 3 we characterized 
changes in gene expression in DU145 prostate carcinoma cells during acute 
hypoxia (4 h hypoxia) and evaluated the contribution of regulation via mRNA 
translation on these changes. An Affymetrix approach was used to evaluate 
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both the transcriptional and translational contribution to gene expression for 
each gene. To assess the translational contribution to gene expression we 
separated cell lysates on sucrose gradients and then we measured RNA levels 
as function of gradient depth. Efficiently translated mRNA is associated with 
many ribosomes (polysomes) simultaneously and therefore sediments deep in 
the gradient. Thus, it is possible to separate mRNAs that are efficiently 
translated (mRNAs with more than 4 ribosomes) from mRNAs that are not or 
not efficiently translated. 120 genes were than 4-fold upregulated by hypoxia in 
the efficiently translated fraction of mRNA, in comparison to only 76 genes at 
the level of transcription. The gene that demonstrated the largest increase in 
translation during hypoxia was the HIF-1 target gene hexokinase 2 (HK-2), 
which is involved in glucose metabolism [11]. In conclusion, these data 
provide evidence that translational regulation plays an important role in 
contributing to the changes in protein expression that occur during hypoxia and 
highlights the importance of examining gene regulatory events that occur post-
transcriptionally.   
 
 
Loss of the tumor suppressor 4E-BP1 contributes to an adverse phenotype 
through specific protein expression  
In chapter 2 we demonstrated that inhibition of cap dependent translation 
during hypoxia is promoted via activation of two distinct inhibitory proteins, 
the mTOR target 4E-BP1 and the eIF4E transporter 4E-T, which disrupts the 
eIF4F complex. In chapter 4 we generated HeLa cells stably expressing a 
short hairpin interfering RNA (shRNA) against 4E-BP1 to assess the 
contribution of 4E-BP1 expression on changes in mRNA translation during 
hypoxia. We found that 4E-BP1 expression did not alter overall levels of 
mRNA translation during normoxia or hypoxia. However, using a proteomics 
approach we identified 7 proteins that were exclusively expressed in the 4E-
BP1 knock-down cells during both normoxic and hypoxic conditions. Further 
investigation of the transcriptional and translational regulation of these genes 
by quantitative RT-PCR indicated that the loss of 4E-BP1 causes a significant 
increase in the rate of protein synthesis of S100 calcium-binding protein A4 
(S100A4) and transgelin 2. S100A4 overexpression is associated with tumor 
development and progression in colorectal cancer [12]. S100A4 has also been 
shown to act as a prognostic factor in thyroid carcinoma, where overexpression 
is associated with the most advanced thyroid carcinomas and lymph node 
metastasis [13]. Recently, a study to identify tumor and tumor-associated 
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antigens in patients with hepatocellular carcinoma (HCC) pointed to transgelin 
2 as a potential diagnostic marker for HCC [14]. Thus, these 4E-BP1 regulated 
proteins have previously been associated with tumor cell motility, invasion and 
metastasis and may thus contribute to an adverse tumor phenotype.  
 
Several of the other 4E-BP1 dependent proteins that we identified have 
previously been associated with cancer and/or hypoxia. These include enolase 
1, lactate dehydrogenase-B, peptidylprolyl isomerase A and heat shock protein 
70 kDA 9B. The enolase 1 gene promoter contains essential binding sites for 
the transcription factor HIF-1α [15] and lactate dehydrogenase-B has 
previously been shown to be hypoxia regulated in primary rat and chick retinal 
cells [16]. Peptidylprolyl isomerise A (also termed cyclophilin A) has been 
reported to be overexpressed in different cancer cells and can lead to resistance 
to hypoxia and cisplatin-induced cell death [17]. Similarly, overexpression of 
heat shock protein 70kDA 9B (also termed mortalin) has been reported to be 
prognostic in colorectal cancer [18]. These observations support a growing co-
operative role between transcriptional (primarily HIF) and translational control 
mechanism during hypoxia that are relevant to cancer. 
 
  
Loss of 4E-BP1 sensitizes U87 tumors to hypoxia and irradiation  
In chapter 5 we demonstrated that the loss of 4E-BP1 expression in HeLa cells 
results in decreased clonogenic survival after hypoxic treatment. We 
hypothesized that this is due to inefficient energy conservation (4E-BP1 loss) 
during hypoxia, together with a compromised energy production due to the 
lack of oxygen.  To investigate if 4E-BP1 knock-down may demonstrate a 
similar phenotype as cells overexpressing eIF4E, we injected nude mice with 
U87 glioblastoma cells stably expressing a shRNA against 4E-BP1 (referred to 
as pRS 4E-BP1 U87). We demonstrated that pRS 4E-BP1 U87 tumors grow 
faster than their wild type counterparts, which was expected based on the 
hypothesis that the loss of 4E-BP1 results in activation of eIF4E, which would 
profoundly affect cellular growth properties [19]. However, a single dose of 10 
Gy resulted in a larger growth delay in the pRS 4E-BP1 U87 cells as compared 
to the pRS U87. Immunohistochemical analysis of tumor sections implies that 
this sensitivity to irradiation is due to decreased hypoxia in pRS 4E-BP1 U87 
tumors. We hypothesize that the pRS 4E-BP1 tumors are more sensitive to 
hypoxia due to increased ATP consumption. Indeed, ATP measurements 
clearly demonstrated lower energy levels in the pRS 4E-BP1 tumors cells.  
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Tumors are known to demonstrate greatly increased rates of metabolism 
due to mutations in oncogenes and tumor suppressors that regulate cell growth 
decisions. In U87 cells, increased rates of metabolism result from pTEN gene 
mutations, which lead to increased Akt activity and cell growth. Loss of 4E-
BP1 in these cells removes an important regulatory control on mRNA 
translation and thus the potential for even higher ATP consumption and 
demand. Our data suggest that cancer cells with elevated metabolism may 
become increasingly dependent on 4E-BP1 for energy homeostasis during 
hypoxia. Consequently, targeting this gene can specifically kill hypoxic tumor 
cells due to their inability to regulate metabolism. This approach is similar to 
the concept of ‘synthetic lethality’ which has been proposed for targeting of 
tumor cells harbouring specific mutational events. For example, treatment of 
repair defecient BRCA1 and BRCA2 mutant cells with Poly (ADP-ribose) 
polymerase (PARP) inhibitors [20] results in selective killing due to increased 
reliance of the PARP pathway. BRCA1 and BRCA2 are important for DNA 
double-strand break repair by homologous recombination [21], and mutations 
in these genes predispose to breast and other cancers [22]. PARP is an enzyme 
involved in base excision repair, a key pathway in the repair of DNA single-
strand breaks [23]. Loss of BRCA1 or BRCA2 profoundly sensitizes cells to 
the inhibition of PARP enzymatic activity, resulting in chromosomal 
instability, cell cycle arrest and subsequent apoptosis.  
 
 
Cancer cells adapt to reoxygenation through specific protein expression 
Human tumors are characterized by large variations in oxygen concentration 
and patients with the most hypoxic tumors have a poor prognosis. Furthermore, 
tumors are subjected to periodic changes in oxygenation characterized by 
hypoxia followed by reoxygenation. Cellular adaptation to hypoxia is well 
documented, nevertheless little is known about adaptive mechanisms to 
reoxygenation or their importance. In chapter 6 we investigated the changes in 
protein expression that occur during reoxygenation using proteomics. HeLa 
cells were exposed to 4 h of hypoxia (<0.01%O2) followed by 1 hr of 
reoxygenation. We identified proteins involved in several cellular processes 
that are responsible for regulating RNA metabolism, protein synthesis and 
degradation, including ribosomal protein P0 (RPP0), vasolin containing protein 
(VCP/p97) and FUSE binding protein 2 (FBP2). Reoxygenation causes damage 
to DNA, RNA, proteins and lipids trough the activation of reactive oxygen 
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species (ROS). We speculate that the proteins induced by reoxygenation serve 
to allow adaptation to this stress.  
 
VCP is a highly abundant protein that is required for the removal of 
misfolded proteins from the ER to allow their degradation by the proteosome in 
the cytoplasm. Our data demonstrated that VCP translocates to the cytoplasm 
during reoxygenation, and might thereby transport unfolded proteins to the 
proteosome for degradation during conditions of reoxygenation where cells are 
recovering from hypoxia induced ER stress.  
 
As mentioned before, oxidative stress also results in RNA damage and 
incorporation of oxidized nucleotides during RNA synthesis, which can impair 
protein synthesis and other RNA functions [24]. This is interesting, given the 
fact that FBP2 is involved in RNA processing. FBP2 (also termed KHRSP) is a 
member of the far-upstream element (FUSE) binding protein family that 
promotes rapid mRNA decay by recruiting the degradation machinery to AU-
rich elements (ARE) containing mRNAs [25]. We found that the efficiency by 
which FBP2 is translated into protein increases by more than 2-fold during 
reoxygenation. We found that RPP0 is also translationally upregulated during 
reoxygenation. This protein may thus contribute to the restoration of protein 
synthesis during reoxygenation which was completely restored after only 1 h 
roxygenation.  
 
In summary, these results shed light on the contribution of 
reoxygenation on specific protein expression. We suggest that this effect may 
contribute to tumor cell survival, due to increased protein quality control and 
decreased cell toxicity and as such these proteins or their regulators would be 
interesting new therapeutic targets to explore. 
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FUTURE PERSPECTIVES 
 
It is clear that cancer is not a single disease but a collection of disorders each 
with their own prognosis and wide range of causes. However, all tumors are 
characterized by common properties including deregulated cell growth. This 
deregulation is caused in part by elevated rates of metabolism including 
increased rates of protein synthesis causing high levels of growth factors and 
proteins with oncogenic potential. This is often associated with a loss of 
control over the regulation of protein synthesis, which seems to occur primarily 
at the level of mRNA translation initiation. Consequently, translation initiation 
factors have been found to be deregulated in numerous types of cancers [26]. 
 
Currently, a variety of novel therapeutics targeting cap-dependent 
translation are being developed as a mechanism for cancer treatment [27]. Our 
data demonstrated that eIF2α targeting might be a good therapeutic approach, 
because the loss of eIF2α phosphorylation renders tumor cells sensitive to 
hypoxia and causes significant changes in gene expression. The most 
straightforward way of targeting eIF2α would be to inhibit the kinase PERK 
which is responsible for its phosphorylation during hypoxia. Indeed, based in 
part upon the work presented in this thesis, new inhibitors are being developed 
by at least two different pharmaceutical companies. 
 
We also demonstrated that the loss of the tumor suppressor 4E-BP1 
results in the translation of specific mRNAs whose products promote 
tumorigenesis. Further investigation is required to define the clinical 
importance of S100A4 and transgelin 2 in hypoxic tumors. It would be 
particularly interesting to examine the clinical evidence for co-ordinated 
expression these proteins with eIF4E, which is often overexpressed in cancer. 
Furthermore, the possible contribution of S100A4 and transgelin 2 to an 
adverse tumor phenotype might be assessed by expressing a stable knock-down 
for both proteins. The metastatic potential of cells expressing a shRNA against 
S100A4 could be addressed both in vitro and in vivo.  
 
Energy levels and tumor metabolism are also interesting future targets 
for therapy in cancer. A balance between ATP production and ATP 
consumption may be considered important if the tumor cell wants to contribute 
to tumor growth. In our study, the loss of two tumor suppressor genes (pTEN 
and 4E-BP1) in U87 tumors which both influence energy demand results in 
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reduced hypoxia tolerance. Interestingly, this finding sheds extra light on a new 
way of cancer therapy that has been presented previously [20].  
 
Finally, data presented in this thesis highlight the potential importance 
of reoxygenation stress as regulators of cell phenotype through changes in gene 
expression. Considering the available data for VCP and FBP2 it might be 
interesting to further investigate their contribution to the adaptation to 
reoxygenation. An important first step will be to target these proteins (eg. 
produce stable knock-downs for each of these proteins) and determine the 
sensitivity to hypoxia or reoxygenation. Furthermore, the use of a ROS inducer 
like the estrogen derivative 2-ME, which causes an accumulation of cellular 
superoxide, might be used to further increase cytotoxicity in vitro during 
normoxia or hypoxia in cells that express a stable knock-down for VCP and 
FBP2. VCP is a very abundant protein and might be difficult to knock-down, 
so an alternative might be to knock-down one of its co-factors.  In vivo 
experiments should also be conducted to monitor tumor growth between cells 
that express a VCP or FBP2 knock-down compared to their WT counterparts. 
Tumors could be treated with irradiation, a ROS inducer or with drugs that are 
known to influence tumor oxgyenation. 
 
This thesis sheds light on the importance of mRNA translational 
regulation during hypoxia tumorigenesis, and potentially during therapy. Using 
both in vitro and in vivo approaches, we have demonstrated for the first time 
the true importance and potential of manipulating control of mRNA translation 
during hypoxia. We reported that the loss of translational control (eIF2α or 4E-
BP1) resulted in increased sensitivity of different tumor cells to hypoxia. 
Furthermore, although the loss of translational control (4E-BP1 loss) resulted 
in faster growing tumors, these tumors demonstrated increased sensitivity to 
irradiation through increased hypoxic cell death. These data suggest that 
therapeutic drugs that specifically target different members of the family of 
translational initiation factors have the potential to improve the treatment of 
cancer. The work in this thesis also addressed the importance of cellular 
responses to reoxygenation and we demonstrated that cancer cells adapt to this 
stress through specific mRNA translation. Our work has uncovered a 
tantalizing list of potential stress response proteins that are likely to be 
important mediators of tuomor cell function and survival. Further investigation 
of these reoxygenation specific genes may reveal new therapeutic targets which 
may be used to sensitize tumors to the stress of reoxygenation. Given the recent 
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understanding of the important and frequent changes in oxygenation that occur 
in tumors, this future work is particularly exciting. 
 
In conclusion, this thesis has highlighted the importance of cellular 
adaptation to hypoxia and reoxygenation through gene specific mRNA 
translation and may open new therapeutic windows for cancer treatment.  
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SAMENVATTING 
(voor referenties zie hoofdstuk 7) 
 
Laag zuurstofgehalte (hypoxie) beïnvloedt belangrijke fysiologische en 
pathologische condities, zoals ontwikkeling, ischemie, beroertes en kanker. 
Hypoxie in solide tumoren ontstaat door insufficienties en onjuiste werking van 
het tumor bloedvatenstelsel, dat de therapie negatief beïnvloedt. Een reeks van 
zuurstofmetingen in primaire en gemetastaseerde tumoren van de 
baarmoederhals, borst, hoofd, nek en rectum (1-3) hebben aangetoond dat 
patiënten met een lager zuurstofgehalte in de tumor een significante lagere 
waarschijnlijkheid van 5 jaar overleving hebben dan patiënten met tumoren 
met een hoger zuurstofgehalte. Deze bevindingen zijn verder nog bevestigd 
door meer recentere studies over hoofd- en nektumoren en sarcomas, en 
suggereren sterk dat hypoxie fundamenteel de tumor fysiologie verandert tot 
een aggressiever fenotype (4). 
 
Dit lijkt op het eerste zicht paradoxaal, gezien hypoxie een conditie is 
die ongunstig is voor celgroei en in vele omstandigheden zelfs rechtstreeks 
celdood stimuleert. De oplossing voor dit paradox ligt in het begrijpen van de 
onderliggende biologische effecten van hypoxie in de tumor als een geheel. 
Gedurende de voorbije decennia zijn we bewust geraakt van de vele 
belangrijke biologische veranderingen die zich voordoen wanneer cellen een 
zuurtsof tekort hebben en de potentiële contributie van deze veranderingen tot 
het kwaadaardig fenotype van deze tumoren. Het biologisch antwoord op 
hypoxie is in staat metastases, angiogenese (aanmaak nieuwe bloedvaten) en de 
selectie van cellen met een verminderde apoptotische (geprogrammeerde 
celdood) capaciteit te promoten. Het blokkeren of verliezen van cascades die 
celdood promoten als antwoord op hypoxie (vb. de p53 cascade) ligt aan de 
basis voor de selectie van cellen met verhoogde tolerentie tot hypoxie (5). 
 
Een algemeen aanpassingsmechanisme, dat heel veel aandacht kreeg in 
de onderzoekswereld gedurende de laatste decennia, is de activatie van een 
transcriptie programma dat in grote delen geleid wordt door hypoxie 
induceerbare factoren, genaamd HIFs. Deze factoren beïnvloeden de expressie 
van vele genen die een invloed hebben in verschillende processen zoals 
angiogenese en glucose metabolisme. 
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In deze thesis, hebben we de snelle en continue inhibitie in mRNA 
translatie (eiwitaanmaak) bestudeerd, hetgene een ander mechanisme is dat ook 
leidt tot tolerentie tegen hypoxie. Eiwitaanmaak kost enorm veel energie, zodat 
deze verhindering in eiwitaanmaak kan fungeren als een overlevings-
mechanisme gedurende hypoxie. Ondanks de verhindering van eiwitaanmaak, 
worden er toch eiwitten aangemaakt die noodzakelijk zijn voor de overleving 
gedurende hypoxie. Wij hebben onderzocht hoe hypoxie eiwitaanmaak 
verhindert en welke eiwitten toch gemaakt worden tijdens hypoxie.  Verder 
hebben we ook de veranderingen in eiwitaanmaak gedurende reoxygenatie 
bestudeerd alsook hun invloed op overleving tijdens deze vorm van stress.  
 
Deze thesis wijst op het belang van de regulatie van eiwitsynthese 
gedurende tumor hypoxie en waarschijnlijk ook gedurende de therapie. Door 
het gebruik van in vitro en in vivo modellen, hebben we voor de eerste keer het 
echte belang aangetoond van het manipuleren van eiwitaanmaak gedurende 
hypoxie. We hebben gerapporteerd dat het verlies van eIF2α of 4E-BP1 
resulteert in verhoogde gevoeligheid tot hypoxie van verschillende 
tumorcellen. Verder leidt het verlies van 4E-BP1 tot sneller groeiende tumoren, 
die een verhoogde gevoeligheid vertoonden aan bestraling door verhoogde 
celdood door hypoxie. Deze data suggereren dat therapeutische medicijnen die 
specifiek translatie initiatie factoren aanvallen, potentieel hebben om de kanker 
therapie te verhogen. Het werk in deze thesis heeft ook de belangen van 
cellulaire antwoorden tijdens reoxygenatie bestudeerd en wij hebben 
aangetoond dat kankercellen zich aanpassen aan deze stress door specifieke 
eiwitaanmaak. Ons werk heeft verschillende eiwitten geïdentificeerd die 
hoogstwaarschijnlijk belangrijk zijn voor tumor celfunctie en overleving.  
 
Toekomstig onderzoek van deze specifieke reoxygenatie eiwitten zou 
deze eiwitten kunnen identificeren als mogelijke nieuwe doelwitten om 
tumoren overgevoelig te maken aan reoxygenatie. Als men denkt over het 
belang en de frequentie waarmee veranderingen in zuurstofgehalte in tumoren 
zich voordoen, is toekomstig onderzoek zeer interessant. 
 
Om te besluiten, heeft deze thesis de belangen van de cellulaire 
aanpassing tot hypoxie en reoxygenatie door specifieke eiwitaanmaak 
aangetoond en ook een nieuwe deur geopend voor het behandelen van kanker. 
 
 
Samenvatting 
194 
 
 
 
                                                                                                                         195               
 
 
 
 
 
 
 
 
 
Dankwoord 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dankwoord 
196 
DANKWOORD 
 
Ik zou graag Prof. Philippe Lambin willen bedanken, die mij de mogelijkheid 
gaf om een doctoraat te doen binnen de capgroep Maastro. 
 
Ik zou graag mijn co-promotor Dr. Marianne Koritzinsky willen bedanken. 
 
Ik zou ook graag Prof. Brad Wouters willen bedanken om al zijn 
constructieve kritiek gedurende de voltooiing en de verwezenlijking van dit 
doctoraat. 
 
De leden van de beoordelingscommissie, te weten Prof. dr. Frans Ramaekers 
(voorzitter), Prof. dr. Bart Devreese, Prof. dr. Hans Kaanders, Prof. dr. 
Edwin Mariman en dr. Willem Voncken, wil ik bedanken voor hun tijd en de 
interesse die zij hebben besteed aan het beoordelen van mijn thesis. 
 
Graag zou ik Prof. Dr. B. Devreese en dr. Kjell Sergeant bedanken voor hun 
hulp met de massa spectrometrie. Die maand die ik bij jullie heb doorgebracht 
in Gent, heeft ons twee mooie artikelen opgeleverd. 
 
Al mijn collega’s van het Maastro Lab zou ik ook graag bedanken. Vooral 
ludwig en Natasja voor hun hulp met het laatste artikel.  
Verder will ik Younan, Twan en Barry bedanken voor al die mooie uitstapjes 
die we gedaan hebben. Ik hoop dat we dit in de toekomst blijven doen. 
 
Verder wil ik mijn twee paranimfen en beste vrienden David en Jan bedanken 
om mij vandaag hier bij te staan. 
 
In het bijzonder wil ik mijn ouders bedanken. Jullie waren er altijd om mij 
steunen en stimuleren in alles wat ik deed. Bedankt om altijd in mij te blijven 
geloven. 
 
As last but certainly not least, Mhaie Mhaie. Bedankt voor al je steun en 
liefde, ik hoop dat we nog vele jaren van elkaar kunnen genieten. 
 
 
 
                                                                                                                         197               
 
 
 
 
 
 
 
 
 
Curriculum Vitae 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Curriculum Vitae 
198 
CURRICULUM VITAE 
 
Michaël Gaston Pietro Magagnin was born on January 7th, 1978 in Luik, 
Belgium. In 1996, he completed high school, with science mathematics as his 
main subject, at the Onze-Lieve Vrouwe College in Tongeren, Belgium. In 
2002, he graduated as an Engineer in Biochemistry from the Katholieke 
Hogeschool Limburg (KHLIM) in Diepenbeek, Belgium. In September 2002 
he joined the Department of Human Biology (NUTRIM), Maastricht 
University, as a Research Technician. In September 2003 he became a PhD 
student at the Department of Radiation Oncology (GROW) under the 
supervision of Prof. dr. B.G. Wouters and Prof. dr. P. Lambin. In January 2008, 
he started to work as a Clinical Research Associate (CRA) at Pharmaceutical 
Product Development (PPD) in Brussels, Belgium. 
 
 
 
 
 
                                                                                                                         199               
 
 
 
 
 
 
 
 
 
List of Publications 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
List of Publications 
200 
LIST OF PUBLICATIONS 
 
[1] Wouters, BG, van den Beucken, T, Magagnin, MGP, Lambin, P, 
Koumenis, C. Targeting hypoxia tolerance in cancer. Drug Resist Updat 
2004;7:25-40. 
 
[2] Koritzinsky, M, Seigneuric, R, Magagnin, MGP, van den Beucken, T, 
Lambin, P, Wouters, BG. The hypoxic proteome is influenced by gene-
specific changes in mRNA translation. Radiother Oncol 2005;76:177-
186. 
 
[3] Wouters, BG, van den Beucken, T, Magagnin, MGP, Koritzinsky, M, 
Fels, D, Koumenis, C. Control of the hypoxic response through 
regulation of mRNA translation. Seminars in cell & developmental 
biology 2005;16:487-501. 
 
[4] Corpeleijn, E, van der Kallen, CJ, Kruijshoop, M, Magagnin, MGP, de 
Bruin, TW, Feskens, EJ, Saris, WH, Blaak, EE. Direct association of a 
promoter polymorphism in the CD36/FAT fatty acid transporter gene 
with Type 2 diabetes mellitus and insulin resistance. Diabet Med 
2006;23:907-911. 
 
[5] Koritzinsky, M, Magagnin, MGP, van den Beucken, T, Seigneuric, R, 
Savelkouls, K, Dostie, J, Pyronnet, S, Kaufman, RJ, Weppler, SA, 
Voncken, JW, Lambin, P, Koumenis, C, Sonenberg, N, Wouters, BG. 
Gene expression during acute and prolonged hypoxia is regulated by 
distinct mechanisms of translational control. The EMBO journal 
2006;25:1114-1125. 
 
[6] Magagnin, MGP, Koritzinsky, M, Wouters, BG. Patterns of tumor 
oxygenation and their influence on the cellular hypoxic response and 
hypoxia-directed therapies. Drug Resist Updat 2006;9:185-197. 
 
[7] Koritzinsky, M, Rouschop, KM, van den Beucken, T, Magagnin, 
MGP, Savelkouls, K, Lambin, P, Wouters, BG. Phosphorylation of 
eIF2alpha is required for mRNA translation inhibition and survival 
during moderate hypoxia. Radiother Oncol 2007;83:353-361. 
 
                                                                                                List of Publications 
 
                                                                                                                         201 
[8] Magagnin, MGP, Sergeant, K, van den Beucken, T, Rouschop, KM, 
Jutten, B, Seigneuric, R, Lambin, P, Devreese, B, Koritzinsky, M, 
Wouters, BG. Proteomic analysis of gene expression following hypoxia 
and reoxygenation reveals proteins involved in the recovery from 
endoplasmic reticulum and oxidative stress. Radiother Oncol 
2007;83:340-345. 
 
[9] Seigneuric, R, Starmans, MH, Fung, G, Krishnapuram, B, Nuyten, DS, 
van Erk, A, Magagnin, MGP, Rouschop, KM, Krishnan, S, Rao, RB, 
Evelo, CT, Begg, AC, Wouters, BG, Lambin, P . Impact of supervised 
gene signatures of early hypoxia on patient survival. Radiother Oncol 
2007;83:374-382. 
 
[10]  van den Beucken, T, Magagnin, MGP, Savelkouls, K, Lambin, P, 
Koritzinsky, M, Wouters, BG. Regulation of Cited2 expression 
provides a functional link between translational and transcriptional 
responses during hypoxia. Radiother Oncol 2007;83:346-352. 
 
[11] Magagnin, MGP, van den Beucken, T, Sergeant, K, Lambin, P, 
Koritzinsky, M, Devreese, B, Wouters, BG. The mTOR target 4E-BP1 
contributes to differential protein expression during normoxia and 
hypoxia through changes in mRNA translation efficiency. Proteomics 
2008;8:1019-1028. 
 
[12]    Magagnin, MGP, Dubois, L, Cleven, AHG, Weppler, SA, Grenacher, 
B, Landuyt, W, Lieuwes, N, Lambin, P, Gorr, TA, Koritzinsky, M, 
Wouters, BG. Inhibition of 4E-BP1 sensitizes U87 glioblastoma 
xenograft tumors to irradiation through increased sensitivity to hypoxia 
induced cell death. (submitted to Radiother Oncol) 
 
 
 
 
 
 
 
 
List of Publications 
202 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                        203
 
 
 
 
 
 
 
 
List of Abbreviations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
List of Abbreviations 
204 
LIST OF ABBREVIATIONS 
 
ARE   AU-Rich Element 
ARNT   Aryl Hydrocarbon Receptor Nuclear Translocator 
ATF6   Activation Transcription Factor 6 
ATP   Adenosine Triphosphate 
BiP   Immunoglobulin Binding Protein  
CA-9   Carbonic Anhydrase-9 
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CITED-2  Cbp/p300 Interacting Transactivator Domain-2 
C-TAD  C-Terminal Transactivation Domain 
DMEM  Dulbecco's Modified Eagle's Medium 
DNA   Deoxyribonucleic Acid 
DTT   Dithiothreitol  
DU145  Prostate Carcinoma  
eIF2α   Eukaryotic Initiation Factor 2α 
eIF4E   Eukaryotic Initiation Factor 4E 
4E-BP1  4E-Binding Protein 1 
EPO   Erythropoietin
ER   Endoplasmatic Reticulum  
ERAD   Endoplasmic Reticulum Associated Degradation 
ESI   Electrospray Ionisation 
4E-T   4E-Transporter 
FBP   FUSE Binding Protein 
FUSE   Far Upstream Element 
GC   Gastric Carcinoma 
GTP   Guanidine Triphosphate 
HCC   Hepatocellular Carcinoma 
HeLa   Cervical Carcinoma  
HIF-1   Hypoxia Inducible Factor-1 
HIG-2   Hypoxia Inducible Protein-2 
HK-2   Hexokinase 2 
HPLC   High Performance Liquid Chromatography 
HRE   Hypoxia Response Element 
IEF   Isoelectric Focusing 
IL-8   Interleukin-8 
IRE-1   Inositol-Requiring Protein-1 
IRES   Internal Ribosomal Entry Sites 
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MEF   Mouse Embryonic Fibroblast  
MMP   Matrix Metalloproteinase 
Mr   Molecular Weight 
(m)RNA  (Messenger) Ribonucleic Acid 
MS   Mass Spectrometry  
mTOR   Mammalian Target of Rapamycin 
N-TAD  N-Terminal Transactivation Domain 
PARP   Poly (ADP-Ribose) Polymerase  
PBS   Phosphate Buffered Saline 
PCR   Polymerase Chain Reaction 
PDGF   Platelet-Derived Growth Factor 
PERK   (PKR)-like ER Kinase 
PHD   Prolyl Hydrolase 
pRS   pRetroSuper 
pVHL   von-Hippel Lindau Protein 
RNAi   RNA Interfering 
ROS   Reactive Oxygen Species 
RPP0   Ribosomal Protein P0 
S100A4  S100 Calcium-Binding Protein A4 
SDS   Sodium Dodecyl Sulphate 
SG   Stress Granules 
shRNA  Short Hairpin RNA 
TCA   Trichloroacetic Acid  
TOP   Terminal Oligopyrimidine 
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uORF   Upstream Open Reading Frame 
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UPS   Ubiquitin Proteasome System 
VCP   Vasolin Containing Protein 
VEGF   Vascular Endothelial Growth Factor 
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